

Curriculum Vitae

Jason D. Wright, M.D.

BUSINESS ADDRESS

Columbia University College of Physicians and Surgeons
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
161 Fort Washington Ave, 4th Floor
New York, New York 10032
Telephone: (212) 305-3410
Fax: (212) 305-3412
jw2459@columbia.edu

HOME ADDRESS

201 E. 21st Street Apt 15J
New York, New York 10010
Telephone: (917) 658-0903

PRIMARY ACADEMIC APPOINTMENT

2014-Present Chief, Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Columbia University College of Physicians and Surgeons

2014-Present Sol Goldman Associate Professor of Obstetrics and Gynecology
Division of Gynecologic Oncology, Department of Obstetrics and
Gynecology
Columbia University College of Physicians and Surgeons

2016-Present Vice Chair of Academic Affairs
Department of Obstetrics and Gynecology
Columbia University College of Physicians and Surgeons

JOINT APPOINTMENTS AND POSITIONS

2009-Present Member, Division of Reproductive Sciences
Department of Obstetrics and Gynecology
Columbia University College of Physicians and Surgeons

2006-Present Full Member, Herbert Irving Comprehensive Cancer Center
Program in Prevention, Control, and Disparities
Columbia University College of Physicians and Surgeons

OTHER APPOINTMENTS

2021-Present Editor-in-Chief, *Obstetrics & Gynecology*

PAST APPOINTMENTS

2014-2021 Director, Gynecologic Oncology Fellowship

Joint Columbia and Cornell University and New York Presbyterian Hospital Fellowship

2011-2014 Florence Irving Assistant Professor of Obstetrics and Gynecology
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology
Columbia University College of Physicians and Surgeons

2010-2018 Founding Co-Director, Center for Placenta Accreta
Department of Obstetrics and Gynecology
Columbia University College of Physicians and Surgeons

2009-2014 Levine Family Assistant Professor of Women's Health
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology
Columbia University College of Physicians and Surgeons

2006-2009 Assistant Professor
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology
Columbia University College of Physicians and Surgeons

2003-2006 Instructor, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology
Washington University School of Medicine

PERSONAL DATA

Place of Birth Sioux Falls, South Dakota
Citizenship United States

EDUCATION

Undergraduate University of Missouri-Kansas City
Kansas City, Missouri
Biological Science
B.A. (1993-1998)

Medical University of Missouri-Kansas City
Kansas City, Missouri
M.D. (1993-1999)

POSTGRADUATE TRAINING

Internship and Residency Obstetrics and Gynecology
Washington University in St. Louis School of Medicine
Barnes Jewish Hospital
(July, 1999-June, 2003)

Fellowship
Gynecologic Oncology
Washington University in St. Louis School of Medicine
Barnes Jewish Hospital
(July, 2003-June, 2006)

BOARD CERTIFICATION

2007 Obstetrics and Gynecology
2008 Gynecologic Oncology

MEDICAL LICENSURE

1999 State of Missouri
2006 State of New York
2014 State of New Jersey

PROFESSIONAL ORGANIZATIONS

American Gynecological and Obstetrical Society (AGOS), Member
American College of Surgeons (ACS), Fellow
American College of Obstetricians and Gynecologists (ACOG), Fellow
Society of Gynecologic Oncology (SGO), Full Member
American Society of Clinical Oncology (ASCO), Member
International Gynecologic Cancer Society (IGCS), Member
New York Obstetrical Society (NYOB), Member
NRG Oncology, Member
Southwest Oncology Group (SWOG), Member

AWARDS AND HONORS

2020 *International Journal of Gynecologic Cancer* 2020 Top Reviewer Award
2019 Roy M. Pitkin Award from *Obstetrics & Gynecology*
2019 Academy of Clinical Excellence, Columbia University College of Physicians and Surgeons
2016 2016 E. Grey Diamond Take Wing Award
2015 Foundation for Women's Cancer Excellence in Ovarian Cancer Research Prize in honor of Ronald Alvarez, MD
2013 2013 Health Care Utilization Project Outstanding Article of the Year Award
2012 American College of Obstetricians and Gynecologists Mentor Award
2011-2014 Florence Irving Chair in Obstetrics and Gynecology
2010 American Gynecological and Obstetrical Society (AGOS) Travel Award
2009-2014 Levine Family Chair in Women's Health
2008 Excellence in Teaching Award, Columbia University College of Physicians and Surgeons Department of Obstetrics and Gynecology
2007 Gynecologic Oncology Group Young Investigator Award

2006	St. Louis Gynecological Society Spring Research Symposium, President's Award
2005	Teacher of the Year Award, Department of Obstetrics and Gynecology
2005	St. Louis Gynecological Society Spring Research Symposium, President's Award
2004-2005	Washington University Department of Obstetrics and Gynecology Excellence in Teaching Award
2004	Clinical Research Award, Glaxo Smith Kline National Gynecologic Oncology Fellows' Forum
2004	St. Louis Gynecological Society Spring Research Symposium, First Place
2003	Resident Research Award, First Place, David Rothman Resident Research Day
2003	Obstetrics and Gynecology Resident Teaching Award
2002	Resident Research Award, First Place, David Rothman Resident Research Day
2002-2003	Department of Obstetrics and Gynecology Administrative Chief Resident
2001	Resident Research Award, First Place, David Rothman Resident Research Day
2000	Outstanding Resident Award, Washington University School of Medicine Students
1998	Alpha Omega Alpha Honor Medical Society

REGIONAL AND NATIONAL COMMITTEES

2021-Present	Member, Ovarian Cancer Research Alliance Scientific Advisory Board
2021-Present	Peking Union Medical College Hospital International Advisory Committee
2021	New York Obstetrical Society, Membership Committee
2021-Present	Member, American Board of Obstetrics and Gynecology (ABOG) Specialty Subcommittee
2020	American Association of Gynecologic Laparoscopy Abstract and Video Review Committee, 49 th Annual Congress
2019-Present	Member, American Society of Clinical Oncology Breast/Gynecologic Cancer Measures Panel
2019-Present	Member, Society of Gynecologic Oncology Board of Directors
2018-2020	Member, American Society of Clinical Oncology Value in Cancer Care Task Force
2018-Present	Medical and Scientific Advisory Board Member, National Ovarian Cancer Coalition (NOCC)
2017-Present	Member, American Society of Clinical Oncology Cancer Research Committee
2017-Present	Examiner, American Board of Obstetrics and Gynecology (ABOG), Gynecologic Oncology Subspecialty

2016-2017	Member, ACOG District II Female Cancers Task Force
2016-2019	Vice Chair, Task Force on the Future of Physician Payment Reform, Society of Gynecologic Oncology
2016-2018	Member, Gynecologic Cancer Guideline Advisory Group, American Society of Clinical Oncology
2016-2019	Health Policy and Socioeconomic Committee, Society of Gynecologic Oncology
2016-2017	Member, Cancer Care Delivery Research Coordinating Committee, National Cancer Institute
2015-2018	American Cancer Society, Eastern Division Board of Directors
2015-2016	Task Force on the Future of Physician Payment Reform, Society of Gynecologic Oncology
2015-2016	Chair, Subgroup on Data Acquisition, Task Force on the Future of Physician Payment Reform, Society of Gynecologic Oncology
2015	Task Force on Policy & Quality, Society of Gynecologic Oncology
2015-2016	National Oncologic Emergencies Research Consortium, National Cancer Institute (NCI), Epidemiology and Genomics Research Program
2014-2018	Cancer Care Delivery Research (CCDR) Committee, NRG Oncology
2014-2015	Chair, PROLOG in Gynecologic Oncology Writing Committee, American College of Obstetricians and Gynecologists
2014-2016	New York State Department of Health Cancer Metrics Technical Expert Panel
2014-2015	Gilda's Club Advisory Council
2013-2015	American Congress of Obstetricians and Gynecologists District II Safe Motherhood Initiative
2012	Voting Member, American Society of Colposcopy and Cervical Pathology Consensus Conference for the Management and Follow-Up of Cervical Cytologic Abnormalities
2012	Organizing Committee, Young Doctors' Summit of International Gynecologic Cancer Society Annual Meeting
2010-2015	Quality and Outcomes Committee, Society of Gynecologic Oncology
2010	Annual Meeting of the Society of Gynecologic Oncology Program Committee Member
2009-2010	PROLOG in Gynecologic Oncology Writing Committee, American College of Obstetricians and Gynecologists
2008-2009	District II Ovarian Cancer Task Force, American College of Obstetricians and Gynecologists
2007-2009	Chairman, Candidates Network, Society of Gynecologic Oncologists
2007-2010	Education Committee, Society of Gynecologic Oncologists
2006-2008	Cervical Cancer Vaccine Consensus Panel, Society of Gynecologic Oncologists
2006	Atypical Squamous Cells of Undetermined Significance (ASC-US)

2005 Subgroup, American Society for Colposcopy and Cervical Pathology Consensus Conference
 American Society of Clinical Oncology/American Association of Cancer Research Workshop “Methods in Clinical Cancer Research”. Vail, Colorado, July 30-August 5, 2005.

INSTITUTIONAL COMMITTEES

2019-Present Herbert Irving Comprehensive Cancer Center Translational and Clinical Research Committee
 2016-Present Columbia Doctors Faculty Practice Finance Committee
 2014-Present Committee on Appointments and Promotions (COAP), Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons
 2014-Present Executive Committee, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons
 2014-Present Education Committee, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons
 2012-2013 Health Practice Research Committee, Columbia University College of Physicians and Surgeons
 2012-2013 Women’s and Children’s Health Committee, Columbia University College of Physicians and Surgeons
 2010-2015 Protocol Review and Monitoring Committee (PRMC), Herbert Irving Comprehensive Cancer Center
 2010-Present Oncology Quality and Patient Safety Committee, Columbia University
 2008-2010 Information Technology Committee, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons
 2007-2008 Institutional Review Board, Columbia University College of Physicians and Surgeons

GRANT REVIEW COMMITTEES

2015 Department of Defense, Defense Medical Research and Development Program (DMRDP)
 2014 Cancer Research UK Grant Review
 2013-2016 Irving Institute/Clinical Trials Office Pilot Awards Program Review Committee, Columbia University College of Physicians and Surgeons
 2013-Present Foundation for Women’s Cancer Research Grants and Awards Committee
 2013 Chairman, New York Obstetrical Society Resident and Fellow Research Program Selection Committee
 2012-2015 American Society of Clinical Oncology Conquer Cancer Foundation Grant Selection Committee

2012 Chairman, New York Obstetrical Society Resident and Fellow
Research Program Selection Committee
2011-Present Department of Defense, Ovarian Cancer Research Program
(OCRP)

EDITORIAL BOARDS

World Journal of Clinical Oncology (2010-Present)
Gynecologic Oncology Case Reports (2011-2016)
Dataset Papers in Medicine (2012-Present)
Obstetrics & Gynecology (2015-2019)
Journal of Minimally Invasive Gynecology (2016-Present)
Gynecologic Oncology (2016-Present)
International Journal of Gynecologic Cancer (2018-Present)

REVIEWERSHIP

Gynecologic Oncology (2006-Present)
Obstetrics & Gynecology (2007-Present)
American Journal of Obstetrics and Gynecology (2007-Present)
Cancer (2007-Present)
Lancet (2008)
Lancet Oncology (2009)
Journal of Surgical Oncology (2009-Present)
International Journal of Gynecologic Cancer (2009-Present)
Journal of Obstetrics and Gynaecology Research (2010-Present)
Fertility and Sterility (2010-2011)
Journal of Clinical Oncology (2011-Present)
British Journal of Cancer (2011-Present)
Canadian Medical Association Journal (2011-Present)
Paediatric and Perinatal Epidemiology (2011-Present)
Acta Obstetrica et Gynecologica Scandinavica (2012-Present)
Cancer Epidemiology (2012-Present)
Annals of Oncology (2012-Present)
Cancer Investigation (2012-Present)
Oncology (2012-Present)
Science Translational Medicine (2012)
JAMA (2013-Present)
Journal of Minimally Invasive Gynecology (2013-Present)
Cancer Prevention Research (2013-Present)
JAMA Internal Medicine (2014-Present)
New England Journal of Medicine (2014-Present)
Journal of the National Comprehensive Cancer Network (2015-Present)
JAMA Oncology (2015-Present)
Journal of the National Cancer Institute (2017-Present)

CURRENT RESEARCH FUNDING AND GRANTS

1. Comparative Modeling for the Prevention and Control of Uterine Cancer. National Cancer Institute (1U01 CA265739). 9/17/21-8/31/26. \$4,456,249 total costs. 30% effort (Role in grant: Principal Investigator).
2. Racial Disparities in Diagnostic Evaluation of Uterine Cancer. National Institute on Minority Health and Health Disparities (1R01 MD016386). 8/27/21-4/30/25. \$1,776,776 total costs. 15% effort (Role in grant: Principal Investigator, MPI).
3. Medication Reminder Applications to Improve Medication Adherence in Women with Breast Cancer. Komen Foundation (SAC190066). 8/1/19-7/31/22 (Dawn Hershman, PI), \$160,000 direct costs. 5.0% effort (Role in grant: Co-Investigator).
4. Columbia University Minority/Underserved Site NCI Community Oncology Research Program. NIH/NCI (2UG1 CA189960-06). 8/1/19-7/31/25 (Gary Schwartz, Andrew Lassman, Alfred Neugut, PI's), \$715,311 direct costs. 5.0% effort (Role in grant: Senior Advisor).
5. Treatment Patterns and Outcomes in Women with Cervical and Endometrial Cancer. 7/13/21-6/30/22. Merck. \$447,162 total costs. 25.0% effort (Role in grant: PI).

Clinical Trials

6. A randomized, double-blind, placebo-controlled study of the efficacy and safety of MORAb-003 (farletuzumab) in combination with paclitaxel therapy in subjects with platinum-resistant or refractory relapsed ovarian cancer. Morphotek. 2/2012-Present, \$40,000 approximate total costs. (Role in grant: Site PI).
7. A Registry of Caris Target Now Test Results and Hematopoietic Diagnostics for Evaluation of Correlation with Clinical Outcomes for Cancer and Other Patients. Caris Diagnostics. 12/2012-Present, \$60,000 approximate total costs. (Role in grant: Site PI).
8. A Randomized, Open-Label Study Comparing the Combination of Yondelis and Doxil/Caelyx with Doxil/Caelyx Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Janssen Pharmaceuticals. 2/2014-Present, \$18,500 approximate total costs. (Role in grant: Site PI).
9. A Multicenter Prospective Study of CA125 and HE4 Serum Biomarkers for Monitoring the Response to First-Line Therapy in Women with Primary Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Excluding Ovarian Tumors of Low Malignant Potential. Fujirebio Diagnostics. 8/2014-Present, \$12,000 approximate total costs. (Role in grant: Site PI).
10. A Blinded, Prospective Study of the Performance of HE4 to Predict Recurrence in Patients with Advanced Ovarian Cancer, Peritoneal Carcinoma and Tubal Carcinoma. Fujirebio Diagnostics. 8/2014-Present, \$14,000 approximate total costs. (Role in grant: Site PI).

11. A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel with or without concurrent and continuation maintenance veliparib (PARP inhibitor) in Subjects with Previously Untreated Stage III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. AbbVie Inc. 12/2015-Present, \$50,000 approximate total costs. (Role in grant: Site PI).
12. A phase III, multicenter, randomized, study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. Hoffman-La Roche Ltd. 4/2017-Present, \$21,000 approximate total costs. (Role in grant: Site PI).
13. Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy. AstraZeneca. 6/2017-Present, \$28,500 approximate total costs. (Role in grant: Site PI).
14. A single arm, open-label, phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation. AstraZeneca. 8/2017-Present, \$34,000 approximate total costs (Role in grant: Site PI).
15. The nCYT study: a powered study to evaluate the sensitivity and specificity of cytological evaluation of fallopian tube samples collected by MAKO 7 in determining the presence of malignancy. nVision. 6/2018-Present, \$17,500 approximate total costs (Role in grant: Site PI).
16. Center for hereditary breast and ovarian cancer. Allergan Foundation. 6/2019-7/20, \$20,000 total costs (Role in grant: PI).

PRIOR RESEARCH FUNDING AND GRANTS

1. The Influence of Hospital Variability on the Management of Cancer-Associated Complications. National Cancer Institute (R01 CA169121-01A1). 1/2013-12/2019 (Jason D. Wright, PI), \$2,075,000 total costs. 25% effort (Role in grant: PI).
2. Surgical Oncology Basic Science and Translational Research Training Program. National Cancer Institute (T32 CA009621-16). 7/2003-6/2004 (Timothy Eberlein, PI). (Role in grant: Investigator).
3. Columbia University Center for Career Development in Reproductive Sciences. National Institutes of Child Health and Human Development (5K12 HD001275). 1/2007-12/2012 (Mary E. D'Alton, PI). 75% effort (Role in grant: Research scholar)

4. Therapeutic Targeting of Angiogenesis in Ovarian Cancer. National Institutes of Health Loan Repayment Grant (GDEN4289). 7/2007-6/2012 (Jason D. Wright, PI). (Role in grant: PI).
5. Therapeutic Targeting of Notch in Ovarian Cancer. Department of Defense Career Development Award (OC080151). 9/2009-8/2013 (Jason D. Wright, PI), \$375,000 direct costs. 75% effort (Role in grant: PI).
6. Notch as a Diagnostic and Prognostic Marker in Ovarian Cancer. Gynecologic Oncology Group/Ovarian Cancer Research Fund Young Investigator's Award. 7/2007-8/2008 (Jason D. Wright, PI), \$25,000 total costs. (Role in grant: PI).
7. Therapeutic Targeting of Follicle Stimulating Hormone in Epithelial Ovarian Cancer. Gynecologic Cancer Foundation, Anne Schreiber Award. 6/2008-5/2009 (Jason D. Wright, PI), \$50,000 total costs. (Role in grant: PI).
8. Using SWOG-Medicare Data to Evaluate Long-Term Toxicities of Cancer Survivors. National Cancer Institute (R01 CA166084-01). 3/2013-2/2016 (Dawn L. Hershman, PI), \$1,660,000 total costs. 10% effort (Role in grant: Co-Investigator).
9. Hippocampal and Cognitive Function, Exercise, and Ovarian Cancer: A Pilot Study. Department of Defense (W81XWH-14-0236). 8/2014-7/2016 (Richard Sloane, PI), \$225,000 direct costs. 2.5% effort (Role in grant: Co-Investigator).
10. Relationship Between Obstetric Outcomes and Publicly Reported Hospital Quality and Satisfaction Measures. Department of Health and Human Services (R40 MC28312-01). 4/1/15-3/30/16 (Jason D. Wright, PI), \$98,606 total costs. 7.5% effort (Role in grant: PI).
11. Comorbidity, Toxicity and Breast Cancer Survival Among Women On and Off Clinical Trials. Susan G. Komen Foundation (SAC160066). 5/2016-4/2019 (Dawn L. Hershman, PI), \$600,000 total costs. 10% effort (Role in grant: Co-Investigator).
12. Effect of Regional Hospital Market Competition on Performance of Immediate Breast Reconstruction in Women with Breast Cancer. Avon Breast Cancer Grant. 1/2017-12/2017 (Jason D. Wright, PI), \$75,000 total costs. 2.5% effort (Role in grant: PI).
13. Power Morcellation of Occult Uterine Cancer in Benign Hysterectomy and Myomectomy. Agency for Healthcare Research and Quality (R01HS024702). 7/2016-4/2019 (Xiao Xu, PI), \$1,006,143 total costs. (Role in grant: Consultant).
14. Decision Support for BRCA Testing in Ethnically Diverse Women. American Cancer Society. 7/1/17-6/30/20 (Rita Kukafka, PI), \$291,550 direct costs. 5.0% effort (Role in grant: Co-Investigator).

15. Hospital Level Analysis of Racial Disparities in Severe Maternal Morbidity. Department of Health and Human Services (R40 MC32879). 7/1/19-8/31/20 (Alexander Friedman, PI), \$99,674 total costs. 2.0% effort (Role in grant: Co-Investigator).
16. Understanding Treatment Patterns, Resource Use, and Patient Outcomes Associated with Novel Treatments in Ovarian Cancer. Merck. 1/9/19-7/9/20. \$307,011 total costs. 25.0% effort (Role in grant: PI).
17. COVID-19 and cancer. Supplement to Columbia University minority/underserved site NCI community oncology research program. NIH/NCI (2UG1CA189960-06). 8/1/20-7/31/21 (Gary Schwartz, Andrew Lassman, Alfred Neugut, PI's), \$100,00 direct costs. 5.0% effort (Role in grant: Project Lead).
18. Development of data for submission of a Cancer Intervention and Surveillance Modeling Network (CISNET) incubator program for new cancer sites. Herbert Irving Comprehensive Cancer Center. 11/1/20-10/31/21. \$25,000 total costs (Role in grant: PI).

Clinical Trials

19. Phase II Trial of Topotecan, Cisplatin, and Bevacizumab for Recurrent/Persistent Cervical Cancer. GlaxoSmithKline and Genentech BioOncology. 7/2006-11/2012, \$250,000 approximate total costs. (Role in grant: Co-PI).
20. The Oncofish Cervical Test for Detection of 3q26 Region Gain. Ikonysis. 5/2009-4/2014, \$11,300 approximate total costs. (Role in grant: Site PI).
21. Acceptance of Human Papillomavirus Vaccination in Postpartum Women. Merck Pharmaceuticals. 8/2009-7/2012, \$240,000 total costs. (Role in grant: PI).
22. A Pivotal Trial to Determine the Efficacy and Safety of AP23573 when Administered as Maintenance Therapy to Patients with Metastatic Soft-Tissue or Bone Sarcoma. ARIAD Pharmaceuticals. 8/2009-3/2010, \$9280 approximate total cost. (Role in grant: Site PI).
23. Carboplatin, Paclitaxel, and Bevacizumab as Neoadjuvant Therapy for Ovarian Cancer. Genentech BioOncology. 9/2009-Present, \$450,000 total costs. (Role in grant: National PI).
24. NCI Protocol 8167: Pilot Phase II Study of Temsirolimus in Patients with Recurrent Mixed Mesodermal and Mullerian Tumors (Carcinosarcoma) of the Uterus. Montefiore Medical Center. 7/2010-3/2012. (Role in grant: Site PI).
25. A Phase III, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women with Recurrent, Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers. Amgen Inc. 8/2011-7/2014, \$66,400 approximate total costs. (Role in grant: Site PI).

26. Phase II Trial of Combination Pemetrexed (Alimta) and Carboplatin (Paraplatin) in Platinum Sensitive, Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma. Montefiore Medical Center. 2/2011-9/2014, \$8000 approximate total costs. (Role in grant: Site PI).
27. A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 (IND#78,416) in Combination with Pegylated Liposomal Doxorubicin (PLD) in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. VentiRx Pharmaceuticals. 6/2013-5/2014, \$16,500 approximate total costs. (Role in grant: Site PI).

TEACHING RESPONSIBILITIES

Courses

- | | |
|--------------|--|
| 2006-2014 | Course Director, Gynecologic Oncology Sub-Internship (OB05P)
Columbia University College of Physicians and Surgeons |
| 2015-Present | Course Director, Applied Comparative Effectiveness and
Outcomes Research (P8586)
Mailman School of Public Health |

PEER-REVIEWED ARTICLES

1. **Wright JD**, Powell MA, Horowitz NS, Huettner PC, White F, Herzog TJ. Placental site trophoblastic tumor presenting as a pneumothorax during pregnancy. *Obstet Gynecol.* 2002;100(5):1141-4.
2. **Wright JD**, Horowitz NS, Rader JS. Primary peritoneal carcinoma presenting as adenocarcinoma on Pap smear. *J Reprod Med.* 2002; 47(11):933-5.
3. Winchester SK, Imamura T, Gross GA, Muglia LM, Vogt SK, **Wright JD**, Watanabe K, Tai HH, Muglia LJ. Coordinate regulation of prostaglandin metabolism for induction of parturition in mice. *Endocrinology.* 2002;143(7):2593-8.
4. **Wright JD**, Herzog TJ, Mutch DG, Gibb RK, Rader JS, Davila R, Cohn DE. Liquid-based cytology for the postirradiation surveillance of women with gynecologic malignancies. *Gynecol Oncol.* 2003;90(1):134-8.
5. Li J, Gerhard DS, Zhang Z, Huettner PC, **Wright JD**, Nguyen L, Lu D, Rader JS. Denaturing high-performance liquid chromatography for detecting and typing genital human papillomavirus. *J Clin Microbiol.* 2003;41(12):5563-71.
6. **Wright JD**, Powell MA, Rader JS, Pfeiffer JD, Huettner PC, Merritt DF. A calcified pelvic mass in an adolescent female. *J Pediatr Adolesc Gynecol.* 2003;16(4):237-41.
7. **Wright JD**, Pinto AB, Powell MA, Lu DW, Gao F, Pinto KR. Atypical squamous cells of undetermined significance in girls and women. *Obstet Gynecol.* 2004;103(4):632-8.

8. **Wright JD**, Herzog TJ, Powell MA. Morbidity of cytoreductive surgery in the elderly. *Am J Obstet Gynecol.* 2004;190(5):1398-400.
9. **Wright JD**, Chaudhari A, Sadovsky Y. Is hypotonic dysfunctional labor associated with hypophosphatemia? *Am J Obstet Gynecol.* 2004;190(5):1447-9.
10. **Wright JD**, Geevarghese S, Marder SJ, Shumway JB. Prenatally diagnosed human caudal appendage. *J Reprod Med.* 2004;49(7):566-8.
11. **Wright JD**, Powell MA, Mutch DG, Rader JS, Gibb RK, Huettner PC, Herzog TJ. Synchronous ovarian metastases at the time of laparotomy for colon cancer. *Gynecol Oncol.* 2004;92(3):851-5.
12. **Wright JD**, Powell MA, Herzog TJ, Mutch DG, Rader JS, Gao F, Gibb RK. Panniculectomy: improving lymph node yield in morbidly obese patients with endometrial neoplasms. *Gynecol Oncol.* 2004;94(2):436-41.
13. Kamelle SA, Rutledge TL, Tillmanns TD, Gould NS, Cohn DE, **Wright JD**, Herzog TJ, Rader JS, Gold MA, Johnson GA, Walker JL, Mannel RS, McMeekin DS. Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? *Gynecol Oncol.* 2004;94(2):249-55.
14. Rutledge TL, Kamelle SA, Tillmanns TD, Gould NS, **Wright JD**, Cohn DE, Herzog TJ, Rader JS, Gold MA, Johnson GA, Walker JL, Mannel RS, McMeekin DS. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? *Gynecol Oncol.* 2004;95(1):70-76.
15. **Wright JD**, Powell MA, Gibb RK, Herzog TJ, Mutch DG, Trinkaus K, Rader JS. Cervical cancer in the elderly: a multivariate analysis of patterns of care and outcome in 1582 patients. *Cancer.* 2005;103(1):85-91. Editorial *Cancer* 2005;103(1):5-10.
16. Brockmeyer AD, **Wright JD**, Gao F, Powell MA. Persistent and recurrent cervical dysplasia after loop electrosurgical excision procedure. *Am J Obstet Gynecol.* 2005;192(5):1379-81.
17. **Wright JD**, Gerhard DS, Zhang Z, Huettner PC, Trinkaus KM, Mutch DG, Herzog TJ, Gibb RK, Rader JS. Molecular and environmental predictors of survival in early stage cervical cancer. *Gynecol Oncol.* 2005;98(1):84-91.
18. **Wright JD**, Davila RM, Pinto KR, Merritt DF, Gibb RK, Rader JS, Mutch DG, Gao F, Powell MA. Cervical dysplasia in adolescents. *Obstet Gynecol.* 2005;106(1):115-120.
19. Kirby TO, Rocconi RP, Numnum TM, Kendrick JE, **Wright JD**, Fowler W, Mutch DG, Bhoola SM, Huh WK, Straughn JM. Outcomes of stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy. *Gynecol Oncol.* 2005;98(2):309-12.

20. **Wright JD**, Dehdashti F, Herzog TJ, Mutch DG, Huettner PC, Rader JS, Gibb RK, Powell MA, Gao F, Siegel BA, Grigsby PW. Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. *Cancer*. 2005;104(11):2484-91.
21. **Wright JD**, Rosenblum K, Huettner PC, Mutch DG, Rader JS, Powell MA, Gibb RK. Cervical sarcomas: an analysis of incidence and outcome. *Gynecol Oncol*. 2005;99(2):348-51.
22. **Wright JD**, Powell MA, Mutch DG, Rader JS, Gibb RK, Gao F, Herzog TJ. Relationship of ovarian neoplasms and body mass index. *J Reprod Med*. 2005;50(8):595-602.
23. **Wright JD**, Rosenbush EJ, Powell MA, Rader JS, Mutch DG, Gao F, Gibb RK. Long-term outcome of women who undergo panniculectomy at the time of gynecologic surgery. *Gynecol Oncol*. 2006;102(1):86-91.
24. **Wright JD**, Rader JS, Davila R, Powell MA, Mutch DG, Gao F, Gibb RK. Human papillomavirus triage for young women with atypical squamous cells of undetermined significance. *Obstet Gynecol*. 2006;107(4):822-829.
25. **Wright JD**, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, Mutch DG, Powell MA. Bevacizumab-combination therapy in relapsed, platinum-refractory, epithelial ovarian carcinoma. *Cancer*. 2006;107(1):83-9.
26. Society of Gynecologic Oncologists Education Resource Panel Writing Group; Collins Y, Einstein MH, Gostout BS, Herzog TJ, Massad LS, Rader JS, **Wright JD**. Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists. *Gynecol Oncol*. 2006;102(3):552-62.
27. **Wright JD**, Viviano D, Powell MA, Gibb RK, Mutch DG, Grigsby PW, Rader JS. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. *Gynecol Oncol*. 2006;103(2):489-93.
28. Baum ME, Rader JS, Gibb RK, McAlister RP, Powell MA, Mutch DG, Gao F, **Wright JD**. Colposcopic accuracy of obstetrics and gynecology residents. *Gynecol Oncol*. 2006;103(3):966-70.
29. Shim TL, **Wright JD**, Rubin BG, Mutch DG. A vascular graft for endometrial cancer groin recurrence. *Gynecol Oncol*. 2007;104(3):753-6.
30. Fayed A, Mutch DG, Rader JS, Gibb RK, Powell MA, **Wright JD**, ElNaqa I, Zoberi I, Grigsby PW. Comparison of high dose rate and low dose rate brachytherapy in the treatment of endometrial carcinoma. *Int J Radiation Oncol Biol Physics*. 2007;67(2):480-4.

31. Lu ZH, **Wright JD**, Belt B, Cardiff RD, Arbeit JM. Hypoxia inducible factor 1 facilitates cervical cancer progression in human papillomavirus type 16 transgenic mice. *Am J Pathol.* 2007;171(2):1-15.
32. **Wright JD**, Powell MA, Rader JS, Mutch DG, Gibb RK. Bevacizumab therapy in patients with recurrent uterine neoplasms. *Anticancer Research.* 2007;27(5B):3525-28.
33. **Wright JD**, Alvarez Secord A, Numnum TM, Rocconi RP, Powell MA, Berchuck A, Alvarez RD, Trinkaus K, Rader JS, Mutch DG. A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent, platinum-resistant ovarian cancer. *Int J Gynecol Cancer.* 2007;17:1-7.
34. **Wright JD**, Grigsby PW, Rader JS, Mutch DG, Powell MA, Rader JS, Gibb RK. Effect of a T0 radical hysterectomy specimen on survival for early stage cervical cancer. *Gynecol Oncol.* 2007;107(2):280-4.
35. **Wright JD**, Grigsby PW, Brooks R, Powell MA, Gibb RK, Gao F, Rader JS, Mutch DG. Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy. *Cancer.* 2007;110(6):181-6.
36. Thomas M, Mariani A, **Wright JD**, Madarek E, Mutch DG, Podratz KC, Dowdy SC. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. *Gynecol Oncol.* 2008;108(2):393-7.
37. **Wright JD**, Doan T, McBride R, Jacobson JS, Hershman D. Variability in chemotherapy for elderly women with advanced stage ovarian cancer and it's impact on survival. *Br J Cancer.* 2008;98(7):1197-1203.
38. **Wright JD**, Tian C, Mutch D, Herzog TJ, Ozols RF, Nagao S, Fujiwara K, Powell MA. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. *Gynecol Oncol.* 2008;109(3):353-8.
39. Scotto L, Narayan G, Nandula SV, Arias-Pulido H, Subramaniam S, Schneider A, Kaufmann AM, **Wright JD**, Pothuri B, Mansukhani M, Murty VV. Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. *Gen Chromosomes Cancer.* 2008;47(9):755-65.
40. Bansal N, **Wright JD**, Cohen CJ, Herzog TH. Natural history of established low grade cervical intraepithelial (CIN1) lesions. *Anticancer Research.* 2008;28:1763-6.
41. Rader JS, Malone JP, Gross J, Gilmore P, Brooks RA, Nguyen L, Crimmins DL, Feng S, **Wright JD**, Taylor N, Zigelboim I, Funk MC, Huettner PC, Ladenson JH, Gius D, Townsend RR. A unified sample preparation protocol for proteomic and genomic profiling of cervical swabs to identify biomarkers for cervical cancer screening. *Proteomics Clin Appl* 2008;2(12):1658-69.

42. Bansal N, Herzog TJ, Seshan VE, Schiff PB, Burke WM, Cohen CJ, **Wright JD**. Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. *Obstet Gynecol*. 2008;112(1):64-70.
43. Scotto L, Narayan G, Nandula SV, Subramaniam S, Kaufmann AM, **Wright JD**, Pothuri B, Mansukhani M, Schneider A, Arias-Pulido H, Murty VV. Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha. *Mol Cancer* 2008;7(1):58.
44. Bansal N, Herzog TJ, Burke W, Cohen CJ, **Wright JD**. The utility of preoperative endometrial sampling for the detection of uterine sarcomas. *Gynecol Oncol* 2008;110(1):43-8.
45. Thomas M, **Wright JD**, Leiser AL, Chi DS, Mutch DG, Podratz KC, Dowdy SC. Clear cell carcinoma of the cervix: A multi-institutional review in the post-DES era. *Gynecol Oncol*. 2008;109(3):335-9.
46. Vallerie AM, Herzog TJ, **Wright JD**. Postpartum sterilization: small incision, big complication. *Obstet Gynecol* 2008;112(2):353-7.
47. Bansal N, Cohen CJ, Shah JN, Schiff PB, Herzog TJ, **Wright JD**. Early metastatic spread after a complete response in locally advanced vulvar cancer treated with neoadjuvant chemoradiation: a case report. *J Reprod Med* 2008;53(9):700-2.
48. Bansal N, Herzog TJ, Brunner-Brown A, Wethington SL, Cohen CJ, Burke WM, **Wright JD**. The utility and cost effectiveness of preoperative computed tomography for patients with uterine malignancies. *Gynecol Oncol* 2008;111(2):208-12.
49. Nguyen TT, **Wright JD**, Powell MA, Gibb RK, Rader JS, Allsworth JE, Mutch DG. Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer. *Int J Gynecol Cancer* 2008;109(3):353-8.
50. **Wright JD**, Seshan VE, Shah M, Schiff PB, Burke WB, Cohen CJ, Herzog TJ. The role of radiation in improving survival for early stage carcinosarcoma and leiomyosarcoma. *Am J Obstet Gynecol* 2008;199(5):536.e1-8.
51. Wethington SL, Herzog TJ, Seshan VE, Bansal N, Schiff PB, Burke WM, Cohen CJ, **Wright JD**. Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer. *Cancer* 2008;113(12):3298-3306.
52. **Wright JD**, Buck AM, Shah M, Burke WM, Schiff PB, Herzog TJ. Safety of ovarian preservation in premenopausal women with endometrial cancer. *J Clin Oncol*. 2009;27(8):1214-19.

53. **Wright JD**, Fiorelli J, Kansler AL, Burke WM, Schiff PB, Cohen CJ, Herzog TJ. Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation. *Am J Obstet Gynecol*. 2009;200(4):419e1-7.
54. **Wright JD**, Fiorelli J, Schiff PB, Burke WM, Kansler AL, Cohen CJ, Herzog TJ. Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. *Cancer*. 2009;115(6):1276-85.
55. Brooks RA, **Wright JD**, Powell MA, Rader JS, Gao F, Mutch DG, Wall LL. Long-term assessment of bladder and bowel dysfunction after radical hysterectomy. *Gynecol Oncol*. 2009;114(1):75-9.
56. Bansal S, Buck AM, Herzog TJ, Deutsch I, Burke WM, **Wright JD**. Stage IIIA endometrial carcinoma: outcome and predictors of survival. *Obstet Gynecol*. 2009;114(1):100-5.
57. **Wright JD**, Shah M, Mathew L, Burke WM, Culhane J, Goldman N, Schiff PB, Herzog TJ. Fertility preservation in young women with epithelial ovarian cancer. *Cancer* 2009;115(18):4118-26.
58. Narayan G, Scotto L, Neelakantan V, Kottoor SH, Wong AH, Loke SL, Mansukhani M, Pothuri B, **Wright JD**, Kaufmann AM, Schneider A, Arias-Pulido H, Tao Q, Murty VV. Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer. *Genes Chromosomes Cancer* 2009;48(11):983-92.
59. Bansal N, Herzog TJ, Shaw RE, Burke WM, Deutsch I, **Wright JD**. Primary therapy for early-stage cervical cancer: radical hysterectomy vs. radiation. *Am J Obstet Gynecol* 2009;201(5):485e1-9.
60. **Wright JD**, Nathavitharana R, Lewin SN, Sun X, Deutsch I, Burke WM, Herzog TJ. Safety and access to fertility-conserving surgery for young women with stage IA1 cervical cancer. *Obstet Gynecol* 2010;115(3):585-90.
61. **Wright JD**, St. Clair CM, Deutsch I, Burke WM, Gorrochurn P, Sun X, Herzog TJ. Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. *Cancer* 2010;116(10):2486-92.
62. **Wright JD**, Devine P, Shah M, Gaddipati S, Lewin SN, Simpson LL, Bonanno C, Sun X, D'Alton ME, Herzog TJ. Morbidity and mortality of peripartum hysterectomy. *Obstet Gynecol* 2010;115(6):1187-93.
63. **Wright JD**, Herzog TJ, Shah M, Bonanno C, Lewin SN, Cleary K, Simpson LL, Gaddipati S, Sun X, D'Alton ME, Devine P. Regionalization of care for obstetric hemorrhage and its effect on maternal mortality. *Obstet Gynecol* 2010;115(6):1194-1200.

64. Park YH, Kim SJ, Jeong BH, Herzog TJ, **Wright JD**, Kitajewski J, Rhim CC, Jang PR, Kang JB, Kim SJ. Follicular stimulating hormone enhances Notch 1 expression in SKOV3 ovarian cancer cells. *J Gynecol Oncol* 2010;21(2):119-24.
65. Bansal S, Lewin SN, Burke WM, Deutsch I, Sun X, Herzog TJ, **Wright JD**. Sarcoma of the cervix: natural history and outcomes. *Gynecol Oncol* 2010;118(2):134-8.
66. St. Clair CM, Shah M, Diver EJ, Lewin SN, Burke WM, Sun X, Herzog TJ, **Wright JD**. Adherence to evidence-based guidelines for preoperative testing in women undergoing gynecologic surgery. *Obstet Gynecol* 2010;116(3):694-700.
67. Arend R, Bagaria M, Lewin SN, Sun X, Deutsch I, Burke WM, Herzog TJ, **Wright JD**. Long-term outcome and natural history of uterine adenosarcomas. *Gynecol Oncol* 2010;119(2):305-8.
68. Lewin SN, Herzog TJ, Barrena Medel NI, Deutsch I, Burke WM, Sun X, **Wright JD**. Comparative performance of the 2009 International Federation of Gynecology and Obstetrics staging system for uterine corpus cancer. *Obstet Gynecol* 2010;116(5):1141-9.
69. Rogo-Gupta LJ, Lewin SN, Kim JH, Burke WM, Sun X, Herzog TJ, **Wright JD**. The effect of surgeon volume on outcomes and resource use for vaginal hysterectomy. *Obstet Gynecol*. 2010;116(6):1341-7.
70. Barrena Medel NI, Herzog TJ, **Wright JD**, Lewin SN. Neoadjuvant bevacizumab in a granulosa cell tumor of the ovary: a case report. *Anticancer Res* 2010;30(11):4767-8.
71. Shah M, Lewin SN, Deutsch I, Burke WM, Sun X, Herzog TJ, **Wright JD**. Therapeutic role of lymphadenectomy for cervical cancer. *Cancer* 2011;117(2):310-7.
72. Brady PC, Chen X, Burke WM, Deutsch I, Sun X, Herzog TJ, **Wright JD**. Detection and significance of parametrial micrometastases in early-stage cervical cancer. *Anticancer Res* 2011;31(1):243-7.
73. Barrena Medel N, Herzog TJ, Deutsch I, Burke WM, Sun X, Lewin SN, **Wright JD**. Comparison of the prognostic significance of uterine factors and nodal status for endometrial cancer. *Am J Obstet Gynecol* 2011;204(3):248:e1-7.
74. **Wright JD**, Lewin SN, Deutsch I, Burke WM, Sun X, Herzog TJ. Effect of surgical volume on morbidity and mortality of abdominal hysterectomy for endometrial cancer. *Obstet Gynecol* 2011;117(5):1051-9.
75. **Wright JD**, Lewin SN, Shah M, Burke WM, Lee SM, Sun X, Herzog TJ. Quality of venous thromboembolism prophylaxis in patients undergoing oncologic surgery. *Ann Surg* 2011;253(6):1140-6.

76. Ritch JM, Kim JH, Lewin SN, Burke WM, Sun X, Herzog TJ, **Wright JD**. Venous thromboembolism and use of prophylaxis among women undergoing laparoscopic hysterectomy. *Obstet Gynecol* 2011;117(6):1367-74.
77. **Wright JD**, Lewin SN, Barrena Medel NI, Sun X, Burke WM, Deutsch I, Herzog TJ. Endometrial cancer in the oldest old: tumor characteristics, patterns of care, and outcome. *Gynecol Oncol* 2011;122(1):69-74.
78. Tong GX, Devaraj K, Hamele-Bena D, Yu WM, Turk A, Chen X, **Wright JD**, Greenbaum E. PAX8: A marker for carcinoma of Mullerian origin in serous effusions. *Diagn Cytopathol* 2011;39(8):562-6.
79. **Wright JD**, Pri-Paz S, Herzog TJ, Shah M, Bonanno C, Lewin SN, Simpson LL, Gaddipati S, Sun X, D'Alton ME, Devine P. Predictors of massive blood loss in women with placenta accreta. *Am J Obstet Gynecol* 2011;205(1):38e1-6.
80. **Wright JD**, Lewin SN, Barrena Medel NI, Sun X, Burke WM, Deutsch I, Herzog TJ. Morbidity and mortality of surgery for endometrial cancer in the oldest old. *Am J Obstet Gynecol* 2011;205(1):66e1-8.
81. **Wright JD**, Pawar N, Gonzalez JSR, Lewin SN, Burke WM, Simpson LL, Charles AS, D'Alton ME, Herzog TJ. Scientific evidence underlying the American College of Obstetricians and Gynecologists' practice bulletins. *Obstet Gynecol* 2011;108(3):505-12. Editorial *Obstet Gynecol* 2011;118(3):501-2.
82. **Wright JD**, Neugut AI, Wilde ET, Buono DL, Malin J, Tsai WY, Hershman DL. Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer. *J Clin Oncol* 2011;29(25):3408-18.
83. **Wright JD**, Lewin SN, Deutsch I, Burke WM, Sun X, Herzog TJ. The influence of surgical volume on morbidity and mortality of radical hysterectomy for cervical cancer. *Am J Obstet Gynecol* 2011;205(3):225e1-7.
84. Schiavone MB, Herzog TJ, Lewin SN, Deutsch I, Sun X, Burke WM, **Wright JD**. Natural history and outcome of mucinous carcinoma of the ovary. *Am J Obstet Gynecol* 2011;205(5):408e1-8.
85. Garg G, Morris RT, Solomon L, Toy EP, Kruger M, Clary K, Munkarah A, **Wright JD**. Evaluating the significance of location of lymph node metastasis and extranodal disease in women with stage IIIC endometrial cancer. *Gynecol Oncol* 2011;123(2):208-13.
86. Schiavone MB, Smok D, Wright TC, **Wright JD**. High-grade uterine sarcoma during pregnancy. *Gynecol Oncol* 2011;123(2):424-5.
87. **Wright JD**, Hershman DL, Shah M, Burke WM, Sun X, Neugut AI, Lewin SN, Herzog TJ. Quality of perioperative venous thromboembolism prophylaxis in gynecologic

- surgery. *Obstet Gynecol* 2011;118(5):978-86. Editorial *Obstet Gynecol* 2011;118(5):973-5.
88. **Wright JD**, Lewin SN, Deutsch I, Burke WM, Sun X, Neugut AI, Herzog TJ, Hershman DL. Defining the limits of radical cytoreductive surgery for ovarian cancer. *Gynecol Oncol* 2011;123(3):467-73.
89. Sharma C, Deutsch I, Lewin SN, Burke WM, Qiao Y, Sun X, Chao CK, Herzog TJ, **Wright JD**. Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer. *Am J Obstet Gynecol* 2011;205(6):562e1-9.
90. Wethington SL, Herzog TJ, Burke WM, Sun X, Lerner JP, Lewin SN, **Wright JD**. Risk and predictors of malignancy in women with endometrial polyps. *Ann Surg Onc* 2011;18(13):3819-23.
91. Stotler B, Padmanabhan A, Devine P, **Wright JD**, Spitalnik SL, Schwartz J. Transfusion requirements in obstetric patients with placenta accreta. *Transfusion* 2011;51(12):2627-33.
92. Spoozak L, Lewin SN, Burke WM, Deutsch I, Sun X, Herzog TJ, **Wright JD**. Microinvasive adenocarcinoma of the cervix. *Am J Obstet Gynecol* 2012;206(1):80e1-6.
93. Berger-Chen S, Herzog TJ, Lewin SN, Burke WM, Neugut AI, Hershman DL, **Wright JD**. Access to conservative surgical therapy for adolescents with benign ovarian masses. *Obstet Gynecol* 2012;119:270-5.
94. Pri-Paz S, Devine PC, Miller RS, Flood PD, Laifer-Narin SL, **Wright JD**. Cesarean hysterectomy requiring emergent thoracotomy: a case report of a complication of placenta percreta requiring a multidisciplinary effort. *J Reprod Med* 2012;57(1-2):58-60.
95. **Wright JD**, Hershman DL, Burke WM, Lu YS, Neugut AI, Lewin SN, Herzog TJ. Influence of surgical volume on outcome for laparoscopic hysterectomy for endometrial cancer. *Ann Surg Oncol* 2012;19(3):948-58.
96. **Wright JD**, Burke WM, Wilde ET, Lewin SN, Charles AS, Kim JH, Goldman N, Neugut AI, Herzog TJ, Hershman DL. Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer. *J Clin Oncol* 2012;30:783-791. Editorial *J Clin Oncol* 2012;30:767-69.
97. Hershman DL, Wilde ET, **Wright JD**, Buono DL, Kalinsky K, Malin JL, Neugut AI. Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer. *J Clin Oncol* 2012;30:806-12. Editorial *J Clin Oncol* 2012;30:772-4.
98. Wallenstein MR, Ananth CV, Kim JH, Burke WM, Hershman DL, Lewin SN, Neugut AI, Lu YS, Herzog TJ, **Wright JD**. Effect of surgical volume on outcomes for

- laparoscopic hysterectomy for benign indications. *Obstet Gynecol* 2012;119(4):709-16.
Editorial *Obstet Gynecol* 2012;119(4):693-4.
99. Galic V, Herzog TJ, Lewin SN, Neugut AI, Burke WM, Lu YS, Hershman DL, **Wright JD**. Prognostic significance of adenocarcinoma histology in women with cervical cancer. *Gynecol Oncol* 2012;125(2):287-91. Editorial *Gynecol Oncol* 2012;125(2):285-6.
 100. Simonds HM, **Wright JD**, du Toit N, Neugut AI, Jacobson JS. Completion of and early response to chemoradiation among human immunodeficiency virus (HIV)-positive and HIV-negative patients with locally advanced cervical carcinoma in South Africa. *Cancer* 2012;118(11):2971-9.
 101. Sharma C, Deutsch I, Horowitz DP, Hershman DL, Lewin SN, Lu YS, Neugut AI, Herzog TJ, Chao CK, **Wright JD**. Patterns of care and treatment outcomes for elderly women with cervical cancer. *Cancer* 2012;118(14):3618-26.
 102. Schiavone MB, Kuo EC, Naumann RW, Burke WM, Lewin SN, Neugut AI, Hershman DL, Herzog TJ, **Wright JD**. The commercialization of robotic surgery: unsubstantiated marketing of gynecologic surgery by hospitals.. *Am J Obstet Gynecol* 2012;207(3):174e1-7.
 103. **Wright JD**, Herzog TJ, Neugut AI, Burke WM, Lu YS, Lewin SN, Hershman DL. Comparative effectiveness of minimally invasive and abdominal radical hysterectomy for cervical cancer. *Gynecol Oncol* 2012;127(1):11-17.
 104. **Wright JD**, Neugut AI, Wilde ET, Buono D, Tsai WT, Hershman DL. Use and benefits of laparoscopic hysterectomy for stage I endometrial cancer among Medicare beneficiaries. *J Oncol Practice* 2012;8(5):e89-99.
 105. **Wright JD**, Govindappagari S, Pawar N, Cleary K, Burke WM, Devine PC, Lu Y, Tsai W, Lewin SN, Herzog TJ. Acceptance and compliance with postpartum human papillomavirus vaccination. *Obstet Gynecol* 2012;120(4):771-82.
 106. **Wright JD**, Herzog TJ, Neugut AI, Burke WM, Lu YS, Lewin SN, Hershman DL. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced stage ovarian cancer. *Obstet Gynecol* 2012;120(4):871-81.
 107. Rogo-Gupta L, Rodriguez LV, Litwin MS, Herzog TJ, Neugut AI, Lu YS, Raz S, Hershman DL, **Wright JD**. Trends in surgical mesh use for pelvic organ prolapse from 2000-2010. *Obstet Gynecol* 2012;120(5):1105-15.
 108. Schiavone MB, Herzog TJ, Ananth CV, Wilde ET, Lewin SN, Burke WM, Lu YS, Neugut AI, Hershman DL, **Wright JD**. Feasibility and economic impact of same-day discharge for women who undergo laparoscopic hysterectomy. *Am J Obstet Gynecol* 2012;207(5):382e1-9.

109. Hershman DL, Richards CA, Kalinsky K, Wilde ET, Lu YS, Ascherman JA, Neugut AI, **Wright JD**. Influence of health insurance, hospital factors and physician volume on receipt of immediate post-mastectomy reconstruction in women with invasive and non-invasive breast cancer. *Breast Cancer Res Treat* 2012;136(2):535-45.
110. **Wright JD**, Herzog TJ, Siddiq Z, Arend R, Neugut AI, Burke WM, Lewin SN, Ananth CV, Hershman DL. Failure to rescue as a source of variation in hospital mortality for ovarian cancer. *J Clin Oncol* 2012;10(32):3976-82.
111. Garg G, Gao F, **Wright JD**, Hagemann AR, Mutch DG, Powell MA. Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer. *Gynecol Oncol* 2013;128(1):77-82.
112. Garg G, Gao F, **Wright JD**, Hagemann AR, Mutch DG, Powell MA. The risk of lymph node metastasis with positive peritoneal cytology in endometrial cancer. *Int J Gynecol Cancer* 2013;23(1):90-7.
113. **Wright JD**, Ananth CV, Lewin SN, Burke WM, Lu YS, Neugut AI, Herzog TJ, Hershman DL. Robotically assisted vs. laparoscopic hysterectomy among women with benign gynecologic disease. *JAMA* 2013;309(7):689-98. Editorial *JAMA* 2013;309(7):721-2.
114. Shah MM, Zerlin M, Li BY, Herzog TJ, Kitajewski JK, **Wright JD**. The role of notch and gamma-secretase inhibition in an ovarian cancer model. *Anticancer Res* 2013;33(3):801-8.
115. Mooney SJ, Winner M, Hershman DL, **Wright JD**, Feingold DL, Allendorf JD, Neugut AI. Bowel obstruction in elderly ovarian cancer patients: A population-based study. *Gynecol Oncol* 2013;129:107-12.
116. **Wright JD**, Neugut AI, Ananth CV, Lewin SN, Wilde ET, Lu YS, Herzog TJ, Hershman DL. Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. *JAMA Intern Med* 2013;173(7):559-68. Editorial *JAMA Intern Med* 2013;173(7):569-70.
117. Perera HK, Ananth CV, Richards CA, Neugut AI, Lewin SN, Lu YS, Herzog TJ, Hershman DL, **Wright JD**. Variation in ovarian conservation in women undergoing hysterectomy for benign indications. *Obstet Gynecol* 2013;121(4):717-26. Editorial *Obstet Gynecol* 2013;121(4):701-2.
118. Winner M, Mooney SJ, Hershman DL, Feingold DL, Allendorf JD, **Wright JD**, Neugut AI. Management and outcomes of bowel obstruction in patients with stage IV colon cancer: A population-based cohort study. *Dis Colon Rectum* 2013;56(7):834-43.

119. **Wright JD**, Neugut AI, Lewin SN, Lu YS, Herzog TJ, Hershman DL. Trends in hospital volume and patterns of referral for women with gynecologic cancers. *Obstet Gynecol* 2013;121(6):1217-25.
120. **Wright JD**, Deutsch I, Wilde ET, Ananth CV, Neugut AI, Lewin SN, Siddiq Z, Herzog TJ, Hershman DL. Uptake and outcomes of intensity-modulated radiation therapy for uterine cancer. *Gynecol Oncol* 2013;130(1):43-8.
121. Zigelboim I, **Wright JD**, Gao F, Case AS, Massad LS, Mutch DG, Powell MA, Thaker PH, Eisenhauer EL, Cohn DE, Valea FA, Alvarez Secord A, Lippmann LT, Dehdashti F, Rader JS. Multicenter phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer. *Gynecol Oncol* 2013;130(1):64-8.
122. Pri-paz S, Fuchs KM, Gaddipati S, Lu YS, **Wright JD**, Devine PC. Comparison between emergent and elective delivery in women with placenta accreta. *J Matern Fetal Neonatal Med* 2013;26(10):1007-11.
123. Spoozak L, Seow H, Liu Y, **Wright JD**, Barbera L. Performance status and symptom scores of women with gynecologic cancer at the end of life. *Int J Gynecol Cancer* 2013;23(5):971-8.
124. **Wright JD**, Herzog TJ, Tsui J, Ananth CV, Lewin SN, Lu YS, Neugut AI, Hershman DL. Nationwide trends in the performance of inpatient hysterectomy in the United States. *Obstet Gynecol* 2013;122(2):233-41.
125. Galic V, Schiavone MB, Herzog TJ, Holcomb K, Lewin SN, Lu YS, Neugut AI, Hershman DL, **Wright JD**. Prognostic significance of mucinous differentiation of endometrioid adenocarcinoma of the endometrium. *Cancer Invest* 2013;31(7):500-4.
126. Sharma C, Deutsch I, Herzog TJ, Lu YS, Neugut AI, Lewin SN, Chao CK, Hershman DL, **Wright JD**. Patterns of care for locally advanced vulvar cancer. *Am J Obstet Gynecol* 2013;209(1):60e1-5.
127. Bashir S, Ananth CV, Lewin SN, Burke WM, Lu, YS, Neugut AI, Herzog TJ, Hershman DL, **Wright JD**. Utilization and safety of sodium hyaluronate-carboxymethylcellulose adhesion barrier. *Dis Colon Rectum* 2013;56(10):1174-84.
128. Winner M, Mooney SJ, Hershman DL, Feingold DL, Allendorf JD, **Wright JD**, Neugut AI. Incidence and predictors of bowel obstruction in elderly patients with stage IV colon cancer: A population-based cohort study. *JAMA Surg* 2013;148(8):715-22.
129. Brady PC, Simpson LL, Lewin SN, Smok D, Lerner JP, D'Alton ME, Herzog TJ, **Wright JD**. Safety of conservative management of ovarian masses during pregnancy. *J Reprod Med* 2013;58(9-10):377-82.

130. Hershman DL, **Wright JD**, Lim E, Buono D, Tsai WY, Neugut AI. “Contraindicated” use of bevacizumab and toxicity in elderly cancer patients. *J Clin Oncol* 2013;31(28):3592-9.
131. **Wright JD**, Silver RM, Bonanno C, Gaddipati S, Lu YS, Simpson LL, Herzog TJ, Schulkin J, D’Alton ME. Practice patterns and knowledge of obstetricians and gynecologists regarding placenta accreta. *J Matern Fetal Neonatal Med* 2013;26(16):1602-9.
132. George EM, Herzog TJ, Neugut AI, Lu YS, Burke WM, Lewin SN, Hershman DL, **Wright JD**. Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome. *Gynecol Oncol* 2013;131(1):42-5.
133. **Wright JD**, Ananth CV, Ojalvo L, Herzog TJ, Lewin SN, Lu YS, Neugut AI, Hershman DL. Failure to rescue after major gynecologic surgery. *Am J Obstet Gynecol* 2013;209:420e1-8.
134. Friedman AM, Ananth CV, Lu YS, D’Alton ME, **Wright JD**. Underuse of post-cesarean thromboembolism prophylaxis. *Obstet Gynecol* 2013;122(6):1197-204.
135. **Wright JD**, Hassan K, Ananth CV, Herzog TJ, Lewin SN, Burke WM, Lu YS, Neugut AI, Hershman DL. Use of guideline-based antibiotic prophylaxis in women undergoing gynecologic surgery. *Obstet Gynecol* 2013;122(6):1145-53. Editorial *Obstet Gynecol* 2013;122(6):1143-4.
136. Hagemann AR, Novetsky AK, Zigelboim I, Gao F, Massad LS, Thaker PH, Powell MA, Mutch DG, **Wright JD**. Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer. *Gynecol Oncol* 2013;131(3):535-40.
137. Samuel A, Bonanno C, Oliphant A, Batey A, **Wright JD**. Fraction of cell-free fetal DNA in the maternal serum as a predictor of abnormal placental invasion—a pilot study. *Prenat Diagn* 2013;33(11):1050-3.
138. Galic V, Shawber CJ, Reeves C, Shah M, Murtomaki A, **Wright JD**, Herzog T, Tong GX, Kitaweski. Notch2 expression is decreased in epithelial ovarian cancer and is related to the tumor histological subtype. *Pathol Discov* 2013;1:4.
139. **Wright JD**, Ananth CV, Lewin SN, Burke WB, Siddiq Z, Neugut AI, Herzog TJ, Hershman DL. Patterns of use of hemostatic agents in patients undergoing major surgery. *J Surg Res* 2014;186(1):458-66.
140. Chen X, Hamela-Bena D, Galic VL, Liu-Jarin X, Ko YC, Herzog T, **Wright JD**, Wright TC. Infiltrating adenomyosis of the cervix with features of a low-grade stromal sarcoma: A case report and a literature review. *Int J Gynecol Pathol* 2014;33(3):253-7.

141. **Wright JD**, Ananth CV, Tsui J, Glied SA, Burke WM, Lu YS, Neugut AI, Herzog TJ, Hershman DL. Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer. *Cancer* 2014;120(8):1246-54.
142. **Wright JD**, Ananth CV, Tergas AI, Herzog TJ, Burke WM, Lewin SN, Lu YS, Neugut AI, Hershman DL. An economic analysis of robotically assisted hysterectomy. *Obstet Gynecol* 2014;123(5):1038-48.
143. George EM, Tergas AI, Ananth CV, Burke WM, Lewin SN, Prendergast E, Neugut AI, Hershman DL, **Wright JD**. Safety and tolerance of radical hysterectomy for cervical cancer in the elderly. *Gynecol Oncol* 2014;134(1):36-41.
144. Son M, Evanko JC, Mongero LB, Lewin SN, Lu YS, Herzog TJ, Kim JH, **Wright JD**. Utility of cell salvage in women undergoing abdominal myomectomy. *Am J Obstet Gynecol* 2014;211(1):28.e1-8.
145. Brubaker SG, Friedman AM, Cleary KL, Prendergast E, D'Alton ME, Ananth CV, **Wright JD**. Patterns of use and predictors of receipt of antibiotics in women undergoing cesarean delivery. *Obstet Gynecol* 2014;124(2):338-44.
146. Woldu SL, Ordonez MA, Devine PC, **Wright JD**. Urologic considerations of placenta accrete: A contemporary tertiary care institutional experience. *Urol Int* 2014;93(1):74-9.
147. Hershman DL, Neugut AI, Shim JJ, Glied S, Tsai WY, **Wright JD**. Erythropoiesis-stimulating agent use after changes in Medicare reimbursement policies. *J Oncol Pract* 2014;10(4):264-9.
148. Weinberg A, **Wright JD**, Deibert C, Lu YS, Hershman DL, Neugut AI, Spencer B. Nationwide practice patterns for the use of venous thromboembolism prophylaxis among men undergoing radical prostatectomy. *World J Urol* 2014;32(5):1313-21.
149. **Wright JD**, Kostolias A, Ananth CV, Burke WM, Tergas AI, Prendergast E, Ramsey SD, Neugut AI, Hershman DL. Comparative effectiveness of robotic-assisted compared to laparoscopic adnexal surgery for benign gynecologic disease. *Obstet Gynecol* 2014;124(5):886-96.
150. **Wright JD**, Tergas AI, Burke WM, Cui RR, Ananth CV, Chen L, Hershman DL. Uterine pathology in women undergoing minimally invasive hysterectomy using morcellation. *JAMA* 2014;312(12):1253-5.
151. Hershman DL, Tsui J, Mayer J, Glied S, Hillyer GC, **Wright JD**, Neugut AI. The change from brand to generic aromatase inhibitors and hormone therapy adherence for early stage breast cancer. *J Natl Can Inst* 2014;106(11):dju319.

152. Friedman AM, Ananth CV, Prendergast E, D'Alton ME, **Wright JD**. Predictors and variation of episiotomy use. *JAMA* 2015;313(2):197-9.
153. **Wright JD**, Tergas AI, Ananth CV, Burke WM, Chen L, Neugut AI, Richards CA, Hershman DL. Relationship between surgical oncologic outcomes and publically reported hospital quality and satisfaction measures. *J Natl Can Inst* 2015;107(1):dju409. Editorial *J Natl Can Inst* 2015;107(1):dju438.
154. Dessources K, Hou JY, Tergas AI, Burke WM, Ananth CV, Prendergast E, Chen L, Neugut AI, Hershman DL, **Wright JD**. Factors associated with thirty-day hospital readmission after hysterectomy. *Obstet Gynecol* 2015;125(2):461-70.
155. Patankar SS, Tergas AI, Deutsch I, Burke WM, Hou JY, Ananth CV, Huang Y, Neugut AI, Hershman DL, **Wright JD**. High versus low-dose rate brachytherapy for cervical cancer. *Gynecol Oncol* 2015;136(3):534-41.
156. Friedman AM, Ananth CV, Prendergast E, Chauhan SP, D'Alton ME, **Wright JD**. Thromboembolism incidence and prophylaxis during vaginal delivery hospitalizations. *Am J Obstet Gynecol* 2015;212(2):221.e1-12.
157. Friedman AM, Ananth CV, Prendergast E, D'Alton ME, **Wright JD**. Evaluation of third-degree and fourth-degree laceration rates as quality indicators. *Obstet Gynecol* 2015;125(4):927-37.
158. Adeleye AJ, Palmeri N, Wang SJ, Liu-Jarin X, **Wright JD**. Spindle cell sarcoma of the vulva with myofibroblastic differentiation. *J Low Genit Tract Dis* 2015;19(2):e38-9.
159. Hershman DL, Tsui J, **Wright JD**, Coromilas EJ, Tsai WY, Neugut AI. Household net worth, racial disparities and hormonal therapy adherence among women with early stage breast cancer. *J Clin Oncol* 2015;33(9):1053-9.
160. **Wright JD**, Tergas AI, Cui R, Burke WM, Hou JY, Ananth CV, Chen L, Richards C, Neugut AI, Hershman DL. Utilization and prevalence of underlying pathology in women who undergo electric power morcellation for myomectomy. *JAMA Oncol* 2015;1(1):69-77. Editorial *JAMA Oncol* 2015;1(1):78-79.
161. Silver RM, Fox KA, Barton J, Abuhamad AZ, Simhan H, Huls CK, Belfort MA, **Wright JD**. Centers of excellence for placenta accreta. *Am J Obstet Gynecol* 2015;212(5):561-8.
162. Dinkelspiel HE, Tergas AI, Zimmerman LA, Burke WM, Hou JY, Chen L, Hillyer G, Neugut AI, Hershman DL, **Wright JD**. Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer. *Gynecol Oncol* 2015;137(2):203-209. Editorial *Gynecol Oncol* 2015;137(2):191-2.

163. **Wright JD**, Chen L, Tergas AI, Patankar S, Burke WM, Hou JY, Neugut AI, Ananth CV, Hershman DL. Trends in relative survival for ovarian cancer from 1975 to 2011. *Obstet Gynecol* 2015;125(6):1345-52.
164. Accordino MK, **Wright JD**, Buono D, Neugut AI, Hershman DL. Trends in use and safety of image-guided transthoracic needle biopsies in cancer patients. *J Oncol* 2015;11(3):e351-9.
165. Patankar S, Burke WM, Hou JY, Tergas AI, Huang Y, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Risk stratification and outcomes of women undergoing surgery for ovarian cancer. *Gynecol Oncol* 2015;138:62-69.
166. Coromilas EJ, **Wright JD**, Huang Y, Neugut AI, Chen L, Hershman DL. The influence of hospital and surgeon factors on the prevalence of axillary evaluation in ductal carcinoma in situ. *JAMA Oncology* 2015;1(3):323-32. Editorial *JAMA Oncol* 2015;1(3):332-33.
167. Friedman AM, Ananth CV, Siddiq Z, D'Alton ME, **Wright JD**. Trends and predictors of cerclage use in the United States from 2005 to 2012. *Obstet Gynecol* 2015;126(2):243-49. Editorial *Obstet Gynecol* 2015;126(2):240-42.
168. Dinkelspiel HD, Champer M, Hou J, Tergas AI, Burke WM, Huang Y, Neugut AI, Ananth CV, Hershman DL, **Wright JD**. Long-term mortality among women with epithelial ovarian cancer. *Gynecol Oncol* 2015;138(2):421-8.
169. **Wright JD**, Cui RR, Wang A, Chen L, Tergas AI, Burke WM, Ananth CV, Hou JY, Neugut AI, Temkin SM, Wang YC, Hershman DL. Economic and survival implications of use of electric power morcellation for hysterectomy for presumed benign gynecologic disease. *J Natl Cancer Inst* 2015;107(11):djv251. Editorial *J Natl Cancer Inst* 2015;107(11):djv283.
170. Jones N, Xiu J, Reddy S, Burke WM, Tergas AI, **Wright JD**, Hou JY. Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma. *Gynecol Oncol* 2015;138(3):620-6.
171. **Wright JD**, Tergas AI, Ananth CV, Burke WM, Hou JY, Chen L, Neugut AI, Richards CA, Hershman DL. Quality and outcomes of treatment of hypercalcemia of malignancy. *Cancer Invest* 2015;33(8):331-9.
172. Malone H, Yang J, Hershman DL, **Wright JD**, Bruce JN, Neugut AI. Complications following stereotactic needle biopsy of intracranial tumors. *World Neurosurg* 2015;84(4):1084-9.
173. Fox KA, Shamshirsaz A, Carusi D, Secord AA, Lee P, Turan O, Huls C, Abuhamad A, Hyagriv S, Barton J, **Wright JD**, Silver R, Belfort MA. Conservative

management of morbidly adherent placenta: clinical commentary. *Am J Obstet Gynecol* 2015;213(6):755-60.

174. Chamie K, Williams SB, Hershman DL, **Wright JD**, Nguyen PL, Hu JC. Population based assessment of determining predictors for quality of prostate cancer surveillance. *Cancer* 2015;121(23):4150-7.
175. **Wright JD**, Chen L, Tergas AI, Burke WM, Hou JY, Neugut AI, Ananth CV, Hershman DL. Population-level trends in relative survival for cervical cancer. *Am J Obstet Gynecol* 2015;213(5):670e1-7.
176. **Wright JD**, Huang Y, Ananth CV, Tergas AI, Duffy C, Deutsch I, Burke WM, Hou JY, Neugut AI, Hershman DL. Influence of treatment center and hospital volume on survival for locally advanced cervical cancer. *Gynecol Oncol* 2015;139(3):506-12.
177. Friedman AM, Ananth CV, Chen L, D'Alton ME, **Wright JD**. An economic analysis of trial of labor after cesarean delivery. *J Matern Fetal Neonatal Med* 2016;29(7):1030-5.
178. Matsuo K, Gualtier M, Jung CE, Cahoon SS, Paulson RJ, Muderspach LI, Wakatsuki A, **Wright JD**, Roman LD. Surgical menopause and increased risk of non-alcoholic fatty liver disease in endometrial cancer. *Menopause* 2016;23(2):189-96.
179. George EM, Burke WM, Hou JY, Tergas AI, Chen L, Neugut AI, Ananth CV, Hershman DL, **Wright JD**. Measurement and validation of frailty as a predictor of outcomes in women undergoing major gynecologic surgery. *BJOG* 2016;123(3):455-61.
180. Accordino MK, **Wright JD**, Vasan S, Neugut AI, Tergas AI, Hershman DL. Serum tumor marker utilization in patients with advanced solid tumors. *J Oncol Practice* 2016;12(1):65-6.
181. Ananth CV, Lavery JA, Vintzileos AM, Skupski DW, Varner M, Saade G, Biggio J, Williams MA, Wapner RJ, **Wright JD**. Severe placental abruption: clinical definition and association with maternal complications. *Am J Obstet Gynecol* 2016;214(2):272.e1-9.
182. Guy MS, Sheeder J, Behbakht K, **Wright JD**, Guntupalli SR. Comparative outcomes in older and younger women undergoing laparotomy or robotic surgical staging for endometrial cancer. *Am J Obstet Gynecol* 2016;214(3):350.e1-10.
183. **Wright JD**, Jorge S, Tergas AI, Hou JY, Burke WM, Huang Y, Hu JC, Ananth CV, Neugut AI, Hershman DL. Utilization and outcomes of ovarian conservation in premenopausal women with endometrial cancer. *Obstet Gynecol* 2016;127(1):101-8.
184. **Wright JD**, Huang Y, Burke WM, Tergas AI, Hou JY, Hu JC, Neugut AI, Ananth CV, Hershman DL. Influence of lymphadenectomy on survival for early-stage endometrial cancer. *Obstet Gynecol* 2016;127(1):109-18.

185. Narayan G, Xie D, Ishdorj G, Scotto L, Mansukhani M, Pothuri B, **Wright JD**, Kaufmann AM, Schneider A, Arias-Pulido H, Murty VV. Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/trail-Cisplatin combination therapy in cervical cancer. *Genes Chromosomes Cancer* 2016;55(2):177-89.
186. Chen X, **Wright JD**, Abellar RG, Koehne de Gonzalez AK, Wright TC, Hamele-Bena D. Cytological features of choriocarcinoma in a Pap smear: a case report and literature review. *Diag Cytopath* 2016;44(4):324-8.
187. Tergas AI, Neugut AI, Chen L, Burke WM, Hershman DL, **Wright JD**. Radiation duration in women with cervical cancer treated with primary chemoradiation: a population-based analysis. *Cancer Invest* 2016;34(3):137-47.
188. **Wright JD**, Tergas AI, Hou JY, Burke WM, Huang Y, Hu JC, Clarke Hillyer G, Ananth CV, Neugut AI, Hershman DL. Trends in periodic surveillance testing for early-stage uterine cancer survivors. *Obstet Gynecol* 2016;127(3):449-58.
189. Jorge S, Hou JY, Tergas AI, Burke WM, Huang Y, Hu JC, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Magnitude of risk for nodal metastasis associated with lymphovascular space invasion for endometrial cancer. *Gynecol Oncol* 2016;140(3):387-93.
190. **Wright JD**, Hou JY, Burke WM, Tergas AI, Chen L, Hu JC, Ananth CV, Neugut AI, Hershman DL. Utilization and toxicity of alternative delivery methods of adjuvant chemotherapy for ovarian cancer. *Obstet Gynecol* 2016;127:985-91. Editorial *Obstet Gynecol* 2016;127:983-4.
191. Chatterjee S, Chen L, Tergas AI, Burke WM, Hou JY, Hu JC, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Utilization and outcomes of chemotherapy in women with intermediate risk, early stage ovarian cancer. *Obstet Gynecol* 2016;127:992-1002.
192. Hershman DL, Unger JM, **Wright JD**, Ramsey S, Till C, Tangen CM, Barlow WE, Blanke C, Thompson IM, Hussain M. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. *JAMA Oncol* 2016;2(4):453-61.
193. **Wright JD**, Burke WM, Tergas AI, Hou JY, Huang Y, Hu JC, Clarke Hillier G, Ananth CV, Neugut AI, Hershman DL. Comparative effectiveness of minimally invasive hysterectomy for endometrial cancer. *J Clin Oncol* 2016;34(10):1087-96.
194. Moroz L, **Wright JD**, Ananth CV, D'Alton ME, Friedman AM. Hospital variation in and predictors of maternal complications following cesarean delivery in the United States: 2006-2010. *BJOG* 2016;123(7):1115-20.

195. Lum DA, Sokol ER, Berek JS, Schulkin J, Chen L, McElwain CA, **Wright JD**. Impact of the 2014 FDA warnings against power morcellation. *J Minim Invasive Gynecol* 2016;23(4):548-56.
196. **Wright JD**, Chen L, Tergas AI, Accordino M, Ananth CV, Neugut AI, Hershman DL. Underuse of BRCA testing in patients with breast and ovarian cancer. *Am J Obstet Gynecol* 2016;214(6):761-3.
197. Margolis B, Tergas AI, Chen L, Hou JY, Burke WM, Hu JC, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Natural history and outcome of neuroendocrine carcinoma of the cervix. *Gynecol Oncol* 2016;141(2):247-54.
198. Cui Z, **Wright JD** Accordino MK, Buono D, Neugut AI, Hu JC, Hershman DL. Safety, utilization, and cost of image-guided percutaneous liver biopsy among cancer patients. *Cancer Invest* 2016;34(4):189-96.
199. **Wright JD**, Chen L, Jorge S, Burke WM, Tergas AI, Hou JY, Hu JC, Neugut AI, Ananth CV, Hershman DL. Prescription of extended-duration thromboprophylaxis after high-risk abdominopelvic cancer surgery. *Gynecol Oncol* 2016;141(3):531-7.
200. Unger JM, Till C, Thompson IM, Tangen CM, Goodman PJ, **Wright JD**, Barlow WE, Ramsey SD, Minasian LM, Hershman DL. Long-term consequences of finasteride versus placebo in the prostate cancer prevention trial. *J Natl Cancer Inst* 108(12):d168.
201. **Wright JD**, Chen L, Burke WM, Hou JY, Tergas AI, Ananth CV, Hershman DL. Trends in use and outcomes of women undergoing hysterectomy with electric power morcellation. *JAMA* 2016;316(8):877-8.
202. Friedman AM, Ananth CV, Huang Y, D'Alton ME, **Wright JD**. Hospital delivery volume, severe obstetrical morbidity, and failure to rescue. *Am J Obstet Gynecol* 2016;125(6):795.e1-795.e14.
203. Yang J, Neugut AI, **Wright JD**, Accordino M, Hershman DL. Nonadherence to oral medications for chronic conditions in breast cancer survivors. *J Oncol Practice* 2016;12(8):e800-9.
204. Coromilas EJ, **Wright JD**, Huang Y, Feldman S, Neugut AI, Hillyer GC, Chen L, Hershman DL. Axillary evaluation and lymphedema in women with ductal carcinoma in situ. *Breast Cancer Res Treat* 2016;158(2):373-84.
205. Hershman DL, Till C, **Wright JD**, Awad D, Ramsey S, Barlow W, Minasian L, Unger JM. Comorbidities and risk of chemotherapy induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group clinical trials. *J Clin Oncol* 2016;34(25):3014-22.

206. Jorge S, Jones N, Chen L, Hou J, Tergas AI, Burke WM, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Characteristics, treatment and outcomes of women with immature ovarian teratoma, 1998-2012. *Gynecol Oncol* 2016;142(2):261-6.
207. Accordino MK, **Wright JD**, Vasan S, Neugut AI, Hillyer GC, Hu JC, Hershman DL. Use and costs of disease monitoring in women with metastatic breast cancer. *J Clin Oncol* 2016;34(24):2820-6.
208. Hershman DL, Kushi LH, Hillyer GC, Coromilas E, Buono D, Lamerato L, Bovbjerg D, Mandelblatt JS, Tsai WY, Zhong X, Jacobson JS, **Wright JD**, Neugut AI. Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL). *Breast Cancer Res Treat* 2016;157(1):133-43.
209. **Wright JD**, Tergas AI, Hou JY, Burke WM, Chen L, Hu JC, Neugut AI, Ananth CV, Hershman DL. Influence of market competition and hospital financial status on use of robotically assisted surgery. *JAMA Surgery* 2016;151(7):612-20. Editorial *JAMA Surgery* 2016;151(7):621.
210. **Wright JD**, Margolis B, Hou JY, Burke WM, Tergas AI, Huang Y, Hu JC, Ananth CV, Neugut AI, Hershman DL. Overuse of external beam radiotherapy for stage I endometrial cancer. *Am J Obstet Gynecol* 2016;215(1):75.e1-7.
211. Brown J, Grudzen C, Kyriacou J, Obermeyer Z, Quest T, Rivera D, Stone S, **Wright JD**, Shelburne N. The emergency care of patients with cancer: setting the research agenda. *Annals Em Med* 2016;68(6):706-11.
212. Friedman AM, Ananth CV, Siddiq Z, D'Alton ME, **Wright JD**. Gastroschisis: epidemiology and mode of delivery, 2005-2013. *Am J Obstet Gynecol* 2016;215(3):348e1-9.
213. Neugut AI, Zhong X, **Wright JD**, Yang J, Hershman DL. Nonadherence to medications for chronic conditions and adherence to adjuvant hormonal therapy in women with breast cancer. *JAMA Oncol* 2016;2(10):1326-32.
214. Friedman AM, **Wright JD**, Ananth CV, Siddiq Z, D'Alton ME, Bateman BT. Population-based risk for peripartum hysterectomy during low and moderate risk delivery hospitalizations. *Am J Obstet Gynecol* 2016;215(5):640.e1-640.e8.
215. Chatterjee S, Chen L, Jones N, Tergas AI, Burke WM, Hou JY, **Wright JD**. National trends in total pelvic exenteration for gynecologic malignancies. *Am J Obstet Gynecol* 2016;215(3):395-6.
216. Hu JC, Chughtai B, O'Malley P, Halpern JA, Mao J, Scherr DS, Hershman DL, **Wright JD**, Sedrakyan A. Perioperative outcomes, health care costs, and survival after

robotic-assisted versus open radical cystectomy: A national comparative effectiveness study. *Eur Urol* 2016;70(1):195-202.

217. Matsuo K, Machida H, Shoupe D, Melamed A, Muderspach LI, Roman LD, **Wright JD**. Ovarian conservation and overall survival in young women with early-stage low-grade endometrial cancer. *Obstet Gynecol* 2016;128(4):761-70.
218. Yoon L, Clarke Hillyer G, Chen L, Hu JC, Neugut AI, Hershman DL, **Wright JD**. Predictors of interventional treatment use for venous thromboembolism in cancer patients. *Cancer Invest* 2016;34(8):408-14.
219. Cham S, Chen L, Burke WM, Hou JY, Tergas AI, Hu JC, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Utilization and outcomes of sentinel lymph node biopsy for vulvar cancer. *Obstet Gynecol* 2016;128(4):754-60.
220. Halpern JA, Shoag JE, Mittal S, Oromendia C, Ballman KV, Hershman DL, **Wright JD**, Shi YCT, Hu JC. Prognostic significance of digital rectal examination and prostate specific antigen in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Arm. *J Urology* 2017;197(2):363-68.
221. Melamed A, Keating NL, Clemmer JT, **Wright JD**, Boruta DM, Schorge JO, del Carmen MG, Rauh-Hain JA. Laparoscopic staging for apparent stage I epithelial ovarian cancer: analysis of the National Cancer Data Base. *Am J Obstet Gynecol* 2017;216(1):50.e1-50.e12.
222. Jones NL, Xiu J, Chatterjee-Paer S, Buckley de Meritens A, Burke WM, Tergas AI, **Wright JD**, Hou JY. Distant molecular landscapes between endometrioid and nonendometrioid uterine carcinomas. *Int J Cancer* 2017;140(6):1396-1404.
223. Jones NL, Schulkin J, Urban R, **Wright JD**, Tergas AI. Physicians' practice patterns and attitudes towards opportunistic salpingectomy without oophorectomy in low risk women and two-step risk-reducing salpingectomies in high-risk women. *Cancer Invest* 2017;35(1):51-61.
224. **Wright JD**, Raglan GB, Fialkow MF, Schulkin J. Attitudes and beliefs regarding the utility of robotically assisted gynecologic surgery among practicing gynecologists. *J Healthcare Qual* 2017;39(4):211-18.
225. Zacharia BE, **Wright JD**, Youngerman B, Bruce S, Hershman DL, Neugut AI, Bruce JN. Quality of perioperative venous thromboembolism prophylaxis in neuro-oncologic surgery. *Neurosurgery* 2017;80(1):73-81.
226. Ananth CV, Lavery JA, Friedman AM, Keyes KM, Hamilton A, **Wright JD**. Primary and repeat cesarean deliveries: a population-based cohort study in the United States, 1979-2010. *Epidemiology* 2017;28(4):567-74.

227. Govindappagari S, Friedman AF, Chen L, Ananth CV, D'Alton ME, Hershman DL, **Wright JD**. Using publicly reported hospital data to predict obstetric quality. *J Matern Fetal Neonatal Med* 2017;30(16):1984-91.
228. Hu JH, O'Malley P, Chughtai B, Isaacs A, Mao J, **Wright JD**, Hershman D, Sedrakyan A. Comparative effectiveness of cancer control and survival after robot assisted versus open radical prostatectomy. *J Urol* 2017;197(1):115-21.
229. Desai VB, Guo XM, Fan L, **Wright JD**, Xu X. Inpatient laparoscopic hysterectomy in the United States: trends and factors associated with approach. *J Minim Invasive Gynecol* 2017;24(1):151-8.e1.
230. Halpern JA, Shoag JE, Artis AS, Ballman K, Sedrakyan A, Hershman DL, **Wright JD**, Shih YC, Hu JC. National trends in prostate biopsy and radical prostatectomy volumes following the United States Preventative Services Task Force guidelines against prostate specific antigen screening. *JAMA Surg* 2017;152(2):192-8.
231. Hehir MP, Ananth CV, **Wright JD**, Siddiq Z, D'Alton ME, Friedman AM. Severe maternal morbidity and comorbid risk in hospitals performing <1000 deliveries per year. *Am J Obstet Gynecol* 2017;216(2):179.e1-179.e12.
232. Matsuo K, Machida H, Shoupe D, Melamed A, Muderspach LI, Roman LD, **Wright JD**. Ovarian conservation and overall survival in young women with early-stage cervical cancer. *Obstet Gynecol* 2017;129(1):139-51.
233. Hu JC, Nguyen P, Mao J, Halpern J, Shoag J, **Wright JD**, Sedrakyan A. Increase in prostate cancer distant metastases at diagnosis in the United States. *JAMA Oncol* 2017;3(5):705-7.
234. Hou JY, Baptiste C, Hombalegowda RB, Tergas AI, Feldman R, Jones NL, Chatterjee-Paer S, Bus-Kwolfski A, **Wright JD**, Burke WM. Vulvar and vaginal melanoma: a unique subclass of mucosal melanoma based on comprehensive molecular analysis of 51 cases compared with 2253 cases of non-gynecologic melanoma. *Cancer* 2017;123(8):1333-44.
235. Govindappagari S, **Wright JD**, Ananth CV, Huang Y, D'Alton ME, Friedman AM. Risk of peripartum hysterectomy and center hysterectomy and delivery volume. *Obstet Gynecol* 2016;128(6):1215-24. Editorial *Obstet Gynecol* 2016;128(6):1203-4.
236. Baptiste CD, de Meritens AB, Jones NL, Chatterjee Paer S, Terags AI, Hou JY, **Wright JD**, Burke WM. Port site metastases: a survey of the Society of Gynecologic Oncology and commentary on the clinical workup and management of port site metastases. *J Minim Invasive Gynecol* 2017;24(4):592-8.

237. Guntupalli SR, Sheeder J, Ioffe Y, Tergas A, **Wright JD**, Davidson S, Behbakht K, Flink DM. Sexual and marital dysfunction in women with gynecologic cancer. *Int J Gynecol Cancer* 2017;27(3):603-7.
238. Accordino MK, **Wright JD**, Vasani S, Neugut AI, Hillyer GC, Hershman DL. Factors and costs associated with delay in treatment initiation and prolonged length of stay with inpatient EPOCH chemotherapy in patients with hematologic malignancies. *Cancer Invest* 2017;35(3):202-14.
239. **Wright JD**, Cham S, Chen L, Burke WM, Hou JY, Tergas AI, Desai V, Hu JC, Ananth CV, Neugut AI, Hershman DL. Utilization of sentinel lymph node biopsy for uterine cancer. *Am J Obstet Gynecol* 2017;216(6):594.e1-594.e13.
240. McLennan AS, Gyamfi-Bannerman C, Ananth CV, **Wright JD**, Siddiq Z, D'Alton ME, Friedman AM. The role of maternal age in twin pregnancy outcomes. *Am J Obstet Gynecol* 2017;217(1):80.e1-80.e8.
241. Hsu JY, Chen L, Gumer AR, Tergas AI, Hou JY, Burke WM, Ananth CV, Hershman DL, **Wright JD**. Disparities in the management of ectopic pregnancy. *Am J Obstet Gynecol* 2017;217(1):49.e1-49.e10.
242. Ananth CV, Friedman AM, Keyes KM, Lavery JA, Hamilton A, **Wright JD**. Primary and repeat Cesarean deliveries: A population-based study in the United States, 1979-2010. *Epidemiology* 2017;28(4):567-74.
243. Cham S, Huang Y, Tergas AI, Hou JY, Burke WM, Deutsch I, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Utility of radiation therapy for early-stage uterine papillary serous carcinoma. *Gynecol Oncol* 2017;145(2):269-76.
244. **Wright JD**, Desai VB, Chen L, Burke WM, Tergas AI, Hou JY, Accordino M, Ananth CV, Neugut AI, Hershman DL. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy. *Am J Obstet Gynecol* 2017;217(1):59.e1-59.e12.
245. **Wright JD**, Chen L, Gabor L, Burke WM, Tergas AI, Hou JY, Ananth CV, Neugut AI, Hershman DL. Patterns of specialty-based referral and perioperative outcomes for women with endometrial cancer undergoing hysterectomy. *Obstet Gynecol* 2017;130(1):81-90.
246. Ananth CV, Lavery JA, Friedman AM, Wapner RJ, **Wright JD**. Serious maternal complications in relation to severe preeclampsia: a retrospective cohort study of the impact of hospital volume. *BJOG* 2017;124(8):1246-53.
247. Lavery J, **Wright JD**, Friedman AM, Keyes K, Ananth CV. Gestational diabetes in the United States: temporal changes in prevalence rates between 1979 and 2010. *BJOG* 2017;124(5):804-13.

248. Matsuo K, Machida H, Horowitz MP, Shahzad MMK, Guntupallil SR, Roman LD, **Wright JD**. Risk of metachronous ovarian cancer after ovarian conservation in young women with stage I cervical cancer. *Am J Obstet Gynecol* 2017;217(5):58-e1-58-e10.
249. Mardy AH, Siddiq Z, Ananth CV, **Wright JD**, D'Alton ME, Friedman AM. Venous thromboembolism prophylaxis during antepartum admissions and postpartum readmissions. *Obstet Gynecol* 2017;130(2):270-78.
250. Matsuo K, Machida H, Stone RL, Soliman PT, Thaker PH, Roman LD, **Wright JD**. Risk of subsequent ovarian cancer after ovarian conservation in young women with endometrioid endometrial cancer. *Obstet Gynecol* 2017;130(2):403-10.
251. Chen X, Arend R, Hamele-Bena D, Tergas AI, Hawver M, Tong GX, **Wright JD**. Uterine carcinosarcomas: clinical, histopathologic and immunohistochemical characteristics. *Int J Gynecol Pathol* 2017;36(5):412-19.
252. Margolis B, Chen L, Accordino MK, Hillyer GC, Hou JY, Tergas AI, Neugut AI, Ananth CV, Hershman DL, **Wright JD**. Trends in end of life care and healthcare spending in women with uterine cancer. *Am J Obstet Gynecol* 2017;217(4):434.e1-434.e10.
253. Accordino MK, **Wright JD**, Vasan S, Neugut AI, Gross T, Hillyer GC, Hershman DL. Association between survival time with metastatic breast cancer and aggressive end-of-life care. *Breast Cancer Res Treat* 2017;166(2):549-58.
254. Buckley de Meritens A, Margolis B, Blinderman C, Prigerson HG, Maciejewski PK, Shen MJ, Hou JY, Burke WM, **Wright JD**, Tergas AI. Practice patterns, attitudes, and barriers to palliative care consultation by gynecologic oncologists. *J Oncol Pract* 2017;13(9):e703-e711.
255. **Wright JD**, Chen L, Hou JY, Burke WM, Tergas AI, Ananth CV, Neugut AI, Hershman DL. Association of hospital volume and quality of care with survival for ovarian cancer. *Obstet Gynecol* 2017;130(3):545-53.
256. Ruiz MP, Huang Y, Hou JY, Tergas AI, Burke WM, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. All-cause mortality in young women with endometrial cancer receiving progesterone therapy. *Am J Obstet Gynecol* 2017;217(6):669.e.13.
257. Matsuo K, Machida H, Frimer M, Marcus JZ, Pejovic T, Roman LD, **Wright JD**. Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer. *Gynecol Oncol* 2017;147(3):558-64.

258. Cohen ME, Salmasian H, Li J, Liu J, Zachariah P, **Wright JD**, Freedberg DE. Surgical antibiotic prophylaxis and risk for postoperative antibiotic-resistant infections. *J Am Coll Surg* 2017;225(5):631-638.e3.
259. Bercow AS, Chen L, Chatterjee S, Tergas AI, Hou JY, Burke WM, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Cost of care for the initial management of ovarian cancer. *Obstet Gynecol* 2017;130(6):1269-75.
260. Hershman DL, Till C, **Wright JD**, Ramsey S, Barlow WE, Unger JM. History of diabetes and survival outcome among participants 65 years or older in SWOG clinical trials. *JCO Clin Cancer Inform* 2017;1:1-12.
261. Merriam AA, **Wright JD**, Siddiq Z, D'Alton ME, Friedman AM, Ananth CV, Bateman BT. Risk for postpartum hemorrhage, transfusion, and hemorrhage-related morbidity at low, moderate, and high volume hospitals. *J Mat Fetal Med* 2018;31(8):1025-34.
262. Wu CC, Wu YR, Yanagihara T, Jani A, Xanthopoulos EP, Tiwari A, **Wright JD**, Burke WM, Hou JY, Tergas AI, Deutsch I. Rectal balloon use limits vaginal displacement, rectal dose, and rectal toxicity in patients receiving IMRT for postoperative gynecological malignancies. *Med Dosim* 2018;43(1):23-29.
263. Margolis B, Blinderman C, de Meritens AB, Chatterjee-Paer S, Ratan RB, Prigerson HG, Hou JY, Burke WM, **Wright JD**, Tergas AI. Educational intervention to improve code status discussion proficiency among obstetrics and gynecology residents. *Am J Hosp Palliat Care* 2018;35(4):724-30.
264. Jones NL, Chen L, Chatterjee S, Tergas AI, Burke WM, Hou JY, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. National trends in extended procedures for ovarian cancer debulking surgery. *Int J Gynecol Cancer* 2018;28(1):19-25.
265. Youngerman BE, Neugut AI, Yang J, Hershman DL, **Wright JD**, Bruce JN. The modified frailty index and 30-day adverse events in oncologic neurosurgery. *J Neurooncol* 2018;136(1):197-296.
266. Champer M, Huaung Y, Hou JY, Tergas AI, Burke WM, Hillyer GC, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence. *Gynecol Oncol* 2018;148(1):19-27.
267. Mukerji B, Baptiste C, Chen L, Tergas AI, Hou JY, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Racial disparities in young women with endometrial cancer. *Gynecol Oncol* 2018;148(3):527-34.

268. Hehir MP, Rouse DJ, Miller RS, Ananth CV, **Wright JD**, Siddiq Z, D'Alton ME, Friedman AM. Second-stage duration and outcomes among women who labored after a prior cesarean delivery. *Obstet Gynecol* 2018;131(3):514-22.
269. Cleary KL, Siddiq Z, Ananth CV, **Wright JD**, Too G, D'Alton ME, Friedman AM. Use of antihypertensive medications during delivery hospitalization complicated by preeclampsia. *Obstet Gynecol* 2018;131(3):441-50.
270. Malone H, Cloney M, Yang J, Hershman DL, **Wright JD**, Neugut AI, Bruce JN. Failure to rescue and mortality following resection of intracranial neoplasms. *Neurosurgery* 2018;83(2):263-69.
271. Richards CA, Rundle AG, **Wright JD**, Hershman DL. Association between hospital financial distress and immediate breast reconstruction surgery after mastectomy among women with ductal carcinoma in situ. *JAMA* 2018;153(4):344-51.
272. Sagaram D, Siddiq Z, Eisenberger AB, Ananth CV, **Wright JD**, D'Alton ME, Friedman AM. Heparin-induced thrombocytopenia during obstetric hospital admissions. *Am J Perinatol* 2018;35(9):898-903.
273. Buskwofie A, Huang Y, Tergas AI, Hou JY, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Impact of hospital volume on racial disparities and outcomes for endometrial cancer. *Gynecol Oncol* 2018;149(2):329-36.
274. Desai VB, **Wright JD**, Schwartz PE, Jorgensen EM, Fan L, Litkouhi B, Lin H, Gross CP, Xu X. Occult gynecologic cancer in women undergoing hysterectomy or myomectomy for benign indications. *Obstet Gynecol* 2018;131(4):642-51.
275. Meriam AA, Huang Y, Ananth CV, **Wright JD**, D'Alton ME, Friedman AM. Postpartum thromboembolism prophylaxis during delivery hospitalizations. *Am J Perinatol* 2018;35(9):873-81.
276. Gomez-Hidalgo NR, Chen L, Hou JY, Tergas AI, St. Clair CM, Ananth CV, Hershman DL, **Wright JD**. Trends in sentinel lymph node mapping and adjuvant therapy in endometrial carcinoma. *Cancer Invest* 2018;36(3):190-98.
277. Agrawal S, Chen L, Tergas AI, Hou JY, St. Clair CM, Ananth CV, Hershman DL, **Wright JD**. Identifying modifiable and non-modifiable risk factors associated with prolonged length of stay after hysterectomy for uterine cancer. *Gynecol Oncol* 2018;149(3):545-53.
278. Ruiz MP, Chen L, Hou JY, Tergas AI, St. Clair CM, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Outcomes of hysterectomy performed by very low-volume surgeons. *Obstet Gynecol* 2018;131(6):981-90. Editorial *Obstet Gynecol* 2018;131(6):977-79.

279. Buckley de Meritens A, Baptiste C, Hou JY, Burke WM, **Wright JD**, Tegas A. A pilot randomized controlled trial of a preoperative patient education intervention to improve satisfaction and reduce resource utilization in gynecologic surgery. *Cur Op Gyn Obs* 2018;1(1):82-87.
280. Cui RR, Chen L, Tegas AI, Hou JY, St. Clair CM, Neugut AI, Ananth CV, Hershman DL, **Wright JD**. Trends in use and survival associated with fertility-sparing trachelectomy for young women with early-stage cervical cancer. *Obstet Gynecol* 2018;131(6):1085-94.
281. Agrawal S, Chen L, Tegas AI, Hou JY, St. Clair CM, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Characteristics associated with prolonged length of stay after hysterectomy for benign gynecologic conditions. *Am J Obstet Gynecol* 2018;219(1):89.e1-89.e15.
282. Booker WA, Siddiq Z, Huang Y, Ananth CV, **Wright JD**, Cleary KL, D'Alton ME, Friedman AM. Use of antihypertensive medications and uterotonics during delivery hospitalizations in women with asthma. *Obstet Gynecol* 2018;132(1):185-92.
283. **Wright JD**, Ruiz MP, Chen L, Gabor LR, Tegas AI, St. Clair CM, Hou JY, Ananth CV, Neugut AI, Hershman DL. Changes in surgical volume and outcomes over time for women undergoing hysterectomy for endometrial cancer. *Obstet Gynecol* 2018;132(1):59-69.
284. Hershman DL, Till C, Shen S, **Wright JD**, Ramsey S, Barlow WE, Unger JM. Association of cardiovascular risk factors with cardiac events and survival outcomes among patients with breast cancer enrolled in SWOG clinical trials. *J Clin Oncol* 2018;36(26):2710-17.
285. Gyamfi-Bannerman C, Srinivas SK, **Wright JD**, Goffman D, Siddiq Z, D'Alton ME, Friedman AM. Postpartum hemorrhage outcomes and race. *Am J Obstet Gynecol* 2018;219(2):185e1-185e10.
286. Accordino MK, **Wright JD**, Vasan S, Buono DL, Hu JC, Neugut AI, Hershman DL. Assessment of electronic alert to reduce overuse of granulocyte colony-stimulating factor in patients hospitalized for febrile neutropenia. *JAMA Oncol* 2018;4(7):996-98.
287. Nieto VL, Huang Y, Hou JY, Tegas AI, St. Clair CM, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Use and outcomes of minimally invasive hysterectomy for women with non-endometrioid endometrial cancer. *Am J Obstet Gynecol* 2018;219(5):463:e1-463.e12.
288. Ruiz MP, Chen L, Hou JY, Tegas AI, St. Clair CM, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Effect of minimum-volume standards on patient outcomes and surgical practice patterns for hysterectomy. *Obstet Gynecol* 2018;132(5):1229-37.

289. Leng S, Lentzsch S, Shen Y, Tsai WY, **Wright JD**, Hershman DL, Neugut AI. Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors. *Leuk Lymphoma* 2018;59(10):2465-69.
290. Selter J, Huang Y, Grossman Becht LC, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Utilization of ovarian transposition for fertility preservation among young women with pelvic malignancies who undergo radiotherapy. *Am J Obstet Gynecol* 2018;219(4):415-17.
291. Matsuo K, Machida H, Blake EA, Holman LL, Rimel BJ, Roman LD, **Wright JD**. Trends and outcomes of women with synchronous endometrial and ovarian cancer. *Oncotarget* 2018;9(47):28,757-71.
292. Booker WA, Gyamfi-Bannerman C, Sheen JJ, **Wright JD**, Siddiq Z, D'Alton ME, Friedman AM. Maternal outcomes by race for women aged 40 years or older. *Obstet Gynecol* 2018;132(2):404-13.
293. Wen T, **Wright JD**, Goffman D, D'Alton ME, Mack WJ, Attenello FJ, Friedman AM. Postpartum venous thromboembolism readmissions in the United States. *Am J Obstet Gynecol* 2018;219(4):401.e1-401.e14.
294. Matsuo K, Machida H, Mariani A, Mandelbaum RS, Glaser GE, Gostout BS, Roman LD, **Wright JD**. Adequate pelvic lymphadenectomy and survival of women with early-stage epithelial ovarian cancer. *J Gynecol Oncol* 2018;29(5):e69.
295. Webster EM, Burke WM, Ware HM, Jones BA, Vattakalam R, Tergas AI, **Wright JD**, Hou JY. Patient reported outcomes in evaluation of chemotherapy toxicity in women with gynecologic malignancies: a pilot study. *Gynecol Oncol* 2018;150(3):487-93.
296. Matsuo K, Blake EA, Machida H, Mandelbaum RS, Roman LD, **Wright JD**. Incidence and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis. *Gynecol Oncol* 2018;150(3):501-8.
297. Ananth CV, Friedman AM, Goldenberg RL, **Wright JD**, Vintzileos AM. Association between temporal changes in neonatal mortality and spontaneous and clinician-initiated deliveries in the United States, 2006-2013. *JAMA Pediatr* 2018;172(10):949-57.
298. Machida H, Mandelbaum RS, Mikami M, Enomoto T, Sonoda Y, Grubbs BH, Paulson RJ, Roman LD, **Wright JD**, Matsuo K. Characteristics and outcomes of reproductive-aged women with early-stage cervical cancer: trachelectomy versus hysterectomy. *Am J Obstet Gynecol* 2018;219(5):461.e1-461.e18.

299. Sheen JJ, **Wright JD**, Goffman D, Kern-Goldberger AR, Booker W, Siddiqui Z, D'Alton ME, Friedman AM. Maternal age and risk for adverse outcomes. *Am J Obstet Gynecol* 2018;219(4):390.e1-390.e15.
300. Matsuo K, Machida H, Mandelbaum RS, Ragab OM, Roman LD, **Wright JD**. Tumor-specific outcome of metachronous uterine malignancy after pelvic irradiation for cervical cancer. *Gynecol Oncol* 2018;151(2):250-56.
301. Duffy CR, **Wright JD**, Landau R, Mourad MJ, Siddiq Z, Kern-Goldberger AR, D'Alton ME, Friedman AM. Trends and outcomes associated with using long-acting opioids during delivery hospitalizations. *Obstet Gynecol* 2018;132(4):937-47.
302. Matsuo K, Machida H, Mandelbaum RS, Mikami M, Enomoto T, Roman LD, **Wright JD**. Trachelectomy for stage IB1 cervical cancer with tumor size >2 cm: trends and characteristics in the United States. *J Gynecol Oncol* 2018;29(6):e85.
303. Matsuo K, Mandelbaum RS, Machida H, Purshotham S, Grubbs BH, Roman LD, **Wright JD**. Association of tumor differentiation grade and survival of women with squamous cell carcinoma of the uterine cervix. *J Gynecol Oncol* 2018;29(6):e91.
304. Melamed A, Margul DJ, Chen L, Keating NL, Del Carmen MG, Yang J, Seagle BL, Alexander A, Barber EL, Rice LW, **Wright JD**, Kocherginsky M, Shahabi S, Rauh-Hain JA. Survival after minimally invasive radical hysterectomy for early-stage cervical cancer. *N Engl J Med* 2018;379(20):1905-14. *Editorial N Engl J Med* 2018;379(20):1955-57.
305. Quyyumi FF, **Wright JD**, Accordino MK, Buono D, Law CW, Hillyer GC, Neugut AI, Hershman DL. Factors associated with follow-up care among women with early-stage breast cancer. *J Oncol Pract* 2019;15(1):e1-e9.
306. **Wright JD**, Chen L, Accordino M, Taback B, Ananth CV, Neugut AI, Hershman DL. Regional market competition and the use of immediate breast reconstruction after mastectomy. *Ann Surg Oncol* 2019;26(1):62-70.
307. Leng S, Chen Y, Tsai WY, Bhutani D, Hillyer GC, Lim E, Accordino MK, **Wright JD**, Hershman DL, Lentzsch S, Neugut AI. Use of bisphosphonates in elderly patients with newly diagnosed multiple myeloma. *J Natl Compr Canc Netw* 2019;17(1):22-28.
308. Matsuo K, Chen L, Mandelbaum RS, Melamed A, Roman LD, **Wright JD**. Trachelectomy for reproductive-aged women with early-stage cervical cancer: minimally-invasive surgery versus laparotomy. *Am J Obstet Gynecol* 2019;220(5):469e13. *Editorial Am J Obstet Gynecol* 2019;220(5):417-419.
309. Booker W, Ananth CV, **Wright JD**, Siddiq Z, D'Alton ME, Cleary KL, Goffman D, Friedman AM. Trends in comorbidity, acuity, and maternal risk associated with

preeclampsia across obstetric volume settings. *J Matern Fetal Neonatal Med* 2019;32(16):2680-87.

310. Cham S, Chen L, St. Clair CM, Hou JY, Tergas AI, Melamed A, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer. *Am J Obstet Gynecol* 2019;220(6):571.e1-e8.
311. Aziz A, Gyamfi-Bannerman C, Siddiq Z, **Wright JD**, Goffman D, Sheen JJ, D'Alton ME, Friedman AM. Maternal outcomes by race during postpartum readmissions. *Am J Obstet Gynecol* 2019;220(5):484.e1-484.e10.
312. Wen T, **Wright JD**, Goffman D, D'Alton ME, Attenello FJ, Mack WJ, Friedman AM. Hypertensive postpartum admissions among women without a history of hypertension or preeclampsia. *Obstet Gynecol* 2019;133(4):712-19.
313. Matsuo K, Mandelbaum RS, Adams CL, Roman LD, **Wright JD**. Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study. *Gynecol Oncol* 2019;153(2):368-75.
314. Neugut AI, Lin A, Raab GT, Hillyer GC, Keller D, O'Neil DS, Accordino MK, Kiran RP, **Wright JD**, Hershman DL. FOLFOX and FOLFIRI use in stage IV colon cancer: analysis of SEER-Medicare data. *Clin Colorectal Cancer* 2019;18(2):133-40.
315. Desai VB, **Wright JD**, Lin H, Gross CP, Sallah YH, Schwartz PE, Xu X. Laparoscopic hysterectomy route, resource use, and outcomes: change after power morcellation warning. *Obstet Gynecol* 2019;134(2):227-38. Editorial *Obstet Gynecol* 2019;134(2):225-26.
316. Desai VB, **Wright JD**, Gross CP, Lin H, Boscoe FP, Hutchison LM, Schwartz PE, Xu X. Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy. *Am J Obstet Gynecol* 2019;221(1):39e1-39e14.
317. Tergas AI, Prigerson HG, Shen MJ, Bates LM, Neugut AI, **Wright JD**, Maciejewski PK. Latino ethnicity, immigrant status, and preference for end-of-life cancer care. *J Palliat Med* 2019;22(7):833-37.
318. Mandelbaum RS, Chen L, Shoupe D, Paulson RJ, Roman LD, **Wright JD**, Matsuo K. Patterns of utilization and outcome of ovarian conservation for young women with minimal-risk endometrial cancer. *Gynecol Oncol* 2019;154(1):45-52.
319. **Wright JD**, Huang Y, Melamed A, Tergas AI, St. Clair CM, Hou JY, Khoury-Collado F, Ananth CV, Neugut AI, Hershman DL. Potential consequences of minimum-volume standards for hospitals treating women with ovarian cancer. *Obstet Gynecol* 2019;133(6):1109-1119.

320. Desai VB, **Wright JD**, Gross CP, Lin H, Boscoe FP, Schwartz PE, Xu X. Risk of unexpected uterine cancer in women undergoing myomectomy: A population-based study. *Eur J Obstet Gynecol Reprod Biol* 2019;238:188-90.
321. Matsuo K, Mandelbaum RS, Machida H, Yoshihara K, Muggia FM, Roman LD, **Wright JD**. Decreasing secondary primary uterine cancer after breast cancer: A population-based analysis. *Gynecol Oncol* 2019;154(1):169-176.
322. Matsuo K, Mandelbaum RS, Machida H, Yoshihara K, Muggia FM, Roman LD, **Wright JD**. Decreasing trends of secondary primary colorectal cancer among women with uterine cancer: A population-based analysis. *J Clin Med* 2019;8(5):pii:E714.
323. Krigel A, Chen L, **Wright JD**, Lebwohl B. Substantial increase in anesthesia assistance for outpatient colonoscopy and associated cost nationwide. *Clin Gastroenterol Hepatol* 2019;17(12):2489-96.
324. Heilbroner SP, Xanthopoulos EP, Buono D, Huang Y, Carrier D, Shah A, Kim J, Corradetti M, **Wright JD**, Neugut AI, Hershman DL, Cheng SK. Impact of estrogen monotherapy on survival in women with stage III-IV non-small cell lung cancer. *Lung Cancer* 2019;129:8-15.
325. Melamed A, Bercow AS, Bunnell K, Rauh-Hain JA, **Wright JD**, Rice LW, Del Carmen MG. Age-associated risk of 90-day postoperative mortality after cytoreductive surgery for advanced ovarian cancer. *JAMA Surg* 2019;154(7):669-71.
326. Praiss AM, Chen L, St. Clair CM, Tergas AI, Khoury-Collado F, Hou JY, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Safety of same day discharge for minimally invasive hysterectomy for endometrial cancer. *Am J Obstet Gynecol* 2019;221(3):329.e1-239.e11.
327. Selter J, Huang Y, Grossman Becht LC, Palmerola KL, Williams SZ, Forman E, Ananth CV, Hur C, Neugut AI, Hershman DL, **Wright JD**. Use of fertility preservation services in female reproductive-age cancer patients. *Am J Obstet Gynecol* 2019;221(4):328.e1-328.e16.
328. **Wright JD**, Chen L, Buskwofie A, Tergas AI, St. Clair CM, Hou JY, Khoury-Collado F, Ananth CV, Hur C, Neugut AI, Hershman DL. Regionalization of care for women with ovarian cancer. *Gynecol Oncol* 2019;154(2):394-400.
329. Syeda S, Chen L, Hou JY, Tergas AI, Khoury-Collado F, Melamed A, St. Clair CM, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Chemotherapy, radiation, or combination therapy for stage III uterine cancer. *Obstet Gynecol* 2019;134(1):17-29.
330. **Wright JD**, Matsuo K, Huang Y, Tergas AI, Hou JY, Khoury-Collado F, St. Clair CM, Ananth CV, Neugut AI, Hershman DL. Prognostic performance of the 2018

International Federation of Gynecology and Obstetrics cervical cancer staging guidelines. *Obstet Gynecol* 2019;134(1):49-57.

331. Raab GT, Lin A, Hillyer GC, Keller D, O'Neil DS, Accordino, MA, Buono DL, Hur C, Kiran RP, **Wright JD**, Hershman DL, Neugut AI. Use of bevacizumab for elderly patients with stage IV colon cancer: analysis of SEER-Medicare data. *Clin Colorectal Cancer* 2019;18(3):e294-99.
332. Matsuo K, Huang Y, Zivanovic O, Shimada M, Machida H, Grubbs BH, Roman LD, **Wright JD**. Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer. *Gynecol Oncol* 2019;154(3):505-15.
333. Quyyumi FF, **Wright JD**, Accordino MK, Buono D, Law CW, Hillyer GC, Neugut AI, Hershman DL. Factors associated with multidisciplinary consultations in patients with early stage breast cancer. *Cancer Invest* 2019;37(6):233-41.
334. **Wright JD**, Huang Y, Melamed A, Tergas AI, St. Clair CM, Hou JY, Khoury-Collado F, Ananth CV, Neugut AI, Hershman DL. Use and misuse of opioids after gynecologic surgical procedures. *Obstet Gynecol* 2019;134(2):250-60.
335. Latham AH, Chen L, Hou JY, Tergas AI, Khoury-Collado F, St. Clair CM, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Sequencing of therapy in women with stage III endometrial carcinoma receiving adjuvant combination chemotherapy and radiation. *Gynecol Oncol* 2019;155(1):13-20.
336. Matsuo K, Cripe JC, Kumit KC, Kaneda M, Garneau AS, Glaser GE, Nizam A, Schillinger RM, Kuznicki ML, Yabuno A, Yanai S, Garofalo DM, Suzuki J, St. Laurent JD, Yen TT, Liu AY, Shida M, Kakuda M, Oishi T, Nishio S, Marcus JZ, Adachi S, Kurokawa T, Ross MS, Horowitz MP, Johnson MS, Kim MK, Melamed A, Machado KK, Yoshihara K, Yoshida Y, Enomoto T, Ushijima K, Satoh S, Ueda Y, Mikami M, Rimel BJ, Stone RL, Growdon WB, Okamoto A, Guntupalli SR, Hasegawa K, Shahzad MMI, Im DD, Frimer M, Gostout BS, Ueland FR, Nagao S, Soliman PT, Thaker PH, **Wright JD**, Roman LD. Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer. *Gynecol Oncol* 2019;155(1):39-50.
337. Lin AJ, **Wright JD**, Dehdashti F, Siegel BA, Markovina S, Schwarz J, Thaker PH, Mutch DG, Powell MA, Grigsby PW. Impact of tumor histology on detection of pelvic and para-aortic nodal metastasis with 18F-fluorodeoxyglucose-positron emission tomography in stage IB cervical cancer. *Int J Gynecol Cancer* 2019;29(9):1351-54.
338. Andrikopoulou M, Huang Y, Duffy CR, Stern-Ascher CN, **Wright JD**, Goffman D, D'Alton ME, Friedman AM. Antibiotic use without indication during delivery hospitalizations in the United States. *Obstet Gynecol* 2019;134(4):718-25.

339. Xu X, Lin H, **Wright JD**, Gross CP, Boscoe FP, Hutchison LM, Schwartz PE, Desai VB. Association between power morcellation and mortality in women with unexpected uterine cancer undergoing hysterectomy or myomectomy. *J Clin Oncol* 2019;37(35):3412-24.
340. Schlechtweg K, Chen L, St. Clair CM, Tergas AI, Khoury-Collado F, Hou JY, Melamed A, Neugut AI, Hershman DL, **Wright JD**. Neuroendocrine carcinoma of the endometrium: disease course, treatment and outcomes. *Gynecol Oncol* 2019;155(2):254-61.
341. Gamble CR, Huang Y, Tergas AI, Khoury-Collado F, Hou JY, St. Clair CM, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Quality of care and outcomes of patients with gynecologic malignancies treated at safety-net hospitals. *JNCI Cancer Spectr* 2019;3(3):pkz039.
342. Lietz AP, Weaver DT, Melamed A, Rauh-Hain JA, **Wright JD**, Wright AA, Knudsen AB, Pandharipande PV. Potential survival benefits from optimized chemotherapy implementation in advanced ovarian cancer: projections from a microsimulation model. *PLoS One* 2019;14(9):e0222828.
343. Gamble CR, Huang Y, Frey MK, **Wright JD**. Careing for patients with uterine cancer in rural and public hospitals. *Obstet Gynecol* 2019;134(6):1260-68.
344. Sia TY, Chen L, Melamed A, Tergas AI, Khoury-Collado F, Hou JY, St. Clair CM, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Trends in use and effect on survival of simple hysterectomy for early-stage cervical cancer. *Obstet Gynecol* 2019;134(6):1132-43. Editorial *Obstet Gynecol* 2019;134(6):1129-31.
345. Sheen JJ, Huang Y, Andrikopoulou M, **Wright JD**, Goffman D, D'Alton ME, Friedman AM. Maternal age and preeclampsia outcomes during delivery hospitalization. *Am J Perinatol* 2020;37(1):44-52.
346. Knisely A, Huang Y, Melamed A, Tergas AI, St. Clair CM, Hou JY, Khoury-Collado F, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Effect of regionalization of endometrial cancer care on site of care and patient travel. *Am J Obstet Gynecol* 2020;222(1):58.e1-58.e10.
347. Stern-Ascher CN, Huang Y, Duffy CR, Andrikopoulou M, **Wright JD**, Goffman D, D'Alton ME, Friedman AM. Antibiotics for 3rd and 4th degree vaginal lacerations, uterine tamponade, and manual placental extraction. *Am J Perinatol* 2020;37(1):92-103.
348. Duffy CR, Huang Y, Andrikopoulou M, Stern-Ascher CN, **Wright JD**, Goffman D, D'Alton ME, Friedman AM. Clindamycin, gentamicin, and risk of clostridium difficile infection and acute kidney injury during delivery hospitalization. *Obstet Gynecol* 2020;135(1):59-67.

349. Youngerman BE, Joiner EF, Wang X, Yang J, Welch MR, McKhann GM, **Wright JD**, Hershamn DL, Neugut AI, Bruce JN. Patterns of seizure prophylaxis after oncologic neurosurgery. *J Neurooncol* 2020;146(1):171-80.
350. Wen T, Yu VX, **Wright JD**, Goffman D, Attenello F, Mack WJ, D'Alton M, Friedman AM. Postpartum length of stay and risk for readmission among women with preeclampsia. *J Matern Fetal Neonatal Med* 2020;33(7): 1086-94.
351. Mourad M, Landau R, **Wright JD**, Siddiq Z, Duffy CR, Kern-Goldberger AR, D'Alton ME, Friedman AM. Oral opioid use during vaginal delivery hospitalizations. *Am J Perinatol* 2020;37(4):390-7.
352. Cham S, Wen T, Friedman A, **Wright JD**. Fragmentation of postoperative care after surgical management of ovarian cancer at 30-days and 90-days. *Am J Obstet Gynecol* 2020;222(3):255e1-255e20.
353. Hershman DL, Accordino MK, Shen S, Buono D, Crew KD, Kalinsky K, Trivedi MS, Hur C, Hu J, Unger JM, **Wright JD**. Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. *Cancer* 2020;26(7):1541-49.
354. Faye AS, Wen T, Ananthkrishnan AN, Lichtiger S, Kaplan GG, Friedman AM, Lawlor G, **Wright JD**, Attenello FJ, Macck WJ, Lebwahl B. Acute venous thromboembolism risk highest within 60 days after discharge from the hospital in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol* 2020;18(5):1133-41.
355. Matsuo K, Machida H, Matsuzaki S, Grubbs BH, Klar M, Roman LD, Sood AK, Gershenson DM, **Wright JD**. Evolving population-based statistics for rare epithelial ovarian cancers. *Gynecol Oncol* 2020;157(1):3-11.
356. Wen T, Krenitsky NM, Clapp MA, D'Alton ME, **Wright JD**, Attenello F, Mack WJ, Friedman AM. Fragmentation of postpartum readmissions in the United States. *Am J Obstet Gynecol* 2020;223(2):252.e1-e14.
357. Miller EC, Zambrano Espinoza MD, Huang Y, Friedman AM, Boehme AK, Bello NA, Kleary KL, **Wright JD**, D'Alton ME. Maternal race/ethnicity, hypertension, and risk for stroke during delivery admission. *J Am Heart Assoc* 2020;9(3):e014775.
358. Matsuo K, Klar M, Mandelbaum RS, Matsuzaki S, Matsushima K, Roman LD, **Wright JD**. Minimally invasive interval debulking surgery after neoadjuvant chemotherapy for metastatic ovarian cancer: a national study in the United States. *Arch Gynecol Obstet* 2020;301(3):863-66.
359. Matsuo K, Matsuzaki S, Mandelbaum RS, Matasushima K, Klar M, Grubbs BH, Roman LD, **Wright JD**. Association between hospital surgical volume and perioperative

outcomes of fertility-sparing trachelectomy for cervical cancer: A national study in the United States. *Gynecol Oncol* 2020;157(1):173-80.

360. Meriam AA, Huang Y, **Wright JD**, Goffman D, D'Alton ME, Friedman AM. Use of uterine tamponade and interventional radiology procedures during delivery hospitalizations. *Obstet Gynecol* 2020;135(3):674-84.
361. Aviki EM, Chen L, Dessources K, Leitao M, **Wright JD**. Impact of hospital volume on surgical management and outcomes for early-stage cervical cancer. *Gynecol Oncol* 2020;157(2):508-13.
362. Matsuo K, Nusbaum DJ, Machida H, Huang Y, Khetan V, Matsuzaki S, Klar M, Grubbs BH, Roman LD, **Wright JD**. Populational trends and outcomes of postoperative radiotherapy for high-risk early-stage cervical cancer with lymph node metastasis: concurrent chemo-radiotherapy versus radiotherapy alone. *Am J Obstet Gynecol* 2020;222(5):484.e1-e15.
363. Margolis B, Cagle-Colon K, Chen L, Tergas AI, Boyd L, **Wright JD**. Prognostic significance of lymphovascular space invasion for stage IA1 and IA2 cervical cancer. *Int J Gynecol Cancer* 2020;30(6):735-43.
364. Matsuo K, Mandelbaum RS, Machida H, Yoshihara K, Matsuzaki S, Klar M, Muggia FM, Roman LD, **Wright JD**. Temporal trends of subsequent breast cancer among women with ovarian cancer: a population-based study. *Arch Gynecol Obstet* 2020;301(5):1235-45.
365. Praiss AM, Huang Y, St. Clair CM, Tergas AI, Melamed A, Khoury-Collado F, Hou JY, Hur C, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. A modern assessment of the surgical pathologic spread and nodal dissemination of endometrial cancer. *Gynecol Oncol* 2020;157(2):329-34.
366. Huang AB, Huang Y, Hur C, Tergas AI, Khoury-Collado F, Melamed A, St. Clair CM, Hou JY, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Impact of quality of care on racial disparities in survival for endometrial cancer. *Am J Obstet Gynecol* 2020;223(3):396.e1-e13. Editorial *Am J Obstet Gynecol* 2020;223(3):309-11.
367. Hershman DL, Till C, **Wright JD**, Accordino M, Vaidya R, Barlow WE, Ramsey S, Unger JM. Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials. *Breast Cancer Res Treat* 2020;181(2):455-63.
368. Matsuo K, Chang EJ, Matsuzaki S, Manelbaum RS, Matsushima K, Grubbs BH, Klar M, Roman LD, Sood AK, **Wright JD**. Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes. *Gynecol Oncol* 2020;158(1):59-65.

369. Hou JY, **Wright JD**, Achariyapota V. An application of ERBB2 receptor inhibitors in a rare case of S310F somatic ERBB2 mutation of primary signet-ring cell adenocarcinoma of vagina: A case report and review literature of S310F somatic ERBB2 mutation in breast and gynecologic cancers. *Gynecol Oncol Rep* 2020;May 1;32:100577.
370. Matsuo K, Matsuzaki S, Nusbaum DJ, Machida H, Nagase Y, Grubbs RH, Roman LD, **Wright JD**, Harter P, Klar M. Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer. *Eur J Cancer* 2020;133:33-46.
371. Knisely A, Huang Y, Melamed A, Tergas AI, St. Clair CM, Hou JY, Khoury-Collado F, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Travel distance, hospital volume and their association with ovarian cancer short- and long-term outcomes. *Gynecol Oncol* 2020;158(2):415-23.
372. Matsuo K, Matsuzaki S, Mandelbaum RS, Chang EJ, Klar M, Matsushima K, Grubbs BH, Roman LD, **Wright JD**. Minimally invasive radical hysterectomy for early-stage cervical cancer: volume-outcome relationship in the early experience period. *Gynecol Oncol* 2020;158(2):390-96.
373. Nitecki R, Ramirez PT, Frumovitz M, Krause KJ, Tergas AI, **Wright JD**, Rauh-Hain JA, Melamed A. Survival after minimally invasive vs. open radical hysterectomy for early-stage cervical cancer: A systematic review and meta-analysis. *JAMA Oncol* 2020;6(7):1019-27. Editorial *JAMA Oncol* 2020;6(7):991-93.
374. Matsuo K, Huang Y, Matsuzaki S, Klar M, Roman LD, Sood AK, **Wright JD**. Minimally invasive surgery and risk of capsule rupture for women with early-stage ovarian cancer. *JAMA Oncol* 2020;6(7):1110-13. Editorial *JAMA Oncol* 2020;6(7):991-93.
375. Emeruwa UN, Ona S, Shaman JL, Turitz A, **Wright JD**, Gyamfi-Bannerman C, Melamed A. Associations between built environment, neighborhood socioeconomic status and SARS-CoV-2 infection among pregnant women in New York City. *JAMA* 2020;324(4):390-92.
376. Syeda SK, Chen L, Hou JY, Tergas AI, Khoury-Collado F, Melamed A, St. Clair CS, Accordino MK, Neugut AI, Hershman DL, **Wright JD**. Trends in venous thromboembolism prophylaxis in gynecologic surgery for benign and malignant indications. *Arch Gynecol Obstet* 2020;302(4):935-45.
377. Wu J, Huang Y, Tergas AI, Melamed A, Khoury-Collado F, Hou JY, St. Clair CM, Ananth CV, Hershman DL, **Wright JD**. The effect of guideline-concordant care in mitigating insurance status disparities in cervical cancer. *Gynecol Oncol* 2020;159:309-16. Editorial *Gynecol Oncol* 2020;159:297-98.

378. Gyamfi-Bannerman C, Pandita A, Miller EC, Boehme AK, **Wright JD**, Siddiq Z, D’Alton ME, Friedman AM. Preeclampsia outcomes at delivery and race. *J Matern Fetal Neonatal Med* 2020;33(21):3619-26.
379. Kern Goldberger AR, Huang Y, Polin M, Siddiq Z, **Wright JD**, D’Alton ME, Friedman AM. Opioid use disorder during antepartum and postpartum hospitalizations. *Am J Perinatol* 2020;37(14):1467-75.
380. Mandelbaum RS, Adams CL, Yoshihara K, Nusbaum DJ, Matsuzaki S, Matsushima K, Klar M, Paulson RJ, Roman LD, **Wright JD**, Matsuo K. The rapid adoption of opportunistic salpingectomy at the time of hysterectomy for benign gynecological disease in the United States. *Am J Obstet Gynecol* 2020;223(5):721.e1-721.e18.
381. Accordino MK, **Wright JD**, Buono D, Lin A, Huang Y, Neugut AI, Hillyer GC, Hershman DL. Incidence and predictors of diabetes mellitus after a diagnosis of early-stage breast cancer in the elderly using real-world data. *Breast Cancer Res Treat* 2020;183(1):201-11.
382. Matsuo K, Nusbaum DJ, Matsuzaki S, Chang EJ, Roman LD, **Wright JD**, Harter P, Klar M. Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer. *Gynecol Oncol* 2020;159(1):43-51.
383. Lara OD, O’Cearbhaill RE, Smith MJ, Sutter ME, Knisley A, McEachron J, Gabor LR, Jee J, Fehniger JE, Lee YC, Isani SS, **Wright JD**, Pothuri B. COVID-19 outcomes of patients with gynecologic cancer in New York City. *Cancer* 2020;126(19):4294-4303.
384. Huang Y, Jacobson JS, Tergas AI, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Insurance-associated disparities in opioid use and misuse among patients undergoing gynecologic surgery for benign indications. *Obstet Gynecol* 2020;136(3):565-75.
385. Knisely A, Wu J, Kaplan SJ, Zhou ZN, Melamed A, Tergas AI, St. Clair CM, Hou JY, Khoury-Collado F, Huang YY, Hershman DL, **Wright JD**. Coronavirus spectrum infections (COVID-19, MERS, SARS) in cancer patients: a systematic review of the literature. *Cancer Invest* 2020;38(8-9):436-4.
386. Sia TY, Wen T, Cham S, **Wright JD**. Effect of frailty on postoperative readmissions and cost of care for ovarian cancer. *Gynecol Oncol* 2020;159(2):426-33.
387. Knisely AT, St. Clair CM, Hou JY, Collado FK, Hershman DL, **Wright JD**, Melamed A. Trends in primary treatment and median survival among women with advanced-stage epithelial ovarian cancer in the US from 2004 to 2016. *JAMA Netw Open* 2020;3(9):e2017517.

388. Matsuo K, Huang Y, Matsuzaki S, Klar M, **Wright JD**. Effect of delay in surgical therapy for early-stage cervical cancer: an implication in the coronavirus pandemic. *Eur J Cancer* 2020;139:173-76.
389. Chen LC, Huang Y, Hou JY, Khoury-Collado F, Melamed A, St. Clair CM, Tergas AI, Hur C, Hillyer GC, Hershman DL, **Wright JD**. Toxicity after adjuvant therapy for stage III uterine cancer. *Gynecol Oncol* 2020;159(3):737-43.
390. Wu J, Logue T, Kaplan SJ, Melamed A, Tergas AI, Khoury-Collado F, Hou JY, St. Clair CM, Hershman DL, **Wright JD**. Less-radical surgery for early stage cervical cancer: a systematic review. *Am J Obstet Gynecol* 2021;224(4):348-58.e5.
391. Praiss AM, Huang Y, St. Clair CM, Tergas AI, Melamed A, Khoury-Collado F, Hou JY, Hu J, Hur C, Hershman DL, **Wright JD**. Using machine learning to create prognostic systems for endometrial cancer. *Gynecol Oncol* 2020;159(3):744-50.
392. Smith M, Lara OD, O’Cearbhail R, Knisely A, McEachron J, Gabor L, Carr C, Blank S, Prasad-Hayes M, Frey M, Jee J, Fehniger J, Wang Y, Lee YC, Isani S, **Wright JD**, Pothuri B. Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection. *Gynecol Oncol* 2020;159(3):618-22.
393. Gemmell LC, **Wright JD**, Brady PC. Triple stimulation (TriStim) before bilateral oophorectomy in a young woman with ovarian cancer: a case report and review of the literature. *Fertil Res Pract* 2020;6:17.
394. Knisely A, Zhou ZN, Wu J, Huang Y, Holcomb K, Melamed A, Advincula AP, Lalwani A, Khoury-Collado F, Tergas AI, St. Clair CM, Hou JY, Hershman DL, D’Alton ME, Huang Y, **Wright JD**. Perioperative morbidity and mortality of patients with COVID-19 who undergo urgent and emergent surgical procedures. *Ann Surg* 2021;273(1):34-40.
395. Blanco M, Chen L, Melamed A, Tergas AI, Khoury-Collado F, Hou JY, St. Clair CM, Ananth CV, Neugut AI, Hershman DL, **Wright JD**. Cost of care for the initial management of cervical cancer in women with commercial insurance. *Am J Obstet Gynecol* 2021;224(3):286.e1-e11.
396. Fein A, Wen T, **Wright JD**, Goffman D, D’Alton ME, Attenello FJ, Mack WJ, Friedman AM. Postpartum hemorrhage and risk for postpartum readmission. *J Matern Fetal Neonatal Med* 2021;34(2):187-94.
397. Wen T, Fein AW, Wright JD, Mack WJ, Attenello FJ, D’Alton ME, **Wright JD**, Friedman AM. Postpartum psychiatric admissions in the United States. *Am J Perinatol* 2021;38(2):115-21.

398. Seguin CL, Lietz AP, **Wright JD**, Wright AA, Knudsen AB, Pandharipande PV. Surveillance in older women with incidental ovarian cysts: maximal projected benefits by age and comorbidity level. *J Am Coll Radiol* 2021;18(1 Pt A):10-18.
399. Matsuo K, Mandelbaum RS, Nusbaum DJ, Matsuzaki S, Klar M, Roman LD, **Wright JD**. National trends and outcomes of morbidly obese women who underwent inpatient hysterectomy for benign gynecological disease in the United States. *Acta Obstet Gynecol Scand* 2021;100(3):459-70.
400. Matsuo K, Matsuzaki S, Roman LD, Klar M, **Wright JD**. Proposal of an endometrial cancer staging schema with stage-specific incorporation of malignant peritoneal cytology. *Am J Obstet Gynecol* 2021;224(3):319-21.
401. Knisely A, Gamble CR, St. Clair CM, Hou JY, Khoury-Collado F, Gockley A, **Wright JD**, Melamed A. The role of minimally invasive surgery in the care of women with ovarian cancer: a systematic review and meta-analysis. *J Minim Invasive Gynecol* 2021;28(3):537-43.
402. Straubhar AM, Wolf JL, Zhou MQC, Iasonos A, Cham S, **Wright JD**, Long Roche K, Chi DS, Zivanovic O. Advanced ovarian cancer and cytoreductive surgery: independent validation of a risk-calculator for perioperative adverse events. *Gynecol Oncol* 2021;160(2):438-44.
403. Lara OD, Smith MJ, Wang Y, O’Cearbhaill R, Blank SV, Kolev V, Carr C, Knisely A, McEachron J, Gabor L, Chapman-Davis E, Jee J, Fenhiger J, Lee YC, Isani S, Liu M, **Wright JD**, Pothuri B. Racial disparities in patients with coronavirus disease 2019 infection and gynecologic malignancy. *Cancer* 2021;127(7):1057-67.
404. Tobias CJ, Chen L, Melamed A, St. Clair C, Khoury-Collado F, Tergas AI, Hou JY, Hur C, Ananth CCV, Neugut AI, Hershman DL, **Wright JD**. Association of neoadjuvant chemotherapy with overall survival in women with metastatic endometrial cancer. *JAMA Netw Open* 2020;3(12):e2028612.
405. Liang MI, Chen L, Hershman DL, Hillyer GC, Huh WK, Guyton A, **Wright JD**. Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients. *Gynecol Oncol* 2021;160(3):793-99.
406. Matsuo K, Matsuzaki S, Mandelbaum RS, Kanao H, Change EJ, Klar M, Roman LD, **Wright JD**. Utilization and perioperative outcome of minimally invasive pelvic exenteration in gynecologic malignancies: A national study in the United States. *Gynecol Oncol* 2021;161(1):39-45.
407. Ke J, Shen Y, Lu Y, Deng J, **Wright JD**, Zhang Y, Huang Q, Wang D, Jing N, Liang X, Jiang F. Quantitative analysis of abnormalities in gynecologic cytopathology with deep learning. *Lab Invest* 2021;101(4):513-24.

408. Sia TY, Wen T, Cham S, Friedman AM, **Wright JD**. The effect of frailty on postoperative readmissions, morbidity, and mortality in endometrial cancer surgery. *Gynecol Oncol* 2021;161(2):353-60.
409. Selter J, Huang J, Williams SZ, Brady PC, Melamed A, Hershman DL, **Wright JD**. Use of fertility preservation services in male reproductive-age cancer patients. *Gynecol Oncol Rep* 2021;36:100716.
410. Matsuo K, Huang Y, Matsuzaki S, Ragab OM, Roman LD, **Wright JD**. Association between definitive chemoradiotherapy wait-time and survival in locally-advanced cervical cancer: Implications during the coronavirus pandemic. *Gynecol Oncol* 2021;161(2):414-21.
411. **Wright JD**, Chen L, Tergas AI, Melamed A, St. Clair CM, Hou JY, Khoury-Collado F, Gockley A, Accordino M, Hershman DL. Overuse of cervical cancer screening tests among women with average risk in the United States from 2013 to 2014. *JAMA Netw Open* 2021;4(4):e218373.
412. **Wright JD**, Cogan JC, Huang Y, Tergas AI, St. Clair CM, Hou JY, Khoury-Collado F, Gockley A, Accordino M, Melamed A, Hershman DL. *JAMA Netw Open* 2021;4(6):e2112478.
413. Fialkow M, Castleberry N, **Wright JD**, Schulkin J, Desia VB. Physician attitudes and knowledge on prophylactic salpingectomy in perimenopausal patients. *Gynecol Oncol Rep*; 2021;37:100824.
414. **Wright JD**, Silver ER, Tan SX, Hur C, Kastrinos F. Cost-effectiveness analysis of genotype-specific surveillance and preventive strategies for gynecologic cancers among women with Lynch syndrome. *JAMA Netw Open* 2021;4(9):e2123616. Editorial *JAMA Netw Open* 2021;4(9):e2124384.
415. Thornton AT, Huang Y, Mourad MJ, **Wright JD**, D'Alton ME, Friedman MA. Obstetric outcomes among women with a liver transplant. *J Matern Fetal Neonatal Med In Press*.
416. Couret M, Huang Y, Khoury-Collado F, Friedman A, Hou JY, St. Clair CM, Tergas AI, Ananth CV, **Wright JD**. Patterns of care for women with placenta accreta spectrum. *J Matern Fetal Neonatal Med In Press*.
417. Matsuo K, Matsuzaki S, Mandelbaum RS, Matsushima K, Klar M, Grubbs BH, Roman LD, **Wright JD**. Hospital surgical volume and perioperative mortality of pelvic exenteration for gynecologic malignancies. *J Surg Oncol In Press*.
418. Kuo JH, Huang Y, Kluger MD, Hershman DL, Chabot JA, Lee JA, **Wright JD**. Use and misuse of opioids after endocrine surgery operations. *Ann Surg In Press*.

419. Duffy CR, Huang Y, Andrikopoulou M, Stern-Ascher CN, **Wright JD**, D'Alton ME, Friedman AM. Vancomycin during delivery hospitalizations for women with group B streptococcus. *J Matern Fetal Neonatal Med In Press*.
420. McKinley LP, Wen T, Gyamfi-Bannerman C, **Wright JD**, Goffman D, Sheen JJ, D'Allton ME, Friedman AM. Hospital safety-net burden and risk for readmissions and severe maternal morbidity. *Am J Perinatol In Press*.
421. Huang YY, Chen L, **Wright JD**. Comparison of perioperative outcomes in heart failure patients with reduced versus preserved ejection fraction after noncardiac surgery. *Ann Surg In Press*.
422. Bello N, Huang Y, Syeda SK, **Wright JD**, D'Alton ME, Friedman AM. Receipt of proton-pump inhibitors during pregnancy and risk for preeclampsia. *Am J Perinatol In Press*.
423. Bousleiman S, Rouse DJ, Gyamfi-Bannerman C, Huang Y, D'Alton ME, Siddiq Z, **Wright JD**, Friedman AM. Decision to incision and risk for fetal acidemia, low Apgar scores, and hypoxi ischemic encephalopathy. *Am J Perinatol In Press*.
424. Blackett JW, Chen L, Li J, **Wright JD**, Freedberg DE. Inappropriateness of proton pump inhibitors after hospital discharge associated with thirty-day readmission. *Dig Dis Sci In Press*.
425. Matsuo K, Klar M, Harter P, Miller H, Nusbaum DJ, Matsuzaki S, Roman LD, **Wright JD**. Trends in peritoneal cytology evaluation at hysterectomy for endometrial cancer in the United States. *Gynecol Oncol In Press*.
426. Syeda SK, Wen T, **Wright JD**, Goffman D, A'Alton ME, Friedman AM. Postpartum cardiac readmissions among women without a cardiac diagnosis at delivery. *J Matern Fetal Neonatal Med In Press*.
427. Xu X, Desai VB, **Wright JD**, Lin H, Schwartz PE, Gross CP. Hospital variation in responses to safety warnings about power morcellation in hysterectomy. *Am J Obstet Gynecol In Press*.
428. Satish T, Raghunathan R, Prigoff JG, **Wright JD**, Hillyer GA, Trivedi MS, Kalinsky K, Crew KD, Hershman DL, Accordino MK. Care delivery impact of the COVID-19 pandemic on breast cancer care. *JCO Oncol Pract In Press*.
429. Ona S, Huang Y, Ananth CV, Gyamfii-Bannerman C, Wen T, **Wright JD**, D'Alton ME, Friedman AM. Services and payer mix of black-serving hospitals and related severe maternal morbidity. *Am J Obstet Gynecol In Press*.
430. Sia TY, Huang Y, Gockley A, Melamed A, Khoury- Collado F, St. Clair C, Hou JY, Tergas AI, Hershman DL, **Wright JD**. Trends in ovarian conservation and assocaiton

with survival in premenopausal patients with stage I leiomyosarcoma. *Gynecol Oncol In Press*.

431. **Wright JD**, Chen L, Hur HC, Melamed A, Hershman DL. Trends in use of myomectomy for the surgical management of uterine leiomyomas in perimenopausal and postmenopausal women. *Obstet Gynecol In Press*.
432. Dioun S, Chen L, Melamed A, Gockley A, St. Clair CM, Hou JY, Tergas AI, Khoury-Collado F, Hur C, Hershman DL, **Wright JD**. Uptake and outcomes of sentinel lymph node mapping in women with atypical endometrial hyperplasia. *Obstet Gynecol In Press*.
433. Schuster M, Ananth CV, Gomez D, Huang Y, Gyamfi-Bannerman C, **Wright JD**, D'Alton ME, Friedman AM. 17-alpha hydroxyprogesterone caproate and risk for venous thromboembolism during pregnancy. *J Matern Fetal Neonatal Med In Press*.
434. O'Shaugnessy F, Syeda SK, Huang Y, D'Alton ME, Wen T, **Wright JD**, Friedman AM. Receipt of anticoagulation after venous thromboembolism diagnoses during delivery hospitalizations. *J Matern Fetal Neonatal Med In Press*.
435. Krenitsky NM, Huang Y, Wen T, Ona S, **Wright JD**, D'Alton ME, Friedman AM. Longitudinal risk adjustment for maternal end-organ injury and death. *J Matern Fetal Neonatal Med In Press*.
436. Wen T, Liao L, Kern-Goldberger A, Guglielminotti J, Gyamfi-Bannerman C, **Wright JD**, D'Alton ME, Friedman AM. Risk for and temporal trends in cesarean surgical complications. *J Matern Fetal Neonatal Med In Press*.
437. Wen T, Faye AS, Lee KE, Friedman AM, **Wright JD**, Lebowhl B, Colombel JF. Risk of postpartum flare hospitalizations in patients with inflammatory bowel disease persists after six months. *Dig Dis Sci In Press*.
438. Albright BB, Monuszko KA, Kaplan SJ, Davidson BA, Moss HA, Huang AB, Melamed A, **Wright JD**, Havrilesky LJ, Previs RA. Primary cytoreductive surgery for advanced stage endometrial cancer: A systematic review and meta-analysis. *Am J Obstet Gynecol In Press*.
439. Gamble CR, Huang Y, **Wright JD**, Hou JY. Precision medicine testing in ovarian cancer: The growing inequity between patients with commercial vs. Medicaid insurance. *Gynecol Oncol In Press*.
440. Cham S, Huang Y, Melamed A, Worley MJ, Hou JY, Tergas AI, Khoury-Collado F, Gockley A, St. Clair CM, Hershman DL, **Wright JD**. Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with survival. *Gynecol Oncol In Press*.

441. Matsuo K, Mandelbaum RS, Klar M, Ciesielski KM, Matsushima K, Matsuzaki S, Roman LD, **Wright JD**. Decreasing utilization of minimally invasive hysterectomy for cervical cancer in the United States. *Gynecol Oncol In Press*.
442. Bogardus MH, Wen T, Gyamfi-Bannerman C, **Wright JD**, Goffman D, Sheen JJ, D'Alton ME, Friedman AM. Racial and ethnic disparities in peripartum hysterectomy risk and outcomes. *Am J Perinatol In Press*.
443. Cogan JC, Raghunathan RR, Beauchemin MP, Accordino MK, Elkin EB, Melamed A, **Wright JD**, Hershman DL. New and persistent controlled substance use among patients undergoing mastectomy and reconstructive surgery. *Breast Cancer Res Treat In Press*.
444. Gyamfi-Bannerman C, Huang Y, Bateman BT, Benson RJ, Pack AM, **Wright JD**, D'Alton ME, Friedman AM. Maternal morbidity and mortality associated with epilepsy. *J Matern Fetal Neonatal Med In Press*.
445. **Wright JD**, Huang Y, Melamed A, Albright AA, Hillyer GC, Previs R, Hershman DL. Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer. *Gynecol Oncol In Press*.
446. Mandelbaum RS, Matsuzaki S, Sangara RN, Klar M, Matsushima K, Roman LD, Paulson RJ, **Wright JD**, Matsuo K. Paradigm shift from tubal ligation to opportunistic salpingectomy at cesarean delivery in the United States. *Am J Obstet Gynecol In Press*.
447. Dioun S, Wu J, Chen L, Kaplan S, Huang Y, Melamed A, Gockley A, St. Clair CM, Hou JY, Tergas AI, Khoury-Collado F, Machida H, Mikami M, Matsuo K, Hershman DL, **Wright JD**. Intraoperative rupture of the ovarian capsule in early-stage ovarian cancer: A meta-analysis. *Obstet Gynecol In Press*.
448. Knisely A, Huang Y, Melamed A, Gockley A, Tergas AI, St. Clair CM, Hou JY, Khoury-Collado F, Accordino M, Hershman DL, **Wright JD**. Disparities in access to high-volume surgeons within high-volume hospitals for hysterectomy. *Obstet Gynecol In Press*.
449. Kho RM, Desai VB, Schwartz PE, **Wright JD**, Gross CP, Hutchison LM, Boscoe FP, Lin H, Xu X. Endometrial sampling for preoperative diagnosis of uterine leiomyosarcoma. *J Minim Invasive Gynecol In Press*.
450. Matsuo K, Huang Y, Matsuzaki S, Deshpande RR, Klar M, Roman LD, **Wright JD**. Association between hysterectomy wait-time and all-cause mortality for micro-invasive cervical cancer: treatment implications during the coronavirus pandemic. *Arch Gynecol Obstet In Press*.

451. Matsuo K, Klar M, Mohrbacher AF, Roman LD, **Wright JD**. Secondary hematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy. *Eur J Cancer In Press*.
452. Moss HA, Chen L, Hershman DL, Davidson B, **Wright JD**. Adherence to PARP inhibitor therapy among women with ovarian cancer. *Gynecol Oncol In Press*.
453. Logue TC, Wen T, Monk C, Guglielminotti J, Huang Y, **Wright JD**, D'Alton ME, Friedman AM. Trends in and complications associated with delivery hospitalizations with mental health condition diagnoses. *Am J Obstet Gynecol In Press*.
454. Melamed A, Rauh-Hain JA, Gockley AA, Nitecki R, Ramirez PT, Hershman DL, Keating N, **Wright JD**. Association between overall survival and the tendency for cancer programs to administer neoadjuvant chemotherapy for patients with advanced ovarian cancer. *JAMA Oncol In Press*.
455. Dioun S, Huang Y, Melamed A, Gockley A, St. Clair CM, Hou JY, Tergas AI, Khoury-Collado F, Hershman DL, **Wright JD**. Trends in use of minimally invasive adnexal surgery in the United States. *Obstet Gynecol In Press*.
456. Dioun S, Chen L, Melamed A, Gockley A, St. Clair CM, Hou JY, Tergas AI, Khoury-Collado F, Elkin E, Accordino M, Hershman DL, **Wright JD**. Minimally invasive surgery for suspected early-stage ovarian cancer: a cost-effectiveness study. *BJOG In Press*.

INVITED ARTICLES

1. **Wright JD**, Herzog TJ. Human papillomavirus: emerging trends in detection and management. *Current Women's Health Reports*. 2002;2:259-265.
2. **Wright JD**, Pinto AB. Clinical manifestations and treatment of gout. *Primary Care Update for OB/GYN* 2002.
3. **Wright JD**, Powell MA, Coleman RL, Herzog TJ. Lower extremity lymphedema. *Women's Oncology Review*. 2002;2(3):269-76.
4. **Wright JD**, Mutch DG. Treatment of high risk gestational trophoblastic tumors. *Clinical Obstet Gynecol*. 2003;46:593-606.
5. **Wright JD**, Merritt DF, Mutch DG. How, when, and why to manage cervical dysplasia in adolescents. *Contemporary Ob/Gyn*. 2005;50(11):40-5.
6. Bansal N, Herzog TJ, **Wright JD**. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian cancer: a retrospective analysis. *Am J Hematol/Oncol*. 2006;5(12):2-4.

7. **Wright JD**, Mutch DG. Getting the message out: RNA interference of human papillomavirus. *Reproductive Sciences*. 2007;14(1):6-7.
8. Bansal N, **Wright JD**, Herzog TH. Uterine leiomyosarcomas. *Women's Oncology Review*. 2007;6(3-4):121-6.
9. Herzog TJ, **Wright JD**. The impact of cervical cancer on quality of life-the components and means for management. *Gynecol Oncol*. 2007;107(3):572-7.
10. Wethington SL, **Wright JD**, Herzog TJ. Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma. *Expert Rev Anticancer Ther*. 2008;8(5):819-31.
11. Myers E, Huh WK, **Wright JD**, Smith JS. The current and future role of screening in the era of HPV vaccination. *Gynecol Oncol*. 2008;109(2 Suppl):S31-9.
12. Fiorelli J, Herzog TJ, **Wright JD**. Current treatment strategies for endometrial cancer. *Expert Rev Anticancer Ther*. 2008;8(7):1149-57.
13. Shah M, **Wright JD**. Surgical intervention in the management of postpartum hemorrhage. *Semin Perinatol*. 2009;33(2):109-15.
14. Devine PC, **Wright JD**. Obstetric hemorrhage. Introduction. *Semin Perinatol*. 2009;33(2):75.
15. Vallerie AM, Lerner JP, **Wright JD**, Baxi LV. Peritoneal inclusion cysts: a review. *Obstet Gynecol Surv*. 2009;64(5):321-34.
16. Medel NI, Bansal S, Miller DS, **Wright JD**, Herzog TJ. Pharmacotherapy of endometrial cancer. *Expert Opin Pharmacother*. 2009;10(12):1939-51.
17. Barrena Medel NI, **Wright JD**, Herzog TJ. Targeted therapies in epithelial ovarian cancer. *J Oncol*. 2010;2010:314-26.
18. **Wright JD**, Bonanno C, Shah M, Gaddipati S, Devine P. Peripartum hysterectomy. *Obstet Gynecol* 2010;116(2 Pt 1):429-34.
19. **Wright JD**. Foreword: Endometrial cancer. *Clin Obstet Gynecol* 2011;54(2):197-8.
20. Shah M, **Wright JD**. Management of endometrial cancer in young women. *Clin Obstet Gynecol* 2011;54(2):219-25.
21. Galic VL, Herzog TJ, **Wright JD**, Lewin SN. Paclitaxel poliglumex for ovarian cancer. *Expert Opin Investig Drugs* 2011;35:1-22.

22. Arend R, Doneza JA, **Wright JD**. Uterine carcinosarcoma. *Curr Op Oncol* 2011;23:531-36.
23. Govindappagari S, Schiavone MB, **Wright JD**. Cervical neoplasia. *Clin Obstet Gynecol* 2011;54(4):528-36.
24. **Wright JD**, Barrena Medel NI, Sehoul J, Fujiwara K, Herzog TJ. Contemporary management of endometrial cancer. *Lancet* 2012;379(9823):1352-60.
25. **Wright JD**, Hershman DL. Comparative effectiveness of robotic gynecologic surgery. *J Comp Eff Res* 2012;5:377-9.
26. **Wright JD**, Hershman DL. Comparative effectiveness research in oncology methodology: observational data. *J Clin Oncol* 2012;30(34):4215-22.
27. **Wright JD**. Take 'em or leave 'em: Management of the ovaries in young women with endometrial cancer. *Gynecol Oncol* 2013;131(2):287-8.
28. Perez-Delboy A, **Wright JD**. Surgical management of placenta accreta: to leave or remove the placenta? *BJOG* 2014;121(2):163-70.
29. **Wright JD**. FDA warns against laparoscopic power morcellation for hysterectomy, myomectomy. Perspective. *HemOnc Today* 2014;15(24):78.
30. **Wright JD**, Hershman DL. Measure for measure: the cost of improving quality. *J Natl Cancer Inst* 2014;106(10):dju266.
31. **Wright JD**. Measuring what matters: quality in gynecologic surgery. *Am J Obstet Gynecol* 2015;212(3):257-8.
32. Frishman GN, Bostros S, Brost BC, Robinson RD, Steinauer J, **Wright JD**, Adams KE. Applying to subspecialty fellowship: clarifying the confusion and conflicts. *Am J Obstet Gynecol* 2016;214(2):243-6.
33. Jorge S, **Wright JD**. Update: HPV prevention. Contemporary *OB/GYN* February 25, 2016.
34. Cui RR, **Wright JD**. Risk of occult sarcoma in presumed uterine fibroids. *Clin Obstet Gynecol* 2016;59(1):103-18.
35. **Wright JD**. Electric power morcellation in gynecology: the path forward. *Obstet Gynecol* 2016;127(1):7-9.
36. Carlson M, Guntupalli S, Ko E, **Wright JD**. SGO health policy and socioeconomic committee: current and future efforts of the future of physician payment reform taskforce and legislative and regulatory affairs taskforce. *Gynecol Oncol* 2016;142(3):385-7.

37. Cohn DE, Ko E, Meyer LA, **Wright JD**, Temkin SM, Foote J, Jones NL, Havrilesky LJ. The “value” of value in gynecologic oncology practice in the United States: Society of Gynecologic Oncology evidence-based review and recommendations. *Gynecol Oncol* 2017;145(1):185-191.
38. **Wright JD**. Laparoscopic hysterectomy for endometrial cancer: A procedure 25 years in the making. *JAMA* 2017;317(12):1215-16.
39. **Wright JD**. Preventing endometrial cancer: weighing the evidence. *J Clin Oncol* 2017;35(11):1149-59.
40. **Wright JD**, Schorge JO, Kilcoyne A, Tambouret RH. Case 16-2017: A 69-year-old woman with urinary incontinence. *N Engl J Med* 2017;376(21):2066-73.
41. **Wright JD**. Is sentinel lymph node mapping associated with acceptable performance characteristics for the detection of nodal metastases in women with endometrial cancer. *OBG Manag* 2017;29(7):16-17.
42. Cui RR, **Wright JD**, Hou JY. Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management, and outcome. *BJOG* 2017;124(7):1028-37.
43. **Wright JD**. Robotic-assisted surgery: balancing evidence and implementation. *JAMA* 2017;318(16):1545-7.
44. **Wright JD**, Buskwofie A. 2017 Update on ovarian cancer. *OBG Manag* 2017;29(3):23-32.
45. Randall LM, Tewari D, **Wright JD**. Patient-centered risk assessment for ovarian cancer: individualizing your approach. *OBG Manag* 2018;30(1):SS1-14.
46. **Wright JD**. 2018 Update on gynecologic cancer. *OBG Manag* 2018;30(3):24-28.
47. Champer M, Wong AM, Champer J, Brito IL, Messer PW, Hou JY, **Wright JD**. The role of the vaginal microbiome in gynecological cancer: a review. *BJOG* 2018;125(3):309-15.
48. Ko EM, Havrilesky LJ, Alvarez RD, Zivanovic O, Boyd LR, Jewell EL, Timmins PF, Gibb RS, Jhingran A, Cohn DE, Dowedy SC, Powell MA, Chalas E, Huang Y, Rathbun J, **Wright JD**. Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP). *Gynecol Oncol* 2018;149(2):232-40.
49. **Wright JD**, Havrilesky LJ, Cohn DE, Huang Y, Rathbun J, Rice LW, Brown CL, Alvarez RD, Ko EM. Estimating potential for savings for low risk endometrial cancer using the Endometrial Cancer Alternative Payment Model (ECAP): A companion paper

to the Society of Gynecologic Oncology Report on the Endometrial Cancer Alternative Payment Model. *Gynecol Oncol* 2018;149(2):241-7.

50. **Wright JD**. What is new in ovarian cancer?: best articles from the past year. *Obstet Gynecol* 2018;132(6):1498-99.
51. Moss HA, Melamed A, **Wright JD**. Measuring cause-and-effect relationships without randomized clinical trials: Quasi-experimental methods for gynecologic oncology research. *Gynecol Oncol* 2019;152(3):533-39.
52. **Wright JD**. Financial toxicity: A severe but underrecognized side effect for cancer patients. *Gynecol Oncol* 2019;154(1):1-2.
53. **Wright JD**, Khoury-Collado F, Melamed A. Harnessing minimally invasive surgery to improve outcomes in endometrial cancer: the robots are coming. *JAMA Surg* 2019;154(6):539.
54. Tergas AI, **Wright JD**. Cancer prevention strategies for women. *Obstet Gynecol* 2019;134(1):30-43.
55. Zhou ZN, **Wright JD**. Gynecologic cancer update. *OBG Manag* 2020;32(5):21-27.
56. Liang MI, Aviki EM, **Wright JD**, Havrilesky LJ, Boyd LR, Moss HA, Jewell EL, Cohn DE, Apte SM, Timmins PF 3rd, Alvarez RD, Rathbun J, Lipinski E, White S, Siverio-Minardi D, Ko EM. Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models. *Gynecol Oncol* 2020;156(3):701-9.
57. **Wright JD**. The volume-outcome paradigm for gynecologic surgery: clinical and policy implications. *Clin Obstet Gynecol* 2020;63(2):252-65.
58. Rice LW, Cedars MI, Sadovsky Y, Siddiqui NY, Teal SB, **Wright JD**, Zorbas A, Del Carmen MG. Increasing NIH funding for academic departments of obstetrics and gynecology: A call to action. *Am J Obstet Gynecol* 223(1):79e1-79e8.
59. Fader AN, Huh WK, Kesterson J, Pothuri B, Wethington S, **Wright JD**, Bakkum-Gamez JN, Soliman PT, Sinno AK, Leitao M, Martino MA, Karam A, Rossi E, Brown J, Blank S, Burke W, Goff B, Yamada SD, Uppal S, Dowdy SC. When to operate, hesitate, and reintegrate: Society of Gynecologic Oncology surgical considerations during the COVID-19 pandemic. *Gynecol Oncol* 2020;158(2):236-43.
60. Divito M, Advincula A, Burgansky A, Westhoff C, Williams SZ, **Wright JD**, McNamara M, Fuchs KM. Intradepartmental redeployment of faculty and staff. *Semin Perinatol* 2020;44(6):151299.

61. **Wright JD**, Advincula AP. Gynecologic surgical considerations in the era of COVID-19. *Semin Perinatol* 2020;44(6):151296.
62. Matsuo K, **Wright JD**, Matsuzaki S, Roman LD, Harter P, Klar M. Malignant peritoneal cytology: areas of unmet need for evidence. *Eur J Cancer* 2020;140:149-59.
63. Matsuo K, Mandelbaum RS, Matsuzaki S, Klar M, Roman LD, **Wright JD**. Ovarian conservation for young women with early-stage, low-grade endometrial cancer: A proposal for a two-step approach. *Am J Obstet Gynecol In Press*.
64. **Wright JD**. Minimal risk for minimally invasive hysterectomy for stage IA cervical cancer? *Int J Gynecol Cancer In Press*.

BOOKS

1. **Wright JD**, Wyatt S. Washington University Obstetrics and Gynecology Survival Guide. Philadelphia: Lippincott Williams & Wilkins. 2003.

BOOK CHAPTERS

1. **Wright JD**. Women's Health. In: Lin G, Elwing J, Sayuk G, ed. Washington University Manual Outpatient Survival Guide. Philadelphia: Lippincott Williams & Wilkins. 2003.
2. Sivaprasad L, **Wright JD**. Osteoporosis. In: Latinis K, ed. Washington University Manual of Rheumatology. Philadelphia: Lippincott Williams & Wilkins. 2004.
3. **Wright JD**, Horowitz NS. Gynecologic Oncology. In: Pillot G, ed. Washington University Manual of Hematology and Oncology. Philadelphia: Lippincott Williams & Wilkins. 2004.
4. **Wright JD**, Sadovsky Y. Liver Disease in Pregnancy. In: Gronowski AM, ed. Laboratory Testing During Pregnancy. 2004.
5. **Wright JD**. The Papanicolaou Smear. Physicians' Information and Education Research (PIER). The American College of Physicians, 2004.
6. **Wright JD**, Herzog TJ. Cytoreductive Surgery: Abdominal Retroperitoneum and Adenopathy. In: Bristow RE, Karlan BY, ed. Surgery for Ovarian Cancer: Principles and Practice. Pantheon Publishing. 2005.
7. **Wright JD**. Virology in the Prevention and Management of Cervical Cancer. In: Levenback C, Lu K, Coleman R, Sood A, ed. Prognostic and Predictive Factors in Cervical Cancer. Taylor & Francis Medical Books. 2006.
8. **Wright JD**. Carcinoma of the Vagina. In: Society of Gynecologic Oncologists, ed. SGO Staging Handbook. Bristol-Myers Squibb. 2008.

9. **Wright JD**, Herzog TJ, Abu Rustum N. Cytoreductive Surgery: Abdominal retroperitoneum and adenopathy. In: Bristow RE, Karlan BY, ed. *Surgery for Ovarian Cancer: Principles and Practice*. Second Edition. Pantheon Publishing. 2010.
10. **Wright JD**. Management of disseminated or recurrent cervical cancer. UpToDate. Walters Kluwer Heath. 2010-present.
11. **Wright JD**. Cervical cancer screening tests: Evidence of effectiveness. UpToDate. Walters Kluwer Heath. 2010-present.
12. Schiavone MB, **Wright JD**. Cervical cancer in pregnancy. *Clinical Decision Support System on Obstetrics*. 2012.
13. **Wright JD**. Screening for cervical cancer: Rationale and recommendations. UpToDate. Walters Kluwer Heath. 2013-present.
14. **Wright JD**. Cervical intraepithelial neoplasia: Terminology, incidence, and pathogenesis. UpToDate. Walters Kluwer Heath. 2013-present.
15. **Wright JD**. Cervical intraepithelial neoplasia: Management of low-grade and high-grade lesions. UpToDate. Walters Kluwer Heath. 2013-present.
16. **Wright JD**. Cervical intraepithelial neoplasia: Treatment and follow-up. UpToDate. Walters Kluwer Heath. 2013-present.
17. **Wright JD**. Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics). UpToDate. Walters Kluwer Heath. 2013-present.
18. **Wright JD**. Fertility-sparing surgery for cervical cancer. UpToDate. Walters Kluwer Heath. 2013-present.
19. Patankar S, Tergas AI, **Wright JD**. Comparative effectiveness in gynecologic oncology. In: Bilimoria K, ed. *Comparative Effectiveness Research in Surgical Oncology: Key Questions and How to Answer Them*. Springer, 2015.
20. Jauniaux E, Bhide A, **Wright JD**. Placenta accreta. In: Gabbe SG, Niebyl JR, Simpson JL, Landon MB, Galan HL, Jauniaux ERM, Driscoll DA, ed. *Obstetrics: Normal and Problem Pregnancies*. Seventh Edition. Elsevier, 2015.
21. **Wright JD**, Perez-Delboy A. Surgery for obstetrical hemorrhage. In: Handa VL and Van Le L, ed. *TeLinde's Operative Gynecology*. Twelfth Edition. Wolters Kluwer, 2020.

INVITED LECTURES

1. **Wright JD**. Murine models of cervical neoplasia. Washington University School of Medicine Gynecologic Oncology Focus Group. February, 2004.

2. **Wright JD.** Biology of cervical neoplasia. Washington University Sanofi Preceptorship. St. Louis, Missouri. April 28, 2004.
3. **Wright JD.** Cervical carcinoma in the elderly: an analysis of patterns of care and outcome. Barnes Jewish Hospital Cancer Committee. St. Louis, Missouri, July 15, 2005.
4. **Wright JD.** Advances in the management of ovarian cancer: focus on intra-peritoneal chemotherapy and inhibition of angiogenesis. Marilyn Fixman Clinical Cancer Conference. St. Louis, Missouri, April 19, 2006.
5. **Wright JD.** High risk endometrial cancer. Washington University Gynecologic Oncology Review Course. St. Louis, Missouri, April 28, 2006.
6. **Wright JD.** Advances in the diagnosis and management of cervical cancer. Cancer Center Grand Rounds, St. Barnabas-Bronx Hospital. January 24, 2007.
7. **Wright JD.** Cervical cancer prevention in the era of prophylactic human papillomavirus vaccines. Columbia-Presbyterian Hospital Cancer Prevention Program. January 25, 2007.
8. **Wright JD.** Update in the diagnosis and management of ovarian cancer. Department of Obstetrics and Gynecology Grand Rounds, Staten Island University Hospital. October 3, 2007.
9. **Wright JD.** The changing paradigm of postpartum hemorrhage from a surgical perspective. The Sixth Annual Sloane Symposium: Current Issues and Controversies in Obstetrics and Gynecology. New York, New York. June 13, 2008.
10. **Wright JD.** Venous thromboembolism prophylaxis for gynecologic surgery: new strategies for an old problem. The Sixth Annual Sloane Symposium: Current Issues and Controversies in Obstetrics and Gynecology. New York, New York. June 14, 2008.
11. **Wright JD.** Interactive tumor board. 12th Biennial Meeting of the International Gynecologic Cancer Society. Bangkok, Thailand. October 25-28, 2008.
12. **Wright JD.** Novel therapeutic strategies for ovarian cancer. Hallym University Medical Center, Kangnam Sacred Heart Hospital. Seoul, South Korea. December 12, 2008.
13. **Wright JD.** Cervical cancer. Grand Rounds, Department of Radiation Oncology, Columbia University College of Physicians and Surgeons. New York, New York. April 17, 2009.
14. **Wright JD.** Update on office-based gynecologic oncology and screening. The Sloane Symposium: Current Issues and Controversies in Obstetrics and Gynecology. New York, New York. June 13, 2009.

15. **Wright JD.** Update on the prevention of cervical cancer. The American College of Obstetricians and Gynecologists District II Annual Meeting. New York, New York. October 23, 2009.
16. **Wright JD.** Update on minimally invasive surgery: lessons learned from the Columbia experience. The Sloane Symposium: Current Issues and Controversies in Obstetrics and Gynecology. New York, New York. June 11, 2010.
17. **Wright JD.** Surgical management of obstetric hemorrhage. Kansas City Gynecological Society, 30th Annual Robert Newman, M.D. Memorial Lecture. Kansas City, Missouri. September 16, 2010.
18. **Wright JD.** Ovarian cancer. Division of Medical Oncology Core Conference. Columbia University College of Physicians and Surgeons. New York, New York. December 7, 2010.
19. **Wright JD.** Surgical management of obstetric hemorrhage. Grand Rounds, Medical College of Wisconsin. Milwaukee, Wisconsin. December 23, 2010.
20. **Wright JD.** Placenta accreta. Department of Obstetrics and Gynecology Research Conference. Columbia University College of Physicians and Surgeons. New York, New York. March 1, 2011.
21. **Wright JD.** Endometrial cancer. New York Presbyterian-Columbia University Medical Center 6 Hudson South Nursing Conference. New York, New York. April 28, 2011.
22. **Wright JD.** Role of notch signaling in gynecologic cancer. Department of Obstetrics and Gynecology Research Conference. Columbia University College of Physicians and Surgeons. New York, New York. May 3, 2011.
23. **Wright JD.** Cancer of the uterus and cervix. Division of Medical Oncology Core Conference. Columbia University College of Physicians and Surgeons. New York, New York. May 10, 2011.
24. **Wright JD.** Placenta accreta research at Columbia University and New York Presbyterian Hospital. Sloane Advisory Committee Meeting. September 19, 2011.
25. **Wright JD.** What's new in up front therapy? Foundation for Women's Cancer 2011 Ovarian Cancer Survivor's Course. Minneapolis, Minnesota. November 18, 2011.
26. **Wright JD.** Ovarian cancer. Division of Medical Oncology Core Conference. Columbia University College of Physicians and Surgeons. New York, New York. December 6, 2011.
27. **Wright JD.** Robotic gynecologic surgery. Englewood Medical Center Department of Obstetrics and Gynecology Grand Rounds. Englewood, New Jersey. March 6, 2012.

28. **Wright JD.** Advances in the Management of Uterine Cancer. Columbia University College of Physicians and Surgeons Department of Radiation Oncology Grand Rounds. New York, New York. March 30, 2012.
29. **Wright JD.** Comparative effectiveness of robotic gynecologic surgery. Department of Obstetrics and Gynecology Grand Rounds, Columbia University College of Physicians and Surgeons. New York, New York. September 7, 2012.
30. **Wright JD.** Ovarian cancer. New York Presbyterian Hospital Nursing Rounds, Columbia University Medical Center. New York, New York. September 13, 2012.
31. **Wright JD.** Surgical management of obstetric hemorrhage. American College of Surgeons Annual Clinical Congress. Chicago, Illinois. September 30-October 4, 2012.
32. **Wright JD.** Comparative effectiveness of robotic hysterectomy. The National Comparative Effectiveness Summit. Washington, District of Columbia. November 5-6, 2012.
33. **Wright JD.** Comparative effectiveness of robotic surgery for gynecologic cancer. Herbert Irving Comprehensive Cancer Center Annual Retreat. Tarrytown, New York. December 5, 2012.
34. **Wright JD.** Comparative effectiveness research using observational data. Division of Gynecologic Surgery Research Meeting, Columbia University College of Physicians and Surgeons. New York, New York. January 11, 2013.
35. **Wright JD.** Comparative effectiveness of robotic gynecologic surgery. Joseph Mailman School of Public Health Special Seminar. New York, New York. February 20, 2013.
36. **Wright JD.** To bleed or not to bleed: there is no question. Sunrise session moderator. 44th Annual Meeting on Women's Cancer. Los Angeles, California. March 10, 2013.
37. **Wright JD.** Statistics for gynecologic oncologists. Gynecologic Oncology Fellows/Allied Health Research Network Symposium. 44th Annual Meeting on Women's Cancer. Los Angeles, California. March 8, 2013.
38. **Wright JD.** Comparative effectiveness research using observational data. Division of Maternal Fetal Medicine Research Meeting, Columbia University College of Physicians and Surgeons. New York, New York. March 29, 2013.
39. **Wright JD.** Use of new technology in the treatment of gynecologic cancer. Annual Meeting of the American Society of Clinical Oncology. Chicago, IL. May 31-June 4, 2013.

40. **Wright JD.** Comparative effectiveness of robotic gynecologic surgery. 39th Annual Washington University School of Medicine Obstetrics and Gynecology Symposium. St. Louis, MO. October 3-4, 2013.
41. **Wright JD.** The American Society for Colposcopy and Cervical Pathology consensus guidelines: pro. 39th Annual Washington University School of Medicine Obstetrics and Gynecology Symposium. St. Louis, MO. October 3-4, 2013.
42. **Wright JD.** Endometrial and cervical cancer. Weill Cornell Medical College and Columbia University College of Physicians and Surgeons and New York Presbyterian Medical Oncology Board Review. New York, NY. October 3-6, 2013.
43. **Wright JD.** Comparative effectiveness of upfront treatment strategies for ovarian cancer. Cancer epidemiology training seminar. Columbia University College of Physicians and Surgeons. New York, NY. October 11, 2013.
44. **Wright JD.** Abnormal cytology. American Congress of Obstetricians and Gynecologists 2013 Annual District II Meeting. New York, NY. October 25, 2013.
45. **Wright JD.** “Ask the Experts” gynecology panel. American Congress of Obstetricians and Gynecologists 2013 Annual District II Meeting. New York, NY. October 27, 2013.
46. **Wright JD.** Gynecologic cancer. Latinas Unidas Contra El Cancer del Seno. New York, NY. October 27, 2013.
47. **Wright JD.** The cost of robotic gynecologic surgery. 2013 Society for Robotic Surgery Annual Meeting. Orlando, FL. November 8-9, 2013.
48. **Wright JD.** New paradigms in the treatment of ovarian cancer. Medical Oncology Grand Rounds. Columbia University College of Physicians and Surgeons. New York, NY. November 21, 2013.
49. **Wright JD.** New paradigms in the treatment of ovarian cancer. Medical Oncology Grand Rounds. Continuum Cancer Center. New York, NY. January 8, 2014.
50. **Wright JD.** Human papillomavirus and gynecologic disease. Gilda’s Club Breakfast Series. New York, NY. January 28, 2014.
51. **Wright JD.** Placenta accreta. Safe Motherhood Initiative Symposium. 34th Society for Maternal-Fetal Medicine Annual Meeting. New Orleans, LA. February 3, 2014.
52. **Wright JD.** Comparative effectiveness of robotic gynecologic. Foundation for Women’s Cancer Gynecologic Cancer Survivors Course. Anchorage, AK. February 8-9, 2014.
53. **Wright JD.** The human papillomavirus vaccine. Foundation for Women’s Cancer Gynecologic Cancer Survivors Course. Anchorage, AK. February 8-9, 2014.

54. **Wright JD.** Electric power uterine morcellation: publicity, politics, and propaganda. Department of Obstetrics and Gynecology Grand Rounds. Beth Israel Medical Center. New York, NY. June 18, 2014.
55. **Wright JD.** Health outcomes research. Herbert Irving Comprehensive Cancer Center Population Sciences Symposium. New York, NY. June 27, 2014.
56. **Wright JD.** Health services research: pitfalls and potentials. Division of Maternal Fetal Medicine Research Conference. Columbia University College of Physicians and Surgeons. New York, NY. October 10, 2014.
57. **Wright JD.** HPV screening in cervical cancer prevention: do women still need Pap smears? American College of Obstetricians and Gynecologists District II Meeting. New York, NY. October 17, 2014.
58. **Wright JD.** Best practices for OB/GYNs: maintaining your knowledge. Cervical dysplasia. American College of Obstetricians and Gynecologists District II Meeting. New York, NY. October 19, 2014.
59. **Wright JD.** Using comparative effectiveness research to guide surgical innovation in oncology. Herbert Irving Comprehensive Cancer Center Annual Symposium. New York Presbyterian Hospital. New York, NY. October 20, 2014.
60. **Wright JD.** Endpoints for drug approval in ovarian cancer. Chemotherapy Foundation Symposium. New York, NY. November 6, 2014.
61. **Wright JD.** The anatomy of wound infections: prevention of surgical site infections in gynecologic surgery. 15th Biennial Meeting of the International Gynecologic Cancer Society. Melbourne, Australia. November 9, 2014.
62. **Wright JD.** Robotics in gynecologic oncology: con. 15th Biennial Meeting of the International Gynecologic Cancer Society. Melbourne, Australia. November 11, 2014.
63. **Wright JD.** Surgical management of postpartum hemorrhage. Department of Obstetrics and Gynecology Grand Rounds. University of Miami. Miami, FL. December 11, 2014.
64. **Wright JD.** Update on placenta accreta. "M" in MFM Special Session. 35th Annual Meeting of the Society for Maternal-Fetal Medicine. San Diego, CA. February 1, 2015.
65. **Wright JD.** Analytic techniques to improve the accuracy of observational studies. Health Outcomes Research in an Era of Cost Containment Symposium. Universite Paris Descartes and Sorbonne Paris Cite. Paris, France. March 12, 2015.

66. **Wright JD.** Electric power morcellation: politics and policy. Department of Obstetrics and Gynecology Grand Rounds. Mt. Sinai St. Lukes-Roosevelt. New York, NY. March 24, 2015.
67. **Wright JD.** Adherence to evidence-based guidelines for the treatment of febrile neutropenia. Cancer and emergency medicine: setting the agenda. National Cancer Institute. Rockville, MD. March 25, 2015.
68. **Wright JD.** Use of observational data in gynecologic oncology. Gynecologic Oncology Fellows Research Network (GOFRN) Symposium. 2015 Annual Meeting on Women's Cancer. Chicago, IL. March 27, 2015.
69. **Wright JD.** Electric power morcellation: epidemiology. SGO Sunrise Seminar: Controversies on Tissue Morcellation and Extraction. 2015 Annual Meeting on Women's Cancer. Chicago, IL. March 30, 2015.
70. **Wright JD.** Management of the ovaries in young women with endometrial cancers. SGO International Symposium on Emerging Fertility-Sparing and Neoadjuvant Therapy: Novel Approaches for Cervical, Uterine and Ovarian Malignancies. 2015 Annual Meeting on Women's Cancer. Chicago, IL. March 30, 2015.
71. **Wright JD.** Morcellation: the controversy-when and when not to. 1st Annual MIGS Conference. Columbia University. New York, NY. April 11, 2015.
72. **Wright JD.** Comparative effectiveness studies in surgical and gynecologic oncology-moving from observational studies to intervention. SWOG Spring 2015 Group Meeting. San Francisco, CA. April 30, 2015.
73. **Wright JD.** Electric power morcellation in gynecology: politics and policy. Magee-Women's Research Institute Research Day, 2015 Celebration of Life: A Lecture Honoring Mothers. Pittsburgh, PA. May 29, 2015.
74. **Wright JD.** Keynote address. American Cancer Society Survivorship and Relay for Life Celebration. New York, NY. June 4, 2015.
75. **Wright JD.** Adoption of robot and new technology in gynecologic oncology. Institute of Medicine Workshop: Appropriate Use of Advanced Technologies for Radiation and Therapy and Surgery in Oncology. Washington, DC. July 20, 2015.
76. **Wright JD.** New paradigms in the treatment of cervical cancer. Advances and Controversies in Gynecologic Oncology. Chicago, IL. July 24, 2015.
77. **Wright JD.** Update in ovarian cancer. SHARE. New York, NY. September 10, 2015.
78. **Wright JD.** Surgical innovation: lessons learned from gynecology. Michigan Surgical Quality Collaborative. Detroit, MI. September 24, 2015.

79. **Wright JD.** Quality in gynecology: what do we measure and why? New York University Department of Obstetrics and Gynecology Grand Rounds. New York, NY. October 7, 2015.
80. **Wright JD.** The morbidly adherent placenta. New York University Department of Obstetrics and Gynecology Research Group Meeting. New York, NY. October 7, 2015.
81. **Wright JD.** New paradigms in the management of placenta accrea. Byford Heskett Visiting Professorship. Northwestern University. Chicago, IL. October 30, 2015.
82. **Wright JD.** Quality in gynecology: what do we measure and why? University of Massachusetts Department of Obstetrics and Gynecology Grand Rounds. Worcester, MA. February 3, 2016.
83. **Wright JD.** Effect of regional hospital competition and hospital financial status on use of robotic-assisted surgery. Brandeis University Executive MBA Webinar. March 5, 2016.
84. **Wright JD.** How to define and deliver value-based care in gynecologic cancer. Education forum. 2016 Annual Meeting on Women's Cancer. Chicago, IL. March 19, 2016.
85. **Wright JD.** New paradigms in the treatment of ovarian cancer. University of Missouri-Kansas City E. Grey Diamond Take Wing Award Lecture. Kansas City, MO. May 23, 2016.
86. **Wright JD.** Commencement address. University of Missouri-Kansas City Health Sciences commencement ceremony. Kansas City, MO. May 23, 2016.
87. **Wright JD.** Improving the quality of oncology care through payment reform. 1st Annual Herbert Irving Comprehensive Cancer Center Oncology Quality Symposium. New York, NY. June 10, 2016.
88. **Wright JD.** Quality in gynecology: what do we measure and why? United States Naval Medical Center 14th Annual Donald G. Gallup Resident Research Day. San Diego, CA. June 17, 2016.
89. **Wright JD.** Laparoscopic uterine power morcellation is an acceptable therapeutic approach to hysterectomy and myomectomy: con. Medical College of Wisconsin Department of Obstetrics and Gynecology Grand Rounds. Milwaukee, WI. July 13, 2016.
90. **Wright JD.** Quality in gynecology: what do we measure and why? Brigham and Women's Hospital Department of Obstetrics and Gynecology Grand Rounds. Boston, MA. September 7, 2016.

91. **Wright JD.** New paradigms in the management of placenta accreta. St. Luke's University Hospital Department of Obstetrics and Gynecology Grand Rounds. Bethlehem, PA. October 19, 2016.
92. **Wright JD.** The ovaries should be removed for early-stage endometrial cancer: Con. 16th Biennial Meeting of the International Gynecologic Cancer Society. Lisbon, Portugal. October 31, 2016.
93. **Wright JD.** Clinicopathology conference. Massachusetts General Hospital Department of Obstetrics and Gynecology Grand Rounds. Boston, MA. November 10, 2016.
94. **Wright JD.** What is the real risk of uterine sarcoma? Massachusetts General Hospital Topics in Contemporary Obstetrics and Gynecology. Boston, MA. November 10, 2016.
95. **Wright JD.** Quality in gynecology: what do we measure and why? University of Missouri-Kansas City Department of Obstetrics and Gynecology Grand Rounds. Kansas City, MO. January 13, 2017.
96. **Wright JD.** Opportunistic salpingectomy. Mercy Hospital 49th Annual Matt Weiss Symposium: Advances in Obstetrics and Gynecology. St. Louis, MO. March 30, 2017.
97. **Wright JD.** Management of adnexal masses. Mercy Hospital 49th Annual Matt Weiss Symposium: Advances in Obstetrics and Gynecology. St. Louis, MO. March 30, 2017.
98. **Wright JD.** IDEAL Abdominal/Gynecologic Surgery: Robotic Surgery. IDEAL 2107 International Conference. New York, NY. May 4, 2017.
99. **Wright JD.** New paradigms in the management of placenta accreta. Texas Tech University Health Sciences Center 12th Annual Obstetrics and Gynecology Symposium. El Paso, TX. June 9, 2017.
100. **Wright JD.** Opportunistic salpingectomy. Texas Tech University Health Sciences Center 12th Annual Obstetrics and Gynecology Symposium. El Paso, TX. June 9, 2017.
101. **Wright JD.** Comparative effectiveness research in gynecology: opportunities and challenges using big data. American Urogynecology Society 38th Annual Meeting. Providence, RI. October 3, 2017.
102. **Wright JD.** Tumor board: obesity surgery. European Gynaecological Oncology Society Congress 2017. Vienna, Austria. November 6, 2017.
103. **Wright JD.** Cervical cancer screening and prevention. Rochester General Hospital Department of Obstetrics and Gynecology Grand Rounds. Rochester, NY. December 14, 2017.

104. **Wright JD.** Quality in gynecology: what do we measure and why? Probststein Visiting Lectureship Washington University in St. Louis Department of Obstetrics and Gynecology. St. Louis, MO. January 31, 2018.
105. **Wright JD.** The nuts and bolts of cost effectiveness analysis. Health Care Disparities Outcomes Research in Gynecologic Oncology Education Forum. Society of Gynecologic Oncology Annual Meeting on Women's Cancer. New Orleans, LA. March 25, 2018.
106. **Wright JD.** The Society of Gynecologic Oncology's endometrial cancer alternative payment model (APM). Health Economics: Advanced Payment Models Sunrise Seminar. Society of Gynecologic Oncology Annual Meeting on Women's Cancer. New Orleans, LA. March 26, 2018.
107. **Wright JD.** New paradigms in the treatment of ovarian cancer. Norwalk Hospital Department of Medicine Grand Rounds. Norwalk, CT. April 12, 2018.
108. **Wright JD.** Quality in gynecology: what do we measure and why? University of Kansas Department of Obstetrics and Gynecology Grand Rounds. Kansas City, KS. May 18, 2018.
109. **Wright JD.** Quality in gynecology: what do we measure and why? Wake Forest Department of Obstetrics and Gynecology Grand Rounds and Resident Research Day Judge. Winston-Salem, NC. June 4, 2018.
110. **Wright JD.** Quality in gynecology: what do we measure and why? The Hunter Lecturship and Resident Research Day Judge. Indiana University Department of Obstetrics and Gynecology. Indianapolis, IN. June 15, 2018.
111. **Wright JD.** Treatment of early-stage cervical cancer: is less really less? Gregorio Delgado Lecture. Mid Atlantic Gynecologic Oncology Society Annual Meeting. Columbus, OH. October 25, 2018.
112. **Wright JD.** New paradigms in the treatment of placenta accreta. Rutgers/Robert Wood Johnson Medical School Department of Obstetrics and Gynecology Grand Rounds. New Brunswick, NJ. January 11, 2019.
113. **Wright JD.** Advances in the treatment of uterine cancer. Columbia University College of Physicians and Surgeons Department of Radiation Oncology Grand Rounds. New York, NY. February 8, 2019.
114. **Wright JD.** Treatment of early-stage cervical cancer: is less really less? Memorial Sloane Kettering Cancer Center Department of Gynecology Grand Rounds. New York, NY. February 21, 2019.

115. **Wright JD.** J. Marion Sims and the controversial birth of modern gynecology. *Obstetrics & Gynecology* Editorial Board Meeting. Phoenix, AZ. February 25, 2019.
116. **Wright JD.** Quality in gynecology: what do we measure and why. St. Louis University Department of Obstetrics and Gynecology Grand Rounds. St. Louis, MO. May, 10, 2019.
117. **Wright JD.** Quality in gynecology: what do we measure and why. Cedars Sinai Medical Center Department of Obstetrics and Gynecology Grand Rounds and Resident Quality Improvement Day Speaker. Los Angeles, CA. June 12, 2019.
118. **Wright JD.** Quality in gynecology: what do we measure and why. Staten Island University Hospital Department of Obstetrics and Gynecology Grand Rounds. New York, NY. October 2, 2019.
119. **Wright JD.** Molecular phenotyping of endometrial cancer: prognostic and therapeutic implications. 2nd Shanghai International Conference on Cancer. Shanghai, China. October 12, 2019.
120. **Wright JD.** The HPV Epidemic. Martin L. Stone, MD, FACOG Lecture. American College of Obstetricians and Gynecologists District II Annual Meeting. New York, NY. October 18, 2019.
121. **Wright JD.** Quality in gynecology: what do we measure and why? Duke University Department of Obstetrics and Gynecology Grand Rounds. Durham, NC. December 18, 2019.
122. **Wright JD.** Uterine and endometrial cancer 101. SHARE and Foundation for Women's Cancer patient education series. Webinar. March 16, 2020.
123. **Wright JD.** New treatments for recurrent ovarian cancer. Herbert Irving Comprehensive Cancer Center Webinar. September 30, 2020.
124. **Wright JD.** Initial and adjuvant therapy for endometrial cancer. Columbia University Department of Radiation Oncology Grand Rounds. New York, NY. October 2 2020.
125. **Wright JD.** Molecular-guided use of targeted therapy in gynecologic cancer. 38th Annual Chemotherapy Foundation Symposium. New York, NY. November 5, 2020.
126. **Wright JD.** New treatment paradigms for cervical cancer. Herbert Irving Comprehensive Cancer Center Webinar. January 20, 2021.
127. **Wright JD.** Quality in gynecology: what do we measure and why? University of Texas Austin Department of Obstetrics and Gynecology Grand Rounds. Austin, TX (virtual presentation). January 21, 2021.

128. **Wright JD.** Quality in gynecology: what do we measure and why? University of North Carolina Department of Obstetrics and Gynecology Grand Rounds. Chapel Hill, NC (virtual presentation). April 7, 2021.
129. **Wright JD.** Quality in gynecology: what do we measure and why? New York University Langone Hospital-Long Island Resident Research Day and Graduation. Mineola, NY (virtual presentation). June 4, 2021.
130. **Wright JD.** Outcomes research in gynecologic oncology. Seoul National University Hospital webinar series (virtual presentation). September 16, 2021.

PUBLISHED ABSTRACTS AND CONFERENCE PROCEEDINGS

1. **Wright JD, Suedekum B, Reisz GR.** Extraskeletal Ewing's sarcoma arising as a primary pulmonary neoplasm. Meeting of the Missouri Academy of Family Physicians. Lake of the Ozarks, Missouri. June, 1999. Poster presentation.
2. **Wright JD, Sadovsky Y.** Phosphorus and uterine contractions. David Rothman Research Day, Washington University School of Medicine, Department of Obstetrics and Gynecology. St. Louis, Missouri. April 27, 2001. Oral presentation.
3. **Wright JD, Gerhard DS, Zhang Z, Huettner PC, Trinkaus KM, Mutch DG, Herzog TJ, Gibb RK, Rader JS.** Molecular/environmental markers as prognostic factors in early stage cervical carcinoma. 33rd Annual Meeting of the Society of Gynecologic Oncologists. Miami, Florida. March 16-20, 2002. Poster presentation.
4. Rutledge TL, Kamelle SA, Tillmanns TD, Cohn DE, **Wright JD**, Rader JS, Herzog TJ, Gold MA, Johnson GA, Walker JL, Mannel RS, McMeekin DS. A comparison of stage IB1 vs. IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? 33rd Annual Meeting of the Society of Gynecologic Oncologists. Miami, Florida. March 16-20, 2002. Poster presentation.
5. Pinto AB, **Wright JD**, Keller SL, Odem RR, Ratts VS, Williams DB. Ultrasound guided embryo transfer in selected patients undergoing IVF. 50th Annual Meeting of the Pacific Coast Reproductive Society. Rancho Mirage, California. April 17-21, 2002. Poster presentation.
6. Pinto KR, Lu DI, **Wright JD**, Pinto AB, Boucher LD. Follow-up of atypical squamous cells of undetermined significance (ASCUS) in adolescents. 50th Annual Clinic Meeting of the American College of Obstetricians and Gynecologists. Los Angeles, California. May 4-8, 2002. Poster presentation.
7. **Wright JD, Rader JS.** Molecular and environmental markers as prognostic factors in early stage cervical carcinoma. David Rothman Resident Research Day, Washington University School of Medicine, Department of Obstetrics and Gynecology. St. Louis, Missouri. April 26, 2002. Oral presentation.

8. **Wright JD**, Powell MA, Gibb RK, Mutch DG, Rader JS, Huettner P, Herzog TJ. Synchronous ovarian metastases at the time of laparotomy for colon cancer. 34th Annual Meeting of the Society of Gynecologic Oncologists. New Orleans, Louisiana. January 31-February 4, 2003. Poster presentation.
9. Powell MA, **Wright JD**, Gibb RK, Mutch DG, Rader JS, Herzog TJ. Morbidity of cytoreductive surgery in the elderly. 51st Annual Clinical Meeting of the American College of Obstetricians and Gynecologists. New Orleans, Louisiana. April 26-31, 2003. Poster presentation.
10. **Wright JD**, Powell MA, Gibb RK, Mutch DG, Rader JS, Herzog TJ. Pelvic masses in obese women. 51st Annual Clinical Meeting of the American College of Obstetricians and Gynecologists. New Orleans, Louisiana. April 26-31, 2003. Poster presentation.
11. **Wright JD**, Chaudhari A, Sadovsky Y. Is hypophosphatemia associated with dysfunctional uterine contractions? 51st Annual Clinical Meeting of the American College of Obstetricians and Gynecologists. New Orleans, Louisiana. April 26-31, 2003. Poster presentation.
12. **Wright JD**, Herzog TJ, Mutch DG, Rader JS, Gibb RK, Powell MA, Davila R, Cohn DE. Liquid based cytology for the follow-up of women with gynecologic malignancies treated with radiation. Annual Meeting of the American Society of Clinical Oncology. Chicago, Illinois. May, 2003. Poster presentation.
13. Herzog TJ, **Wright JD**, Powell MA, Huettner PC, Mutch DG, Rader JS, Tan BJ, Gibb RK. Appendiceal tumors mimicking ovarian cancer. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. Chicago, Illinois. May, 2003. Poster presentation.
14. **Wright JD**, Powell MA, Herzog TJ, Mutch DG, Rader JS, Gao F, Gibb RK. Panniculectomy: improving lymph node yield in the morbidly obese patient with endometrial cancer. 35th Annual Meeting of the Society of Gynecologic Oncologists. San Diego, California. February 7-11, 2004. Poster presentation.
15. **Wright JD**, Mutch DG, Herzog TJ, Gibb RK, Powell MA, Trinkaus K, Rader JS. Cervical cancer in the elderly: a multivariate analysis of patterns of care and outcome in 1582 patients. 35th Annual Meeting of the Society of Gynecologic Oncologists. San Diego, California. February 7-11, 2004. Poster presentation.
16. **Wright JD**, Rader JS. Molecular and environmental predictors of survival in early stage cervical carcinoma. Glaxo Smith Kline National Gynecologic Oncology Fellows' Forum. San Diego, California. March 18-21, 2004. Oral presentation.

17. **Wright JD**, Rader JS. Molecular and environmental predictors of survival in early stage cervical carcinoma. St. Louis Gynecological Society Spring Research Symposium. St. Louis, Missouri. April 20, 2004. Oral presentation.
18. **Wright JD**. The role of tobacco-mediated carcinogens in cervical neoplasia. Glaxo Smith Kline National Gynecologic Oncology Fellows' Forum. Tucson, Arizona. January 27-30, 2005. Oral presentation.
19. **Wright JD**, Noll M, Arbeit JM. HIF-1: an epithelial carcinogenesis progression factor. 58th Annual Cancer Symposium of the Society of Surgical Oncology. Atlanta, Georgia. March 3-6, 2005. Poster presentation.
20. **Wright JD**, Davila RM, Pinto KR, Merritt DF, Gibb RK, Rader JS, Mutch DG, Powell MA. Cervical dysplasia in adolescents. 36th Annual Meeting of the Society of Gynecologic Oncologists. Miami, Florida. March 19-23, 2005. Oral presentation.
21. **Wright JD**, Herzog TJ, Huettner PC, Dehdashti F, Siegel BA, Mutch DG, Rader JS, Gibb RK, Powell MA, Grigsby PW. Positron emission tomography for early stage cervical cancer. 36th Annual Meeting of the Society of Gynecologic Oncologists. Miami, Florida. March 19-23, 2005. Poster presentation.
22. **Wright JD**, Mutch DG, Brooks R, Powell MA, Gibb RK, Rader JS, Gao F, Wall LL. Long-term assessment of bladder and bowel dysfunction after radical hysterectomy. 36th Annual Meeting of the Society of Gynecologic Oncologists. Miami, Florida. March 19-23, 2005. Poster presentation.
23. **Wright JD**, Huettner PC, Mutch DG, Rader JS, Gibb RK, Powell MA. Villoglandular carcinoma of the cervix: is conservative treatment appropriate? 36th Annual Meeting of the Society of Gynecologic Oncologists. Miami, Florida. March 19-23, 2005. Poster presentation.
24. **Wright JD**, Noll M, Arbeit JM. Tobacco mediated carcinogens and cervical carcinogenesis. 36th Annual Meeting of the Society of Gynecologic Oncologists. Miami, Florida. March 19-23, 2005. Poster presentation.
25. Brockmeyer AD, **Wright JD**, Gibb RK, Rader JS, Mutch DG, Gao F, Powell MA. Persistent and recurrent cervical dysplasia after loop electrosurgical excision procedure. 36th Annual Meeting of the Society of Gynecologic Oncologists. Miami, Florida. March 19-23, 2005. Poster presentation.
26. Brockmeyer AD, **Wright JD**, Mutch DG, Rader JS, Gibb RK, Powell MA, Gao F, Herzog TJ. Outcome and prognosis of endometriosis associated ovarian malignancies. 36th Annual Meeting of the Society of Gynecologic Oncologists. Miami, Florida. March 19-23, 2005. Poster presentation.

27. **Wright JD**, Davila RM, Pinto KR, Merritt DF, Gibb RK, Rader JS, Mutch DG, Powell MA. Cervical dysplasia in adolescents. St. Louis Gynecological Society Spring Symposium. St. Louis, Missouri. April 19, 2005. Oral presentation.
28. **Wright JD**, Rosenblum K, Mutch DG, Rader JS, Powell MA, Huettner PC, Gibb RK. Cervical sarcomas: an analysis of treatment and outcome. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. Orlando, Florida. May 13-17, 2005. Poster presentation.
29. **Wright JD**, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, Mutch DG, Powell MA. Bevacizumab-combination therapy in relapsed, platinum-refractory, epithelial ovarian carcinoma. 37th Annual Meeting of the Society of Gynecologic Oncologists. Palm Springs, California. March 22-26, 2006. Oral presentation.
30. **Wright JD**, Belt B, Manning K, Noll M, Arbeit JA. Hypoxia inducible factor 1 is a progression factor for cervical cancer. 37th Annual Meeting of the Society of Gynecologic Oncologists. Palm Springs, California. March 22-26, 2006. Poster presentation.
31. Thomas MB, Podratz K, **Wright JD**, Madarek E, Mutch DG. Uterine clear cell carcinoma: a multi-institutional review, 1982-2004. 37th Annual Meeting of the Society of Gynecologic Oncologists. Palm Springs, California. March 22-26, 2006. Poster presentation. Poster presentation.
32. **Wright JD**, Rader JS, Davila R, Powell MA, Mutch DG, Gao F, Gibb RK. ASC-US in adolescents: is HPV testing appropriate? St. Louis Gynecological Society Spring Research Symposium. St. Louis, Missouri. April 25, 2006. Oral presentation.
33. **Wright JD**, Alvarez Secord A, Numnum TM, Rocconi RP, Powell MA, Berchuck A, Alvarez RD, Trinkaus K, Rader JS, Mutch DG. A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent, platinum-resistant ovarian cancer. 42nd Annual Meeting of the American Society of Clinical Oncologists. Atlanta, Georgia. June 1-6, 2006. Poster presentation.
34. Bansal N, **Wright JD**, Cohen CJ, Herzog TJ, Wright TC. Utility of endocervical curettage at the time of colposcopy. 38th Annual Meeting of the Society of Gynecologic Oncologists. San Diego, California. March 3-7, 2007. Poster presentation.
35. **Wright JD**, Grigsby PW, Rader JS, Mutch DG, Powell MA, Rader JS, Gibb RK. Effect of a T0 radical hysterectomy specimen on survival for early stage cervical cancer. 38th Annual Meeting of the Society of Gynecologic Oncologists. San Diego, California. March 3-7, 2007. Poster presentation.
36. **Wright JD**, Grigsby PW, Brooks R, Powell MA, Gibb RK, Gao F, Rader JS, Mutch DG. Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy. 38th Annual Meeting of the Society of Gynecologic Oncologists. San Diego, California. March 3-7, 2007. Poster presentation.

37. **Wright JD**, Tian C, Mutch D, Herzog TJ, Ozols RF, Nagao S, Fujiwara K, Powell MA. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. 38th Annual Meeting of the Society of Gynecologic Oncologists. San Diego, California. March 3-7, 2007. Oral presentation.
38. **Wright JD**, Bansal N, Herzog TJ, S Finkelstein, Wright TC. The value of mutational genotyping in cervical^[11] intraepithelial neoplasia. 42nd Annual Meeting of the American Society of Clinical Oncologists. Chicago, Illinois. June 1-5, 2007. Poster presentation.
39. **Wright JD**, Fiorelli J, Cohen CJ, Schiff PB, Burke WM, Kansler A, Herzog TJ. Racial disparities in the patterns of care and outcome for uterine neoplasms. 39th Annual Meeting of the Society of Gynecologic Oncologists. Tampa, Florida. March 9-12, 2008. Poster presentation.
40. Bansal N, Patel P, Brunner-Brown A, Burke WM, Cohen CJ, Herzog TJ, **Wright JD**. The utility and cost effectiveness of preoperative computed tomography for patients with uterine malignancies. 39th Annual Meeting of the Society of Gynecologic Oncologists. Tampa, Florida. March 9-12, 2008. Poster presentation.
41. **Wright JD**, Neugut AI, Doan T, McBride R, Jacobson JS, Hershman D. Quality of chemotherapy delivery for women with advanced stage ovarian cancer and its impact on survival. 39th Annual Meeting of the Society of Gynecologic Oncologists. Tampa, Florida. March 9-12, 2008. Poster presentation.
42. **Wright JD**, Fiorelli J, Cohen CJ, Schiff PB, Burke WM, Kansler A, Herzog TJ. Defining the optimal management of stage II endometrial cancer: is radical hysterectomy or radiation necessary? 39th Annual Meeting of the Society of Gynecologic Oncologists. Tampa, Florida. March 9-12, 2008. Poster presentation.
43. Shah M, Butala A, Ricci S, Burke WM, Cohen CJ, Herzog TJ, **Wright JD**. Quality of prophylactic, perioperative antibiotic prophylaxis in gynecologic surgery: too much of a good thing? 39th Annual Meeting of the Society of Gynecologic Oncologists. Tampa, Florida. March 9-12, 2008. Poster presentation.
44. Bansal N, Herzog TJ, Burke WM, Cohen CJ, Seshan VE, **Wright JD**. Uterine carcinosarcoma versus grade 3 endometrioid cancers: the debate revisited. 39th Annual Meeting of the Society of Gynecologic Oncologists. Tampa, Florida. March 9-12, 2008. Poster presentation.
45. **Wright JD**, Vallerie A, Cohen CJ, Seshan V, Burke WM, Herzog TJ. Low-grade serous carcinomas of the ovary represent a distinct clinicopathologic entity. 12th Biennial Meeting of the International Gynecologic Cancer Society. Bangkok, Thailand. October 25-28, 2008. Poster presentation.

46. **Wright JD**, Wethington SL, Burke WM, Seshan VE, Schiff PB, Cohen CJ, Herzog TJ. Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer. 12th Biennial Meeting of the International Gynecologic Cancer Society. Bangkok, Thailand. October 25-28, 2008. Poster presentation.
47. Bansal N, Shaw RE, Herzog TJ, Burke WM, Goldman N, Schiff PB, **Wright JD**. Radical hysterectomy versus radiation for early-stage cervical cancer: How big is too big? 40th Annual Meeting of the Society of Gynecologic Oncologists. San Antonio, Texas. February 4-8, 2009. Poster presentation.
48. Bansal S, Buck AM, Herzog TJ, Burke WM, Schiff PB, **Wright JD**. Stage IIA endometrial carcinoma: Outcome and predictors of survival. 40th Annual Meeting of the Society of Gynecologic Oncologists. San Antonio, Texas. February 4-8, 2009. Poster presentation.
49. **Wright JD**, Shah M, Mathew L, Burke WM, Culhane J, Schiff PB, Herzog TJ. Patterns of care and access to fertility-conserving surgery for patients with ovarian sex cord stromal and germ cell tumors. 40th Annual Meeting of the Society of Gynecologic Oncologists. San Antonio, Texas. February 4-8, 2009. Poster presentation.
50. Lewin SN, Herzog TJ, Barrena Medel NI, Deutsch I, Sun X, Burke WM, **Wright JD**. Comparative performance of the new versus old FIGO staging system for endometrial cancer. 41st Annual Meeting of the Society of Gynecologic Oncologists. San Francisco, California. March 14-17, 2010. Oral presentation.
51. Shah M, Lewin SN, Deutsch I, Burke WM Sun X, Herzog TJ, **Wright JD**. Therapeutic role of lymphadenectomy in women with early-stage cervical cancer. 41st Annual Meeting of the Society of Gynecologic Oncologists. San Francisco, California. March 14-17, 2010. Oral presentation.
52. St. Clair CN, Shah M, Diver L, Lewin SN, Burke WM, Herzog TJ, **Wright JD**. Adherence to evidence-based guidelines for preoperative testing in women undergoing gynecologic surgery. 41st Annual Meeting of the Society of Gynecologic Oncologists. San Francisco, California. March 14-17, 2010. Oral presentation.
53. Shah M, Herzog TJ, Burke WM, Sun X, Lewin SN, **Wright JD**. Quality of venous thromboembolism prophylaxis among women undergoing gynecologic surgery. 41st Annual Meeting of the Society of Gynecologic Oncologists. San Francisco, California. March 14-17, 2010. Poster presentation.
54. Wethington S, Herzog TJ, Burke WM, Sun X, Lewin SN, **Wright JD**. Low risk of malignancy in endometrial polyps. 41st Annual Meeting of the Society of Gynecologic Oncologists. San Francisco, California. March 14-17, 2010. Poster presentation.

55. Barrena Medel NI, Lewin SN, Burke WM, Sun X, Herzog TJ, **Wright JD**. High-risk uterine factors are as important as nodal status in defining the prognosis of endometrioid endometrial cancer. 41st Annual Meeting of the Society of Gynecologic Oncologists. San Francisco, California. March 14-17, 2010. Poster presentation.
56. Arend R, Herzog TJ, Sun X, Deutsch I, Burke WM, Lewin SN, **Wright JD**. Long-term outcome and natural history of uterine adenosarcoma. 41st Annual Meeting of the Society of Gynecologic Oncologists. San Francisco, California. March 14-17, 2010. Poster presentation.
57. St. Clair CN, Herzog TJ, Barrena Medel NI, Burke WM, Sun X, Deutsch I, Lewin SN, **Wright JD**. Utility of staging lymphadenectomy in women with granulosa cell tumors of the ovary. 41st Annual Meeting of the Society of Gynecologic Oncologists. San Francisco, California. March 14-17, 2010. Poster presentation.
58. **Wright JD**, Nathavitharana R, Lewin SN, Sun X, Deutsch I, Burke WM, Herzog TJ. Safety and access to fertility-conserving surgery for young women with stage IA1 cervical cancer. 41st Annual Meeting of the Society of Gynecologic Oncologists. San Francisco, California. March 14-17, 2010. Poster presentation.
59. **Wright JD**, Zerlin M, Shah M, Herzog TJ, Kitajewski J. Role of notch signaling in ovarian cancer. 13th Biennial Meeting of the International Gynecological Cancer Society. Prague, Czech Republic. October 23-26, 2010. Oral presentation.
60. **Wright JD**, Lewin SN, Barrena Medel NI, Sun X, Burke WM, Herzog TJ. Morbidity and mortality of surgical treatment of the oldest old women with endometrial cancer. 13th Biennial Meeting of the International Gynecological Cancer Society. Prague, Czech Republic. October 23-26, 2010. Poser presentation.
61. Barrena Medel NI, Herzog TJ, Burke WM, Sun X, Lewin SN, **Wright JD**. Whole pelvic radiotherapy and the risk of secondary lymphoma. 13th Biennial Meeting of the International Gynecological Cancer Society. Prague, Czech Republic. October 23-26, 2010. Oral presentation.
62. **Wright JD**, Lewin SN, Barrena Medel NI, Sun X, Burke WM, Herzog TJ. Endometrial cancer in the oldest old: tumor characteristics, patterns of care, and outcome. 13th Biennial Meeting of the International Gynecological Cancer Society. Prague, Czech Republic. October 23-26, 2010. Oral presentation.
63. **Wright JD**, Shah M, Burke WM, Sun X, Lewin SN, Herzog TJ. Quality of venous thromboembolism prophylaxis in patients undergoing gynecologic cancer surgery. 13th Biennial Meeting of the International Gynecological Cancer Society. Prague, Czech Republic. October 23-26, 2010. Poster presentation.
64. Pri-Paz S, Fuchs K, Bonanno C, Cleary K, Gaddipati S, **Wright JD**, Devine P. Antenatal predictors of the need for emergent delivery in cases of suspected placenta accreta. 31st

Annual Meeting of the Society of Maternal Fetal Medicine. San Francisco, California. February 7-12, 2011. Poster presentation.

65. Pri-Paz S, Meccariello L, Smok D, Perez-Delboy A, **Wright JD**, Devine P. Ultrasound findings predictive of adverse maternal outcome in cases of placenta previa. 31st Annual Meeting of the Society of Maternal Fetal Medicine. San Francisco, California. February 7-12, 2011. Poster presentation.
66. Pri-Paz S, Devine P, Bonanno C, Fuchs K, Gaddipati S, Sun X, **Wright JD**. Predictors of massive blood loss in women with placenta accreta. 58th Annual Meeting of the Society for Gynecologic Investigation. Miami Beach, Florida. March 16-19, 2011.
67. Pri-Paz S, Devine P, Bonanno C, Fuchs K, Gaddipati S, **Wright JD**. Outcome of pregnancies complicated by placenta accreta at different gestational ages. 58th Annual Meeting of the Society for Gynecologic Investigation. Miami Beach, Florida. March 16-19, 2011. Poster presentation.
68. **Wright JD**, Lewin SN, Deutsch I, Sun X, Burke WM, Herzog TJ. Effect of hospital volume on outcome for women undergoing radical hysterectomy for cervical cancer. 42nd Annual Meeting of the Society of Gynecologic Oncologists. Orlando, Florida. March 6-9, 2011. Poster presentation.
69. Lewin SN, Herzog TJ, Deutsch I, Sun X, Burke WM, **Wright JD**. Surgical volume and its effect on morbidity and mortality for endometrial cancer. 42nd Annual Meeting of the Society of Gynecologic Oncologists. Orlando, Florida. March 6-9, 2011. Poster presentation.
70. Schiavone MB, Herzog TJ, Lewin SN, Deutsch I, Sun X, Burke WM, **Wright JD**. The unique natural history of mucinous tumors of the ovary. 42nd Annual Meeting of the Society of Gynecologic Oncologists. Orlando, Florida. March 6-9, 2011. Poster presentation.
71. Spoozak L, Lewin SN, Burke WM, Deutsch I, Sun X, Herzog TJ, **Wright JD**. Is there a microinvasive cervical adenocarcinoma? 42nd Annual Meeting of the Society of Gynecologic Oncologists. Orlando, Florida. March 6-9, 2011. Poster presentation.
72. Barrera Medel NI, Lewin SN, Deutsch I, Qiao Y, Sun X, Burke WM, Herzog TJ, **Wright JD**. Stage IC ovarian cancer: tumor rupture vs. ovarian surface involvement. 42nd Annual Meeting of the Society of Gynecologic Oncologists. Orlando, Florida. March 6-9, 2011. Poster presentation.
73. **Wright JD**, Lewin SN, Deutsch I, Sun X, Burke WM, Herzog TJ. Defining the limits of radical cytoreductive surgery for ovarian cancer. 42nd Annual Meeting of the Society of Gynecologic Oncologists. Orlando, Florida. March 6-9, 2011. Oral presentation.

74. **Wright JD**, Neugut AI, Wilde ET, Buono D, Malin J, Tsai WY, Hershman DL. Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer. 47th Annual Meeting of the American Society of Clinical Oncology. Chicago, Illinois. June 3-7, 2011. Oral poster presentation.
75. **Wright JD**, Burke WM, Sun X, Lewin SN, Herzog TJ. Patterns of venous thromboembolism prophylaxis in women undergoing major gynecologic surgery. 17th International Meeting of the European Society of Gynaecological Oncology. Milan, Italy. September 11-14, 2011. Poster presentation.
76. **Wright JD**, Burke WM, Lu YS, Lewin SN, Herzog TJ. Effect of surgeon and hospital volume on outcomes for women with endometrial cancer who undergo laparoscopic hysterectomy. 17th International Meeting of the European Society of Gynaecological Oncology. Milan, Italy. September 11-14, 2011. Poster presentation.
77. **Wright JD**, Burke WM, Lewin SN, Charles AS, Neugut AI, Herzog TJ, Hershman DL. Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer. 17th International Meeting of the European Society of Gynaecological Oncology. Milan, Italy. September 11-14, 2011. Oral presentation.
78. Sharma CS, Deutsch I, Burri RJ, Chao C, Lewin S, Burke W, Qiao Y, Sun X, Herzog TJ, **Wright JD**. Lymphadenectomy influences the utilization of adjuvant radiation therapy in early stage endometrial cancer. 53rd Annual Meeting of American Society of Radiation Oncology. Miami, Florida. October 2-6, 2011. Poster presentation.
79. Garg G, Mutch DG, Gao F, Zigelboim I, Hagemann AR, **Wright JD**, Morris RT, Kizer NT, Powell MA. Positive peritoneal cytology is an independent risk factor among women diagnosed with endometrial cancer confined to the uterus. 43rd Annual Meeting on Women's Cancer. Austin, Texas. March 24-27, 2012. Poster presentation.
80. Shah M, Li BY, Reeves CV, Galic VL, Kitajewski JK, **Wright JD**. The importance of NOTCH signaling in endometrial adenocarcinoma. 43rd Annual Meeting on Women's Cancer. Austin, Texas. March 24-27, 2012. Poster presentation.
81. **Wright JD**, Herzog TJ, Neugut AI, Burke WM, Lu Y, Lewin SN, Hershman DL. Comparative effectiveness of minimally invasive radical hysterectomy for cervical cancer. 43rd Annual Meeting on Women's Cancer. Austin, Texas. March 24-27, 2012. Poster presentation.
82. **Wright JD**, Herzog TJ, Neugut AI, Burke WM, Lu Y, Lewin SN, Hershman DL. Association of radical cytoreductive surgery and perioperative complications with delay or omission of chemotherapy for ovarian cancer. 43rd Annual Meeting on Women's Cancer. Austin, Texas. March 24-27, 2012. Poster presentation.
83. Schiavone MB, Kuo EC, Naumann RW, Burke WM, Lewin SN, Herzog TJ, **Wright JD**. The commercialization of robotic surgery: unsubstantiated marketing of gynecologic

surgery by hospitals. 43rd Annual Meeting on Women's Cancer. Austin, Texas. March 24-27, 2012. Oral presentation.

84. Bashir S, Ananth CV, Lewin SN, Burke WM, Lu Y, Herzog TJ, **Wright JD**. Utilization of sodium hyaluronate-carboxymethylcellulose (HA-CMC) adhesion barrier in hysterectomy. 43rd Annual Meeting on Women's Cancer. Austin, Texas. March 24-27, 2012. Oral poster presentation.
85. Doneza J, Arend R, Chen X, Galatioto J, Kitajewski J, Li B, Herzog TJ, **Wright JD**. Role of PI3-kinase signaling in uterine carcinosarcoma. 43rd Annual Meeting on Women's Cancer. Austin, Texas. March 24-27, 2012. Poster presentation.
86. Berger-Chen S, Herzog TJ, **Wright JD**. Access to conservative surgical therapy in adolescents with benign ovarian masses. 60th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists. San Diego, California. May 5-9, 2012. Poster presentation.
87. Hagemann AR, Zigelboim I, Gao F, Novetsy AP, Massad LS, Thaker PH, Powell MA, Mutch DG, **Wright JD**. Phase II trial of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. 48th Annual Meeting of the American Society of Clinical Oncology. Chicago, Illinois. June 1-5, 2012. Poster presentation.
88. **Wright JD**, Neugut AI, Lewin SN, Burke WM, Lu YS, Herzog TJ, Hershman DL. Deviations from guideline-based therapy for febrile neutropenia in cancer patients. 48th Annual Meeting of the American Society of Clinical Oncology. Chicago, Illinois. June 1-5, 2012. Poser presentation.
89. Zigelboim I, **Wright JD**, Gao F, Case AS, Massad LS, Mutch DG, Powell MA, Eisenhower EL, Cohn DE, Valea FA, Alvarez Secord A, Lippmann LT, Rader JS. Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent of persistent cervical cancer. 48th Annual Meeting of the American Society of Clinical Oncology. Chicago, Illinois. June 1-5, 2012. Poster presentation.
90. Richards CA, **Wright JD**, Neugut AI, Ascherman J, Hershman DL. Influence of hospital characteristics on immediate breast reconstruction following mastectomy. 48th Annual Meeting of the American Society of Clinical Oncology. Chicago, Illinois. June 1-5, 2012. Poser presentation.
91. Rogo-Gupta L, **Wright JD**, Litwin MS, Lu YS, Raz S, Rodriguez LV. Trends in mesh use for pelvic organ prolapse repairs in the U.S., 2000-2010. 33rd Annual Scientific Meeting of the American Urogynecologic Society. Chicago, Illinois. October 3-6, 2012. Oral presentation.
92. Rogo-Gupta L, **Wright JD**, Litwin MS, Lu YS, Raz S, Rodriguez LV. The influence of surgeon and hospital characteristics on mesh use for pelvic organ prolapse and

incontinence repairs. 33rd Annual Scientific Meeting of the American Urogynecologic Society. Chicago, Illinois. October 3-6, 2012. Poster presentation.

93. **Wright JD**, Herzog TJ, Neugut AI, Burke WM, Lewin SN, Siddiq Z, Hershman DL. Utilization and effectiveness of intensity modulated radiation therapy for uterine cancer. 14th Biennial Meeting of the International Gynecological Cancer Society. Vancouver, Canada. October 12-16, 2012. Poster presentation.
94. **Wright JD**, Lewin SN, Cleary K, Burke WM, Devine PC, Lu YS, Herzog TJ. Prospective evaluation of the acceptability and compliance with postpartum human papillomavirus vaccination in young women. 14th Biennial Meeting of the International Gynecological Cancer Society. Vancouver, Canada. October 12-16, 2012. Poster presentation.
95. **Wright JD**, Herzog TJ, Siddiq Z, Arend R, Neugut AI, Burke WM, Lewin SN, Ananth CV, Hershman DL. Failure to rescue as a source of variation in hospital mortality for ovarian cancer. 14th Biennial Meeting of the International Gynecological Cancer Society. Vancouver, Canada. October 12-16, 2012. Poster presentation.
96. Spoozak L, Seow H, **Wright JD**, Barbera L. Trajectory of performance status and symptom score in patients with gynecological cancer during the last six months of life. 14th Biennial Meeting of the International Gynecological Cancer Society. Vancouver, Canada. October 12-16, 2012. Oral presentation.
97. Garg G, Siddiq Z, Yee C, Zhou G, Schwartz K, Powell MA, Herzog TJ, Mutch DG, Morris RT, **Wright JD**. Temporal trends, predictors, and outcome of chemotherapy in elderly women with advanced-stage endometrial cancer. Annual Meeting of American Association for Cancer Research. Washington, DC. April 6-10, 2013. Poster presentation.
98. Samuel A, Bonanno C, Musci T, Batey A, **Wright JD**. Fraction of cell-free fetal DNA in the maternal serum as a predictor of abnormal placental invasion. 33rd Annual Meeting of the Society for Maternal-Fetal Medicine. San Francisco, CA. February 11-16, 2013. Poster presentation.
99. **Wright JD**, Herzog TJ, Burke WM, Lu YS, Lewin SN, Neugut AI, Hershman DL. Trends in hospital volume and patterns of referral for women with gynecologic cancers. 44th Annual Meeting on Women's Cancer. Los Angeles, California. March 9-12, 2013. Poster presentation.
100. **Wright JD**, Ananth CV, Herzog TJ, Burke WM, Lu YS, Lewin SN, Neugut AI, Hershman DL. Comparative effectiveness of upfront treatment strategies for advanced stage ovarian cancer. 44th Annual Meeting on Women's Cancer. Los Angeles, California. March 9-12, 2013. Poster presentation.
101. **Wright JD**, Neugut AI, Siddiq Z, Glied S, Hershman DL. Use of high-intensity surveillance in patients following a diagnosis of stage I-II non-small cell lung cancer. 49th

Annual Meeting of the American Society of Clinical Oncology. Chicago, IL. May 31-June 4, 2013. Oral presentation.

102. Hershman DL, Neugut AI, Buono D, Richards C, Glied S, **Wright JD**. Off-label and compendia use of chemotherapy in patients with metastatic cancer. 49th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL. May 31-June 4, 2013. Oral presentation.
103. **Wright JD**, Herzog TJ, Siddiq Z, Arend R, Neugut AI, Burke WM, Lewin SN, Ananth CV, Hershman DL. Failure to rescue as a source of variation in hospital mortality for ovarian cancer. AcademyHealth 30th Annual Research Meeting. Baltimore, MD. June 23-25, 2013. Poster presentation.
104. Brubaker SG, Friedman A, Cleary K, Prendergast E, Lu YS, D'Alton ME, Ananth CV, **Wright JD**. Poor compliance with recommendations for perioperative antibiotic prophylaxis in women undergoing cesarean delivery. 34th Annual Society of Maternal Fetal Medicine Meeting-The Pregnancy Meeting. New Orleans, LA. February 3-8, 2014. Poster presentation.
105. **Wright JD**, Neugut AI, Lu YS, Lewin SN, Wilde ET, Hershman DL. Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their impact on outcomes. Division of Cancer, Control and Population Sciences new Grantee Workshop. Rockville, MD. January 6-7, 2014. Poster presentation.
106. Kostolias A, Herzog TJ, Prendergast E, Hershman DL, **Wright JD**. Diffusion and outcomes of robotic adnexal surgery. 61st Annual Scientific Meeting of the Society for Gynecologic Investigation. Florence, Italy. March 26-29, 2014. Poster presentation.
107. **Wright JD**, Neugut AI, Tergas AI, Lewin SN, Burke WM, Lu YS, Herzog TJ, Hershman DL. Surveillance testing in women following a diagnosis of early-stage endometrial cancer. 45th Annual Meeting on Women's Cancer. Tampa, FL. March 22-25, 2014. Poster presentation.
108. George E, Tergas AI, Lewin SN, Burke WM, Prendergast E, Lu YS, Herzog TJ, **Wright JD**. Comparative effectiveness of radical hysterectomy in elderly women with cervical cancer. 45th Annual Meeting on Women's Cancer. Tampa, FL. March 22-25, 2014. Oral presentation.
109. Tergas AI, George E, **Wright JD**, Chen X, Wright T. Diagnosis of adenocarcinoma in situ (AIS): changing trends and the impact of human papillomavirus. 45th Annual Meeting on Women's Cancer. Tampa, FL. March 22-25, 2014. Poster presentation.
110. Dinkelspiel HE, Zimmerman LD, Lewin SN, Tergas AI, Burke WM, Lu YS, Herzog TJ, **Wright JD**. Use and duration of chemotherapy and its impact on survival in

early-stage ovarian cancer. 45th Annual Meeting on Women's Cancer. Tampa, FL. March 22-25, 2014. Poster presentation.

111. Van Arsdale A, Einstein MH, Brewer MA, Timmins PF, **Wright JD**, Leiser AL, Astrow AB, Cohen S, Goldberg GL, Kuo DYS. Phase II trial of pemetrexed and carboplatin in platinum-resistant recurrent ovarian, fallopian tube, and primary peritoneal cancer. 45th Annual Meeting on Women's Cancer. Tampa, FL. March 22-25, 2014. Poster presentation.
112. **Wright JD**, Tergas AI, Lewin SN, Burke WM, Chen L, Neugut AI, Hershman DL. Relationship between surgical oncologic outcomes and publically reported hospital quality measures. 50th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL. May 30-June 3, 2014. Oral presentation.
113. Tergas AI, Neugut AI, Chen L, Lewin SN, Burke WM, Hershman DL, **Wright JD**. Prolonged duration of radiation in women with cervical cancer: A population-based analysis of associated factors and impact on survival. 50th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL. May 30-June 3, 2014. Poster presentation.
114. Tergas AI, Goldberg M, Crooks D, Neugut AI, Burke WM, Hershman DL, **Wright JD**. A multi-ethnic study of cervical cancer stage at diagnosis among Hispanic women in the United States. 15th Biennial Meeting of the International Gynecologic Cancer Society. Melbourne, Australia. November 8-11, 2014. Poster presentation.
115. Tergas AI, Narvaez J, Bancroft C, Neugut AI, Burke WM, Hershman DL, **Wright JD**. Influence of insurance status on treatment and survival for invasive cervical cancer. 15th Biennial Meeting of the International Gynecologic Cancer Society. Melbourne, Australia. November 8-11, 2014. Poster presentation.
116. Moroz L, Friedman AM, Ananth CV, Prendergast E, D'Alton ME, **Wright JD**. Epidemiology and Predictors of Cesarean Delivery Complications in the United States. 62nd Annual Scientific Meeting of the Society for Reproductive Medicine. San Francisco, CA. March 25-28, 2015.
117. Obican S, **Wright JD**, Vink J. Urine matrix metalloproteinase 2: A possible novel biomarker of invasive placentation. 35th Annual Meeting of the Society for Maternal-Fetal Medicine. San Diego, CA. February 2-7, 2015. Poster presentation.
118. Friedman AF, Ananth CV, Prendergast E, D'Alton ME, **Wright JD**. Are low volume hospitals low risk for maternal morbidity? 35th Annual Meeting of the Society for Maternal-Fetal Medicine. San Diego, CA. February 2-7, 2015. Oral presentation.
119. Friedman AF, Ananth CV, Prendergast E, D'Alton ME, **Wright JD**. Are third and fourth degree perineal lacerations a good care quality metric? 35th Annual Meeting of

the Society for Maternal-Fetal Medicine. San Diego, CA. February 2-7, 2015. Poster presentation.

120. Jones NL, Xiu J, Reddy SK, Tergas AI, Burke WM, **Wright JD**, Hou JY. Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma. 2015 Annual Meeting on Women's Cancer. Chicago, IL. March 28-31, 2015. Oral presentation.
121. Patankar SS, Tergas AI, Burke WM, Hou JY, Ananth C, Huang Y, Neugut AI, Hershman DL, **Wright JD**. High versus low-dose rate brachytherapy for locally advanced cervical cancer. 2015 Annual Meeting on Women's Cancer. Chicago, IL. March 28-31, 2015. Poster presentation.
122. Guntupalli SR, Flink D, Ioffe YJM, Sheeder J, Tergas AI, **Wright JD**, Davidson SA, Leiferman J, Behbakht K. Sexual and marital dysfunction in women with gynecologic cancer: Results of a multi-institutional, cross-sectional trial. 2015 Annual Meeting on Women's Cancer. Chicago, IL. March 28-31, 2015. Poster presentation.
123. George E, Burke WM, Hou YJ, Tergas AI, Prendergast E, Chen L, Neugut AI, Ananth CV, Hershman DL, **Wright, JD**. Measurement and validation of frailty as a predictor of outcomes in women undergoing major gynecologic surgery. 2015 Annual Meeting on Women's Cancer. Chicago, IL. March 28-31, 2015. Poster presentation.
124. Jones NL, Xiu J, Reddy SK, Tergas AI, Burke WM, **Wright JD**, Hou JY. Molecular characterization of 361 cases of uterine carcinosarcoma reveals alterations in the DNA repair and PI3K pathways as potential therapeutic targets. 2015 Annual Meeting on Women's Cancer. Chicago, IL. March 28-31, 2015. Poster presentation.
125. Tergas AI, Chen L, Ananth CV, Hou JY, Burke WM, Neugut AI, Hershman DL, **Wright JD**. Population-level survival trends for uterine cancer. 2015 Annual Meeting on Women's Cancer. Chicago, IL. March 28-31, 2015. Poster presentation.
126. Jones NL, Xiu J, Reddy SK, Tergas AI, Burke WM, **Wright JD**, Hou JY. Identifying potential therapeutics by molecular profiling of 136 cases of uterine clear cell carcinoma. 2015 Annual Meeting on Women's Cancer. Chicago, IL. March 28-31, 2015. Poster presentation.
127. **Wright JD**, Chen L, Ananth CV, Tergas AI, Hou JY, Burke WM, Neugut AI, Hershman DL. Secular trends in relative survival for ovarian cancer. 2015 Annual Meeting on Women's Cancer. Chicago, IL. March 28-31, 2015. Poster presentation.
128. Jones NL, Xiu J, Reddy SK, Tergas AI, Burke WM, **Wright JD**, Hou JY. Distinct molecular landscapes between endometrioid and non-endometrioid uterine carcinoma. 2015 Annual Meeting on Women's Cancer. Chicago, IL. March 28-31, 2015. Poster presentation.

129. Patankar SS, Burke WM, Hou JY, Tergas AI, Ananth CV, Huang Y, **Wright JD**. Risk stratification and outcomes of women undergoing surgery for ovarian cancer. 2015 Annual Meeting on Women's Cancer. Chicago, IL. March 28-31, 2015. Poster presentation.
130. Duffy C, Burke WM, Hou JY, Tergas AI, **Wright JD**. Real world effectiveness of minimally invasive hysterectomy for uterine cancer. 2015 Annual Meeting on Women's Cancer. Chicago, IL. March 28-31, 2015. Poster presentation.
131. Radossi A, Mira-Falkenstern C, Ladas EJ, Taromina K, Kelly KM, **Wright JD**. Use and beliefs of CAM therapies among women with gynecologic cancer. 12th International Conference of Integrative Oncology. Boston, MA. November 14-16, 2015. Poster presentation.
132. Lavery JA, Friedman AM, Keyes KM, **Wright JD**, Ananth CV. Gestational diabetes in the United States: temporal changes in prevalence rates between 1979 and 2010. 36th Annual Pregnancy Meeting. Atlanta, GA. February 1-6, 2016. Poster presentation.
133. Ananth CV, Lavery JA, Friedman AM, **Wright JD**. Maternal complications in relation to severe preeclampsia: impact of regionalization of care in the United States. 36th Annual Pregnancy Meeting. Atlanta, GA. February 1-6, 2016. Poster presentation.
134. Ananth CV, Lavery JA, Friedman AM, Keyes KM, Hamilton A, **Wright JD**. Trends in primary and repeat cesarean deliveries: a population-based cohort study in the United States, 1979-2010. 36th Annual Pregnancy Meeting. Atlanta, GA. February 1-6, 2016. Poster presentation.
135. Friedman AM, Ananth CV, Siddiq Z, D'Alton ME, **Wright JD**. Factors associated with smoking cessation during pregnancy. 63rd Annual Scientific Meeting of the Society of Reproductive Investigation. Montreal, Canada. March 16-19, 2016. Poster presentation.
136. Friedman AM, Ananth CV, Siddiq Z, D'Alton ME, **Wright JD**. Cigarette smoking during pregnancy in the United States from 2005 to 2013. 63rd Annual Scientific Meeting of the Society of Reproductive Investigation. Montreal, Canada. March 16-19, 2016. Poster presentation.
137. Friedman AM, Ananth CV, Siddiq Z, D'Alton ME, **Wright JD**. Mode of delivery for gastroschisis. 63rd Annual Scientific Meeting of the Society of Reproductive Investigation. Montreal, Canada. March 16-19, 2016. Poster presentation.
138. Friedman AM, Ananth CV, Siddiq Z, D'Alton ME, **Wright JD**. Factors associated with gastroschisis in the United States, 2005-2013. 63rd Annual Scientific Meeting of the Society of Reproductive Investigation. Montreal, Canada. March 16-19,

2016. Poster presentation.

139. Merriam AA, Ananth CV, **Wright JD**, Huang MS, D'Alton ME, Friedman AM. Maternal morbidity associated with hysterectomy after vaginal delivery at low, moderate, and high volume hospitals. 63rd Annual Scientific Meeting of the Society of Reproductive Investigation. Montreal, Canada. March 16-19, 2016. Poster presentation.
140. Friedman AM, Ananth CV, Merriam AA, Siddiq Z, D'Alton ME, **Wright JD**. Factors associated with operative delivery in the United States, 2005-2013. 63rd Annual Scientific Meeting of the Society of Reproductive Investigation. Montreal, Canada. March 16-19, 2016. Poster presentation.
141. Friedman AM, Ananth CV, Siddiq Z, D'Alton ME, **Wright JD**. Trends in trial of labor after cesarean delivery in the United States, 2005-2012. 63rd Annual Scientific Meeting of the Society of Reproductive Investigation. Montreal, Canada. March 16-19, 2016. Poster presentation.
142. Friedman AM, Gyamfi-Bannerman C, Ananth CV, Siddiq Z, D'Alton ME, **Wright JD**. Stillbirth and neonatal adverse outcomes in pregnancies complicated by chronic hypertension. 63rd Annual Scientific Meeting of the Society of Reproductive Investigation. Montreal, Canada. March 16-19, 2016. Poster presentation.
143. Friedman AM, Ananth CV, Merriam AA, Siddiq Z, D'Alton ME, **Wright JD**. Maternal morbidity associated with postpartum hemorrhage after vaginal delivery at low, moderate, and high-volume hospitals. 63rd Annual Scientific Meeting of the Society of Reproductive Investigation. Montreal, Canada. March 16-19, 2016. Poster presentation..
144. McLennan AA, Ananth CV, **Wright JD**, Siddiq Z, D'Alton ME, Friedman AM. Advanced maternal age with twin pregnancy: mode of delivery and risk for gestational diabetes and gestational hypertension/preeclampsia. 63rd Annual Scientific Meeting of the Society of Reproductive Investigation. Montreal, Canada. March 16-19, 2016. Poster presentation.
145. McLennan AA, Ananth CV, **Wright JD**, Siddiq Z, D'Alton ME, Friedman AM. Twin pregnancy in the setting of advanced maternal age: risk of prematurity, neonatal morbidity, and stillbirth. 63rd Annual Scientific Meeting of the Society of Reproductive Investigation. Montreal, Canada. March 16-19, 2016. Poster presentation.
146. Ananth CV, Lavery JA, Friedman AM, Keyes KM, Hamilton A, **Wright JD**. Trends in Primary and Repeat Cesarean Deliveries: A Population-based Cohort Study in the United States, 1979-2010. 36th Annual Pregnancy Meeting. Atlanta, GA. February 1-6, 2016. Poster presentation.
147. Lavery JA, Friedman AM, Keyes KM, **Wright JD**, Ananth CV. Gestational diabetes in the United States: Temporal changes in prevalence rates between 1979 and 2010. 36th Annual Pregnancy Meeting. Atlanta, GA. February 1-6, 2016. Poster

presentation.

148. Friedman AM, Ananth CV, Siddiq Z, D'Alton ME, **Wright JD**. Is expectant management of preterm preeclampsia leading to delivery at later gestational ages? 36th Annual Pregnancy Meeting. Atlanta, GA. February 1-6, 2016. Poster presentation.
149. Friedman AM, Gyamfi-Bannerman C, **Wright JD**, Siddiq Z, D'Alton ME, Ananth CV. Stillbirth and neonatal adverse outcomes in pregnancies complicated by preexisting and gestational diabetes. 36th Annual Pregnancy Meeting. Atlanta, GA. February 1-6, 2016. Poster presentation.
150. Friedman AM, Ananth CV, Siddiq Z, D'Alton ME, **Wright JD**. Factors associated with successful trial of labor after cesarean delivery. 36th Annual Pregnancy Meeting. Atlanta, GA. February 1-6, 2016. Poster presentation.
151. Friedman AM, Ananth CV, Siddiq Z, D'Alton ME, **Wright JD**. Trends in external version for preventing primary cesarean deliveries, 2005-2012. 36th Annual Pregnancy Meeting. Atlanta, GA. February 1-6, 2016. Poster presentation.
152. Friedman AM, Ananth CV, Siddiq Z, D'Alton ME, **Wright JD**. Neonatal outcomes after high-order cesarean delivery. 36th Annual Pregnancy Meeting. Atlanta, GA. February 1-6, 2016. Poster presentation.
153. Friedman AM, Gyamfi-Bannerman C, **Wright JD**, Siddiq Z, D'Alton ME, Ananth CV. Timing of delivery for pre-existing diabetes. 36th Annual Pregnancy Meeting. Atlanta, GA. February 1-6, 2016. Poster presentation.
154. Friedman AM, Gyamfi-Bannerman C, **Wright JD**, Siddiq Z, D'Alton ME, Ananth CV. Timing of delivery for chronic hypertension: a population-based cohort in the United States. 36th Annual Pregnancy Meeting. Atlanta, GA. February 1-6, 2016. Poster presentation.
155. Friedman AM, Gyamfi-Bannerman C, **Wright JD**, Siddiq Z, D'Alton ME, Ananth CV. Timing of delivery for gestational diabetes. 36th Annual Pregnancy Meeting. Atlanta, GA. February 1-6, 2016. Poster presentation.
156. Ananth CV, Lavery JA, Friedman AM, **Wright JD**. Maternal complications in relation to severe preeclampsia: impact of regionalization of care in the United States. 36th Annual Pregnancy Meeting. Atlanta, GA. February 1-6, 2016. Poster presentation.
157. Merriam AA, Ananth CV, **Wright JD**, Siddiq Z, D'Alton ME, Friedman AM. Neonatal injuries after operative delivery, 2005-2012. 36th Annual Pregnancy Meeting. Atlanta, GA. February 1-6, 2016. Poster presentation.
158. **Wright JD**, Chen L, Jorge S, Burke WM, Tergas AI, Hou JY, Hu JC, Neugut AI, Ananth CV, Hershman DL. Utilization and effectiveness of extended-duration

thromboprophylaxis after high-risk abdominopelvic surgery. ASCO Quality Care Symposium, Phoenix, AZ. February 26-27, 2016. Poster presentation.

159. Hsu J, Chen L, **Wright JD**. Disparities in the management of ectopic pregnancy. 63rd Society for Reproductive Investigation Annual Scientific Meeting. Montreal, Canada. March 16-19, 2016. Poster presentation.
160. Matsuo K, Java J, Muderspach LI, Roman LD, **Wright JD**. Significance of risk-weighted surgical-pathological factors on survival of stage IB cervical cancer: An ancillary analysis of Gynecologic Oncology Group study. 2016 Annual Meeting on Women's Cancer. San Diego, CA. March 19-22, 2016. Plenary presentation.
161. Jorge S, Huang Y, Tergas AI, Burke WM, Hou JY, **Wright JD**. Magnitude of risk for nodal disease in women with endometrial cancer and lymphovascular space invasion. 2016 Annual Meeting on Women's Cancer. San Diego, CA. March 19-22, 2016. Poster presentation.
162. **Wright JD**, Jorge S, Burke WM, Hou JY, Tergas AI, Huang Y, Hershman DL. Use of whole pelvic radiotherapy for high-intermediate risk endometrial cancer. 2016 Annual Meeting on Women's Cancer. San Diego, CA. March 19-22, 2016. Poster presentation.
163. Chatterjee S, Xiu J, Reddy SK, Jones NL, Buckley de Meritens A, Tergas AI, Burke WM, **Wright JD**, Hou JY. Uterine leiomyosarcomas exhibit distinct drug resistance molecular profiles compared to extrauterine leiomyosarcomas: A comprehensive analysis of 1023 leiomyosarcomas. 2016 Annual Meeting on Women's Cancer. San Diego, CA. March 19-22, 2016. Poster presentation.
164. Chatterjee S, Chen L, Jones NL, Buckley de Meritens A, Burke WM, Tergas AI, Hou JY, **Wright JD**. Safety of ovarian preservation in women with stage I epithelial ovarian cancer. 2016 Annual Meeting on Women's Cancer. San Diego, CA. March 19-22, 2016. Poster presentation.
165. Jones NL, Jorge S, Chen L, Chatterjee S, Buckley de Meritens A, Tergas AI, Hou JY, Burke WM, **Wright JD**. Patterns of care and predictors of survival for ovarian dysgerminoma. 2016 Annual Meeting on Women's Cancer. San Diego, CA. March 19-22, 2016. Poster presentation.
166. Jones NL, Xiu J, Reddy SK, Chatterjee S, Buckley de Meritens A, Tergas AI, Burke WM, **Wright JD**, Hou JY. Molecular profiling of triple-negative endometrial cancers and triple-negative breast cancers reveals unique expression profiles. 2016 Annual Meeting on Women's Cancer. San Diego, CA. March 19-22, 2016. Poster presentation.
167. Jones NL, Xiu J, Reddy SK, Buckley de Meritens A, Chatterjee S, Tergas AI, Burke WM, **Wright JD**, Hou JY. Molecular profiling reveals distinct molecular

landscape in 545 cases of triple-negative endometrial cancer. 2016 Annual Meeting on Women's Cancer. San Diego, CA. March 19-22, 2016. Poster presentation.

168. Margolis BA, **Wright JD**, Chen L, Hou JY, Tergas AI, Burke WM. Neuroendocrine carcinoma of the cervix: poor survival despite aggressive treatment. 2016 Annual Meeting on Women's Cancer. San Diego, CA. March 19-22, 2016. Poster presentation.
169. Melamed A, Clemmer JT, Keating NL, **Wright JD**, Schorge JO, del Carmen M, Rauh-Hain JA. Laparoscopic staging for stage I epithelial ovarian cancer: analysis of the National Cancer Data Base. 2016 Annual Meeting on Women's Cancer. San Diego, CA. March 19-22, 2016. Poster presentation.
170. Baptiste C, Burke WM, Feldman R, **Wright JD**, Tergas AI, Hou JY. Vulvar and vaginal melanoma: A distinct subclass of melanoma based on a comprehensive molecular analysis of 51 cases. 2016 Annual Meeting on Women's Cancer. San Diego, CA. March 19-22, 2016. Poster presentation.
171. Chatterjee S, Chen L, Jones NL, Buckley de Meritens A, Burke WM, Tergas AI, Hou JY, **Wright JD**. Use and efficacy of adjuvant chemotherapy for stage I ovarian cancer. 2016 Annual Meeting on Women's Cancer. San Diego, CA. March 19-22, 2016. Poster presentation.
172. Jorge S, Jones NL, Chen L, Hou JY, Tergas AI, Burke WM, **Wright JD**. Patterns of care and predictors of survival in patients with immature teratoma. 2016 Annual Meeting on Women's Cancer. San Diego, CA. March 19-22, 2016. Poster presentation.
173. Margolis BA, Buckley de Meritens A, Jones NL, Chatterjee S, **Wright JD**, Burke WM, Hou JY, Tergas AI. Opinion and attitudes of gynecologic oncologists about interactions with palliative care specialists. 2016 Annual Meeting on Women's Cancer. San Diego, CA. March 19-22, 2016. Poster presentation.
174. George E, Zhang X, Simpkins F, Latif NA, Giuntoli RL, Morgan MA, Schmitz K, **Wright JD**, Ko E. Frailty as a predictor of adverse outcomes in patients undergoing surgery for gynecologic malignancies. 2016 Annual Meeting on Women's Cancer. San Diego, CA. March 19-22, 2016. Poster presentation.
175. Jones NL, Xiu J, Reddy SK, Chatterjee S, Buckley de Meritens A, Tergas AI, Burke WM, **Wright JD**, Hou JY. Unique molecular signatures between high-grade and low-grade endometrial stromal sarcoma: An analysis of 96 cases. 2016 Annual Meeting on Women's Cancer. San Diego, CA. March 19-22, 2016. Poster presentation.
176. Elvin JA, Chalmers ZR, Chudnovsky Y, Sun J, Hou JY, Ali SM, Vergilio JA, Suh J, Chmielecki J, Frampton G, Del Priore G, Ross JS, Castro M, **Wright JD**, Gaillard S. Comprehensive genomic profiling of ovarian clear cell carcinomas identifies clinically

relevant genomic alterations and targeted therapy options. 2016 Annual Meeting on Women's Cancer. San Diego, CA. March 19-22, 2016. Poster presentation.

177. Elvin JA, Chalmers ZR, Hou JY, Del Priore G, Ali SM, Vergilio JA, Suh J, Chmielecki J, Frampton G, Lipson D, Stephens PJ, Miller V, Ross JS, **Wright JD**. Comprehensive genomic profiling of ovarian carcinomas identifies both ERBB2 amplifications and activating point mutations as biomarkers for anti-HER2 targeted therapy. 2016 Annual Meeting on Women's Cancer. San Diego, CA. March 19-22, 2016. Poster presentation.
178. Jones N, Chen L, Burke W, Chatterjee S, Tergas A, Hou J, Buckley de Meritens A, **Wright JD**. National trends in extended procedures for ovarian cancer debulking surgery. 16th Biennial Meeting of the International Gynecologic Cancer Society. Lisbon, Portugal. October 29-31, 2016. Oral poster presentation.
179. Jones N, Schulkin J, Urban R, **Wright JD**, Burke WM, Hou J, McElwain C, Tergas AI. Physicians' perspectives and practice patterns towards opportunistic salpingectomy in high and low-risk women. 16th Biennial Meeting of the International Gynecologic Cancer Society. Lisbon, Portugal. October 29-31, 2016. Oral poster presentation.
180. Baptiste C, Buckley de Meritens A, **Wright JD**, Hou J, Tergas AI, Chatterjee-Paer S, Jones N, Burke WM. Workup and management of isolated port site metastases: a survey of the Society of Gynecologic Oncology. 16th Biennial Meeting of the International Gynecologic Cancer Society. Lisbon, Portugal. October 29-31, 2016. Poster presentation.
181. Chatterjee S, Xiu J, Jones N, Tergas A, Burke WM, **Wright JD**, Hou J. Comprehensive molecular profiling of 19 perivascular epithelioid cell tumors (PEComa): implications for novel therapy. 16th Biennial Meeting of the International Gynecologic Cancer Society. Lisbon, Portugal. October 29-31, 2016. Poster presentation.
182. Burke WM, Hou J, Tergas AI, Chen L, **Wright JD**. Adherence to established guidelines for chemotherapy induced nausea and vomiting in women undergoing treatment for gynecologic cancer. 16th Biennial Meeting of the International Gynecologic Cancer Society. Lisbon, Portugal. October 29-31, 2016. Poster presentation.
183. Burke WM, Chen L, Hou JY, Tergas AI, Chatterjee-Paer S, **Wright JD**. Trends in panniculectomy for uterine cancer in the United States from 1998 to 2013: extinction of a common practice. 16th Biennial Meeting of the International Gynecologic Cancer Society. Lisbon, Portugal. October 29-31, 2016. Poster presentation.
184. **Wright JD**, Cham S, Chen L, Burke WM, Hou JY, Tergas AI, Hershman DL. Uptake of sentinel lymph node biopsy for uterine cancer. 16th Biennial Meeting of the International Gynecologic Cancer Society. Lisbon, Portugal. October 29-31, 2016. Poster presentation.

185. Guntupalli S, Ioffe Y, Behbakht K, **Wright JD**, Sheeder J, Flink D. Sexual and marital dysfunction in women with gynecologic cancer. 16th Biennial Meeting of the International Gynecologic Cancer Society. Lisbon, Portugal. October 29-31, 2016. Oral presentation.
186. Cui RR, **Wright JD**, Burke WM, Tergas AI, Hou JY. Platinum sensitivity is associated with distinct gene signatures and biological functional pathways in epithelial ovarian cancer. 16th Biennial Meeting of the International Gynecologic Cancer Society. Lisbon, Portugal. October 29-31, 2016. Poster presentation.
187. Davies A, Hou J, Shi IM, **Wright JD**, Ciznadija D, Katz A, Sidransky D. Patient-derived xenograft (PDX) models of BRCA-deficient and BRCA-like ovarian tumors reflect clinical responses to PARP inhibition. European Organization for Research and Treatment of Cancer- National Cancer Institute-American Association for Cancer Research Molecular Targets and Cancer Therapeutics Symposium. Munich, Germany. November 29-December 2, 2016. Poster presentation.
188. Neff R, **Wright JD**, Cohn DE, Havrilesky LJ. Enhanced recovery after surgery (ERAS) for ovarian cancer: analyzing the cost effectiveness of a recovery program after primary cytoreductive surgery. 2017 Annual Meeting on Women's Cancer. National Harbor, MD. March 12-15, 2017. Oral presentation.
189. Ruiz MP, Huang Y, Hou JY, Tergas AI, Burke WM, Hershman DL, **Wright JD**. Safety of progestational therapy in young women with endometrial cancer. 2017 Annual Meeting on Women's Cancer. National Harbor, MD. March 12-15, 2017. Poster presentation.
190. Jain J, Ananth CV, Siddiq Z, **Wright JD**, D'Alton ME, Friedman AM. Trends and severe morbidity associated with postpartum admissions for hypertensive diseases of pregnancy. 64th Annual Meeting of the Society for Reproductive Investigation. Orlando, FL. March 15-18, 2017. Poster presentation.
191. Jain J, Ananth CV, Siddiq Z, **Wright JD**, D'Alton ME, Friedman AM. Variation in endometritis rates following cesarean section. 64th Annual Meeting of the Society for Reproductive Investigation. Orlando, FL. March 15-18, 2017. Poster presentation.
192. Merriam AA, Ananth CV, Siddiq Z, **Wright JD**, D'Alton ME, Friedman AM. Interventions for postpartum hemorrhage requiring transfusion. 64th Annual Meeting of the Society for Reproductive Investigation. Orlando, FL. March 15-18, 2017. Poster presentation.
193. Merriam AA, Ananth CV, Siddiq Z, **Wright JD**, D'Alton ME, Friedman AM. Interventions for uterine atony prior to hysterectomy. 64th Annual Meeting of the Society for Reproductive Investigation. Orlando, FL. March 15-18, 2017. Poster presentation.

194. Mardy A, Ananth CV, **Wright JD**, Siddiq Z, D'Alton ME, Friedman AM. Venous thromboembolism prophylaxis during antepartum hospitalizations. 37th Annual Pregnancy Meeting. Las Vegas, NV. January 23-28, 2017. Poster presentation.
195. Margolis BA, Chen L, Tergas AI, Hou JY, Burke WM, Hershman DL, **Wright JD**. Trends in end-of-life care and health care spending in women with uterine cancer. 2017 Annual Meeting on Women's Cancer. National Harbor, MD. March 12-15, 2017. Poster presentation.
196. Buskwofie A, Tergas AI, Huang Y, Burke WM, Hou JY, Jones NL, Chatterjee S, **Wright JD**. Association between hospital surgical volume and racial disparities in access to care and outcomes for endometrial cancer. 2017 Annual Meeting on Women's Cancer. National Harbor, MD. March 12-15, 2017. Poster presentation.
197. Baptiste C, Buckley de Meritens A, Burke WM, Hou JY, **Wright JD**, Tergas AI. A randomized controlled trial of a preoperative patient education program to improve satisfaction and reduce resource utilization. 2017 Annual Meeting on Women's Cancer. National Harbor, MD. March 12-15, 2017. Poster presentation.
198. Jones NL, Huang Y, Burke WM, Chatterjee S, Buskwofie A, Tergas AI, Hou JY, **Wright JD**. Patterns of care and outcomes for women with uterine cancer and ovarian metastases. 2017 Annual Meeting on Women's Cancer. National Harbor, MD. March 12-15, 2017. Poster presentation.
199. Champer MS, Hou JY, Tergas AI, Burke WM, Huang Y, Hershman D, **Wright JD**. Adherence to treatment recommendations and outcomes for women with ovarian cancer at the time of first recurrence. 2017 Annual Meeting on Women's Cancer. National Harbor, MD. March 12-15, 2017. Poster presentation.
200. Sia T, Burke WM, Tergas AI, **Wright JD**, Hou JY. Identifying factors impacting hospital length of stay and potentially avoidable discharge delay in patients with gynecologic cancer. 2017 Annual Meeting on Women's Cancer. National Harbor, MD. March 12-15, 2017. Poster presentation.
201. Chatterjee S, Jones NL, Buskwofie A, Hou JY, Burke WM, **Wright JD**, Tergas AI. Association between social integration and cervical cancer screening among women in the United States. 2017 Annual Meeting on Women's Cancer. National Harbor, MD. March 12-15, 2017. Poster presentation.
202. Chatterjee S, Gabor L, Jones NL, Buskwofie A, Burke WM, Hou JY, Tergas AI, **Wright JD**. Estimating financial toxicity in patients with gynecological malignancies undergoing chemotherapy. 2017 Annual Meeting on Women's Cancer. National Harbor, MD. March 12-15, 2017. Poster presentation.
203. Buskwofie A, Huang Y, Tergas AI, Hou JY, Burke WM, Jones NL, Chatterjee S, **Wright JD**. Influence of site of care on racial disparities and outcomes for endometrial

- cancer. 2017 Annual Meeting on Women's Cancer. National Harbor, MD. March 12-15, 2017. Poster presentation.
204. Margolis BA, Buckley de Meritens A, Blinderman C, Chatterjee S, Tergas AI, Burke WM, Hou JY, **Wright JD**. Educational intervention to improve code status discussion skills and confidence for obstetrics and gynecology residents. 2017 Annual Meeting on Women's Cancer. National Harbor, MD. March 12-15, 2017. Poster presentation.
205. Cham S, Huang Y, Deutsch I, Hou JY, Tergas AI, Burke WM, Hershman D, **Wright JD**. Patterns of use and outcomes of adjuvant chemotherapy and radiation for early-stage uterine papillary serous carcinoma. 2017 Annual Meeting on Women's Cancer. National Harbor, MD. March 12-15, 2017. Oral presentation.
206. **Wright JD**, Havrilesky LJ, Cohn DE, Huang Y, Rice LW, Brown CL, Ko EM, Alvarez ED. Development of an alternative payment model (APM) for endometrial cancer: opportunities to reduce cost and improve outcomes. 2017 Annual Meeting on Women's Cancer. National Harbor, MD. March 12-15, 2017. Oral presentation.
207. Ko EM, Havrilesky LJ, Cohn DE, Huang Y, Alvarez RD, Rice LW, Brown CL, **Wright JD**. Utilizing public and commercial payer sources to develop endometrial cancer alternative payment models to bridge provider and payer cost sharing. 2017 Annual Meeting on Women's Cancer. National Harbor, MD. March 12-15, 2017. Oral presentation.
208. Desai VB, **Wright JD**, Schwartz PE, Jorgensen EM, Fan L, Litkouhi B, Gross CP, Xu X. Gynecologic cancer in women undergoing hysterectomy for presumed benign indications. American College of Surgeons Quality and Safety Conference. New York, NY. July 21-24, 2017. Poster presentation.
209. Wen T, **Wright JD**, Landau R, D'Alton ME, Friedman AM. Risk of postpartum readmissions among women with opioid abuse and dependence. Society for Obstetric Anesthesia and Perinatology Annual Meeting May 2018, Miami, FL. Poster presentation.
210. **Wright JD**, Havrilesky LJ, Alvarez RD, Cohn DE, Huang Y, Boyd LR, Ko EM. Development of an alternative payment model (APM) for early-stage cervical cancer: Opportunities to reduce cost and improve quality. 2018 Annual Meeting on Women's Cancer. New Orleans, LA. March 24-27, 2018. Oral presentation.
211. Sagaram D, Siddiq Z, Ananth CV, Esienberger AB, **Wright JD**, D'Alton ME, Friedman AM. Heparin-induced thrombocytopenia during obstetric hospital admissions. March 2018, the Society for Reproductive Investigation Annual Scientific Meeting, San Diego, CA. Poster presentation.
212. Booker W, Ananth CV, Siddiq Z, **Wright JD**, D'Alton ME, Friedman AM. Hospital volume, preeclampsia and maternal risk. March 2018, the Society for

Reproductive Investigation Annual Scientific Meeting, San Diego, CA. Poster presentation.

213. Purisch SE, Siddiq Z, Ananth CV, **Wright JD**, D'Alton ME, Friedman AM. Are women with High-risk cardiac disease delivering at more experienced centers? March 2018, the Society for Reproductive Investigation Annual Scientific Meeting, San Diego, CA. Poster presentation.
214. Webster EM, Chatterjee S, Gabor L, Vattakalam RM, Hou JY, Tergas AI, **Wright JD**. Evaluation of financial toxicity in women with gynecologic malignancies: A cross-sectional study. 2018 Annual Meeting on Women's Cancer. New Orleans, LA. March 24-27, 2018. Oral presentation.
215. Booker WA, Huang Y, Ananth CV, **Wright JD**, Cleary KL, D'Alton ME, Friedman AM. Administration of carboprost and intravenous labetalol to asthmatic patients during delivery hospitalizations. January 2018, the Annual Meeting for the Society for Maternal Fetal Medicine, Dallas, TX. Poster presentation.
216. Cleary KE, Siddiq Z, Ananth CV, **Wright JD**, D'Alton ME, Friedman AM. Use of antihypertensive medications during delivery hospitalizations complicated by preeclampsia and risk of stroke. January 2018, the Annual Meeting for the Society for Maternal Fetal Medicine, Dallas, TX. Poster presentation.
217. Mourad M, Chen L, Landau R, Ananth CV, **Wright JD**, D'Alton ME, Friedman AM. Hospital variation in administration of oral opioid medications during vaginal delivery hospitalizations. January 2018, the Annual Meeting for the Society for Maternal Fetal Medicine, Dallas, TX. Poster presentation.
218. Duffy C, Chen L, Landau R, Ananth CV, **Wright JD**, D'Alton ME, Friedman AM. Long acting opioid use during delivery hospitalizations and risk for severe maternal morbidity. January 2018, the Annual Meeting for the Society for Maternal Fetal Medicine, Dallas, TX. Poster presentation.
219. Cham S, Tergas AI, Hou JY, St. Clair C, Ananth CV, Hershman DL, **Wright JD**. Development and validation of a risk calculator for adverse perioperative outcomes for women with ovarian cancer. 2018 Annual Meeting on Women's Cancer. New Orleans, LA. March 24-27, 2018. Poster presentation.
220. Chatterjee S, Achariyapota V, Tergas AI, Burke WM, **Wright JD**, Hou JY. Comprehensive molecular profiling of 19 perivascular epithelioid tumors (PEComas): Implications for therapy. 2018 Annual Meeting on Women's Cancer. New Orleans, LA. March 24-27, 2018. Poster presentation.
221. Matsuo K, Machida H, Glaser GE, Gostout BS, Roman LD, **Wright JD**. Trends in performance of lymphadenectomy for women with early-stage epithelial ovarian

- cancer between 1988 and 2013. 2018 Annual Meeting on Women's Cancer. New Orleans, LA. March 24-27, 2018. Poster presentation.
222. Nieto VL, Huang Y, Tergas AI, Hou JY, St. Clair C, Ananth CV, Hershman DL, **Wright JD**. Use and safety of minimally invasive hysterectomy for women with non-endometrioid endometrial cancer. 2018 Annual Meeting on Women's Cancer. New Orleans, LA. March 24-27, 2018. Poster presentation.
223. Cham S, Huang Y, Tergas AI, Hou JY, St. Clair C, Ananth CV, **Wright JD**. Cancer hospital facility type affects the quality of care and survival in ovarian cancer treatment. 2018 Annual Meeting on Women's Cancer. New Orleans, LA. March 24-27, 2018. Poster presentation.
224. Ruiz MP, Chen L, Hou JY, Tergas AI, St. Clair C, Ananth C, **Wright JD**. Trends in regionalization of care and outcomes for uterine cancer. 2018 Annual Meeting on Women's Cancer. New Orleans, LA. March 24-27, 2018. Poster presentation.
225. Huang Y, Buskwofie A, Ruiz MP, Tergas AI, Hou JY, St. Clair C, Ananth CV, Hershman DL, **Wright JD**. Patient profile, patterns of care, and mortality among Asian and white women with uterine cancer. 2018 Annual Meeting on Women's Cancer. New Orleans, LA. March 24-27, 2018. Poster presentation.
226. Buskwofie A, Chatterjee S, Tergas AI, Hou JY, St. Clair C, **Wright JD**, Burke WM. Are gynecology oncology fellows ready for independent practice? 2018 Annual Meeting on Women's Cancer. New Orleans, LA. March 24-27, 2018. Poster presentation.
227. Chatterjee S, Sia T, **Wright JD**, Burke WM, Tergas AI, Hou JY. The state of women in academic gynecologic oncology programs. 2018 Annual Meeting on Women's Cancer. New Orleans, LA. March 24-27, 2018. Poster presentation.
228. Ruiz MP, Chen L, Hou JY, Tergas AI, St. Clair C, Ananth C, Hershman DL, **Wright JD**. Performance of hysterectomy by very low-volume surgeons and their outcomes. 2018 Annual Meeting on Women's Cancer. New Orleans, LA. March 24-27, 2018. Poster presentation.
229. Achariyapota V, Cham S, Vattakalam RM, Burke WM, Chatterjee S, **Wright JD**, Tergas AI, Hou JY. Tumor genetic sequencings as predictor for surgical outcomes in epithelial ovarian cancer. 2018 Annual Meeting on Women's Cancer. New Orleans, LA. March 24-27, 2018. Poster presentation.
230. Cham S, Achariyapota V, Sia T, Ritchie J, Vattakalam RM, **Wright JD**, Tergas AI, Hou JY. Clinical genomic profiling identifies potential prognostic markers in patients with gynecologic carcinosarcoma. 2018 Annual Meeting on Women's Cancer. New Orleans, LA. March 24-27, 2018. Poster presentation.

231. Achariyapota V, Burke WM, Ruiz MP, Sia T, Tergas AI, St. Clair C, Wright JD, Hou JY. The utility of comprehensive genomic profiling in selection of actionable targeted therapy in recurrent or refractory epithelial ovarian, fallopian tube and peritoneal carcinoma. 201 Annual Meeting on Women's Cancer. New Orleans, LA. March 24-27, 2018. Poster presentation.
232. Gomez-Hidalgo NR, Chen L, Hou JY, Tergas AI, St. Clair C, Ananth CV, Hershman DL, Wright JD. Trends in performance of sentinel lymph node mapping and its association with adjuvant therapy for women with uterine cancer. 2018 Annual Meeting on Women's Cancer. New Orleans, LA. March 24-27, 2018. Poster presentation.
233. Agrawal S, Chen L, Tergas AI, Hou JY, St. Clair C, Ananth CV, Hershman DL, **Wright JD**. Identifying modifiable and non-modifiable risk factors for prolonged length of stay after hysterectomy for uterine cancer. 2018 Annual Meeting on Women's Cancer. New Orleans, LA. March 24-27, 2018. Poster presentation.
234. Webster EM, Ware H, Jones BA, Vattakalam RM, **Wright JD**, Tergas AI, Burke WM, Hou JY. Patient-reported outcomes in evaluation of chemotherapy toxicity in women with gynecologic malignancies. 2018 Annual Meeting on Women's Cancer. New Orleans, LA. March 24-27, 2018. Poster presentation.
235. Cui RR, Chen L, Hou JY, Tergas AI, St. Clair C, Ananth CV, Hershman DL, **Wright JD**. Trends in use and survival associated with trachelectomy for young women with cervical cancer. 2018 Annual Meeting on Women's Cancer. New Orleans, LA. March 24-27, 2018. Poster presentation.
236. Cham S, Wen T, Friedman A, **Wright JD**. Fragmentation of postoperative care after surgical management of ovarian cancer at 30 and 90 days. 2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Plenary presentation.
237. Gay L, Schinck JC, **Wright JD**, Lele SB, Mayor PC, Odunsi K, Hemmerich A, Ngo N, Secord AA, Hou JY, Konecny GE, Santin AD, Elvin JA. Targeting ERBB family genomic alterations in gynecologicall malignancies. 2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Poster presentation.
238. Mandelbaum RS, Chen L, Shoupe D, Roman LD, **Wright JD**, Matsuo K. Patterns of utilization and outcomes of ovarian conservation for young women with minimum-risk endometrial cancer. 2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Poster presentation.
239. Buskwofie A, Chen L, Hou JY, St. Clair CM, Tergas AI, Khoury Collado F, **Wright JD**. Role of para-aortic nodal evaluation in women with uterine cancer. 2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Poster presentation.

240. Gamble CR, Huang Y, Tergas AI, Hou JY, Khoury Collado F, St. Clair CM, **Wright JD**. Trends in uterine cancer care at rural and public hospitals. 2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Poster presentation.
241. Praiss A, Chen L, St. Clair CM, Tergas AI, Khoury Collado F, Hou JY, **Wright JD**. Safety of same day discharge for minimally invasive hysterectomy for endometrial cancer. 2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Poster presentation.
242. Xu X, **Wright JD**, Gross CP, Lin H, Boscoe FP, Hutchison LM, Schwartz PE, Desai VB. Impact of morcellation on mortality in women with unexpected uterine cancer who underwent hysterectomy and myomectomy. 2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Poster presentation.
243. Schlechtweg K, Chen L, St. Clair CM, Khoury Collado F, Hou JY, Melamed A, Tergas AI, **Wright JD**. Neuroendocrine carcinoma of the endometrium: disease course, treatment and survival. 2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Poster presentation.
244. Sia TY, Chen L, Melamed A, Hou JY, St. Clair CM, Tergas AI, Khoury Collado F, **Wright JD**. Trends in use and outcomes of less radical surgery for early-stage cervical cancer. 2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Poster presentation.
245. Matsuo K, Mandelbaum RS, Adams CL, Roman LD, **Wright JD**. Performance and outcome of pelvic exenteration for gynecologic malignancies. 2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Poster presentation.
246. Latham H, Chen L, Hou JY, Khoury Collado F, St. Clair C, Tergas AI, **Wright JD**. Sequencing of therapy in women with stage III endometrial carcinoma receiving adjuvant combination chemotherapy and radiation. 2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Poster presentation.
247. **Wright JD**, Huang Y, Tergas AI, Khoury Collado F, St. Clair CM, Hou JY, Melamed A, Hershman D. Patterns of perioperative use and persistent use of opioids after gynecologic surgery. 2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Poster presentation.
248. **Wright JD**, Huang Y, St. Clair CM, Tergas AI, Melamed A, Hou JY, Khoury Collado F, Hershman D. Effect of implementing hospital level minimum-volume standards for ovarian cancer. 2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Poster presentation.
249. Buskwofie A, Chen L, Hou JY, St. Clair CM, Tergas AI, Khoury Collado F, **Wright JD**. Role of paraaortic nodal evaluation in women with type II uterine cancer.

2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Poster presentation.

250. Gamble CR, Huang Y, **Wright JD**, Tergas AI, Hou JY, Khoury Collado F, St. Clair CM. Quality of care for women with uterine cancer at US safety net hospitals. 2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Poster presentation.
251. Aviki EM, **Wright JD**, Chen L, Leitao M. Hospital surgical volume impacts the likelihood of NCCN-recommended surgery for patients with early-stage cervical cancer. 2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Poster presentation.
252. Buskwofie A, Chen L, Hou JY, St. Clair CM, Tergas AI, Khoury Collado F, **Wright JD**. Changes in surgical volume and outcomes over time for women with ovarian cancer. 2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Poster presentation.
253. Tergas AI, Chen L, St. Clair CM, Hou JY, Khoury Collado F, Neugut A, Hershman DL, **Wright JD**. Brain metastases in patients with gynecologic cancers: national trends in incidence and management.
254. Tobias CJ, Chen LL, St. Clair C, Tergas AI, Hou JY, Melamed A, Ananth CV, Neugut A, Hershman DL, **Wright JD**. Use and outcomes of neoadjuvant chemotherapy for metastatic endometrial cancer. 2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Poster presentation.
255. Syeda S, Chen L, Hou JY, Tergas AI, Khoury Collado F, Melamed A, St. Clair C, **Wright JD**. Chemotherapy versus chemotherapy and radiation for stage III uterine cancer: generalizability of cooperative group data to real world populations. 2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Poster presentation.
256. Bercow A, Melamed A, Eisenhauer EI, Rauh-Hain JA, **Wright JD**, Rice LW, del Carmen MG. Age-related risk of postoperative mortality after cytoreductive surgery for advanced ovarian cancer. 2019 Annual Meeting on Women's Cancer. Honolulu, HI. March 16-19, 2019. Poster presentation.